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We are living within the age of information. The ever increasing flow of data and
publications poses a monumental bottleneck to scientific progress as despite the
amazing abilities of the human mind, it is woefully inadequate in processing such
a vast quantity of multidimensional information. The small bits of flotsam and
jetsam that we leverage belies the amount of useful information beneath the
surface. It is imperative that automated tools exist to better search, retrieve, and
summarize this content. Combinations of document indexing and search engines
can quickly find you a document whose content best matches your query - if the
information is all contained within a single document. But it doesn’t draw
connections, make hypotheses, or find knowledge hidden across multiple
documents. Literature-based discovery is an approach that can uncover hidden
interrelationships between topics by extracting information from existing
published scientific literature. The proposed study utilizes a semantic-based
approach that builds a graph of related concepts between two user specified sets
of topics using semantic predications. In addition, the study includes properties of
bibliographically related documents and statistical properties of concepts to
further enhance the quality of the proposed intermediate terms. Our results show
an improvement in precision-recall when incorporating citations.
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Chapter 1
Introduction

1.1 Relevance and Significance
We are living within the age of information. Since the 1970’s we have progressed
from traditional industrialization into an age categorized by the creation, distribution, and
manipulation of information as a significant factor to society. This Information Age
continues to redefine not only our technology but the level of integration the technology
impacts each of us on a daily basis. Already there are more mobile connected devices
than there are people across the planet, and within a few years there will be 50 billion
smart connected devices collecting, storing, and sharing information.
No matter where you go you’ll find people on their cell phones, tablets, laptops,
and computers creating data. Every second there are 6,000 tweets over Twitter and
40,000 Google searches. Every minute there are 125,000 photos uploaded to Facebook
along with half a million comments posted. Every day there are 200 billion emails sent.
Numerous other cameras, scanners, and sensors actively record anything that might be
useful from the weather, to traffic patterns measured by the GPS movements of cellular
phones, to heart rate information collected by fitness devices that is used within medical
studies. We are drowning in a vast sea of information of which less than a single percent
is used.
Over 100 million scientific papers have been published to date and approximately
two million a year join their ranks. In some fields there may be tens of thousands of
articles published every year. Despite the amazing abilities of the human mind, it is
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woefully inadequate in processing such a vast quantity of multidimensional information.
The small bits of flotsam and jetsam that we leverage belies the amount of useful
information beneath the surface. As such, our tools to organize and examine this everexpanding flow of information becomes a bottleneck to scientific progress. Traditional
techniques such as document indexing and search engines can quickly find you a
document whose content best matches your query - if the information is all contained
within a single document. But it doesn’t draw connections, make hypotheses, or find
knowledge hidden across multiple documents. The volume of scientific literature being
published may be overwhelming for an individual researcher, and it is nigh impossible to
keep track of the developments in other research areas, which can cause logical
connections between separate areas of knowledge to be overlooked (Weeber, Vos, Klein,
Aronson, and Molema 2003).

1.2 Literature Based Discovery
Literature-based discovery (LBD) was first proposed by Don R. Swanson in 1986
through the Raynaud Syndrome–Dietary Fish Oils hypothesis (Swanson 1986). By
reading portions of more than four thousand MEDLINE articles, Swanson discovered that
dietary fish oils lowers blood viscosity, reduces platelet aggregation, and inhibit
vasoconstriction. He also observed that a reduction in both blood viscosity and platelet
aggregation, as well as the inhibition of vasoconstriction, appeared to prevent Raynaud
disease (Cameron et al. 2015).
Swanson therefore theorized that dietary fish oil might prevent Raynaud’s
syndrome - this hypothesis was later confirmed clinically in 1989 (DiGiacomo, Kremer,
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and Shah 1989). The significance of the observation was that at the time none of the
literature had a direct association between fish oils and Raynaud disease but it was
possible to derive an implicit indirect association via existing intermediate topics.
Although Swanson has been largely credited with the concept of LBD, the general
concept predates him. Several decades earlier, American biologist James Peters stated
that:

When an author takes a series of apparently unrelated facts and ideas from two
areas of investigation, combines them so that they make new sense, and develops
a new hypothesis from the combination, he not only aids in the advance of both
fields but also is quite likely to open up a new one... In Sutton’s paper (Sutton
1902) you will see this development of relationships between the fields of
cytology and heredity, which, at the time Sutton wrote, were considered to be
fairly divergent from one another, in that no research techniques were shared...
Sutton’s paper can be considered the beginning of cytogenetics... This paper is a
good model to follow in the preparation of a study involving synthesis and
correlation (Peters 1959, p. 27).

This notion has been studied, such as reports from the US National Research
Council of the National Academies. They indicate that many scientific discoveries
involve drawing new connections between scientific domains (Feller and Stern 2007).
Furthermore, many scientific breakthroughs can be characterized by linking disjoint
collections of research papers (Chen 2009). Similarly, in a study on US Patent records in
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between 1790 and 2010 they discovered that many previously reported inventions
featured new combinations between already existing technologies and techniques (Youn,
Strumsky, Bettencourt, and Lobo 2015).
To date there have been many connections and discoveries made due to the use of
literature based discovery: Fish oils and Raynaud’s syndrome (Swanson 1986), migraines
and magnesium (Swanson 1988), estrogen and Alzheimer’s disease (Smalheiser and
Swanson 1996), Parkinson’s Disease and Crohn’s disease (Kostoff 2014), new
treatments for cataracts (Kostoff 2008) and breast cancer (Li, Zhu, and Chen 2010), and
others. Given that the number of new scientific papers added to the human body of
knowledge each year is only going to continue to grow, it is essential that we improve our
existing tools to better search, process, and visualize this expanding volume.
As a research field, LBD aims at exploring approaches to discover these hidden
connections between pieces of already existing knowledge, either in automatic or
semiautomatic fashion (Smalheiser 2012). Its main goal is to produce both interesting and
novel knowledge that has yet to be published in scientific literatures (Swanson 2008).

1.3 Semantic-Based Literature Based Discovery
Most LBD systems produce a list of intermediate terms as their results. This
serves to illuminate a potential relationship, but does nothing to illustrate the underlying
mechanisms of those interactions. Semantic-based approaches are designed to provide
this contextual relevance in addition to the association. Existing research in this area have
made use of natural language processing (NLP) tools such as SemRep (Rindflesch and
Fiszman 2003) and BioMedLEE (Lussier, Borlawsky, Rappaport, Liu, and Friedman
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2006) to extract semantic propositions from free-text documents. These relationships can
help to illuminate the mechanisms of interaction and the causality between concepts.
Here, not only is the correlation between the two concepts captured, but the
contextual relevance of that relationship as well. For example, a predicate such as
[Serotonin - CAUSES - Contraction] indicates that the concepts of Serotonin and
Contraction show up together, and that Serotonin causes Contraction. As the predicates
relate one concept to another it is straightforward to utilize these to construct graphs for
visualization where nodes represent concepts and connecting edges as predicates.
Recent work by Cameron et al. has done just this, extracting semantic predicates
via SemRep to form a directed predication graph (Cameron et al. 2015). As an example,
Magnesium has been known to exert an inhibitory effect on platelet prostacyclin
(Epoprostenol) interaction, and prostacyclin is known to affect migraines (Briel, Lippert,
and Zahradnik 1985; Peatfield, Gawel, and Rose 1981). These relationships are
illustrated as directed edges in Figure 1 where the concepts of Magnesium, Epoprostenol,
and Migraine Disorders comprise the graph vertices.

Figure 1. Example relationship between Magnesium and Migraine Disorders
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1.4 Goals
A challenge of LBD is the reliance on having a collection of text documents with
which to study, as frequently only the title and abstracts of a reference are available in
large quantities. In the study by Cameron et al. they extracted predicates by using the
full-text of documents as input to the SemRep tool to achieve their results (Cameron et al.
2015). In addition, Cameron noted in his dissertation that the “results collectively suggest
that titles and abstracts alone, might NOT be sufficient for LBD” (Cameron 2014).
The goal of this dissertation is to measure the effectiveness of incorporating
bibliographic citations into semantic-based LBD. When an author chooses to cite another
document, they do so because there is some important piece of information that is
foundational or related to their own work.
LBD approaches typically start with a literature search of all documents that
contain those concepts specified by the user. By also utilizing references that are
bibliographically related to our search terms, we are leveraging additional documents that
are semantically related to our primary terms of interest that don’t already include those
terms.

Figure 2. Content of References
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Illustrated in Figure 2, the initial search returns a set of documents (S) that contain those
concepts. We then expand this set, naming it S’, to also include the cited documents of S.
Any documents within S’ that are not within S do not contain the search concepts but are
related. Therefore this approach provides the benefit of potentially adding new
intermediate terms and possible pathways from these documents with a low risk of
cluttering up the results with totally unrelated knowledge.
This study proposes to accomplish this goal by modifying the approach by
Cameron et al. (2015) to take into account cited documents. This will then be followed by
performing a retrospective analysis against past LBD discoveries to investigate if the
inclusion of citation information can retrieve better results such as revealing new
relationships. The studies in chapter four show a comparison of the results of the
expanded document set S’ and the baseline set S.

1.5 Research Questions
This proposed dissertation research concerning the blend of bibliographic
citations with semantic-based predicate graphs suggests the following research questions:
Quantitative Study: Many LBD approaches begin with an initial set of references
which include one or more concepts of interest to the user. This is generally done to
reduce the scope of the problem down from the full corpus to a smaller more manageable
subset that is more likely to have points of interest. Cameron’s approach constructs
predication subgraphs using only those predicates that exist in that collection of
documents. By expanding the initial set of documents via citations, how does this affect
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the precision and recall of the returned answers? Many LBD studies use retrospective
studies as a means of evaluation, comparing the results to those of the original discovery.
We have performed several retrospective studies to investigate this question with positive
results, discussed in Chapter 4.
Qualitative Study: Many concepts will appear related to other terms, but what are
good ways to ignore concepts that provide little information? This can be accomplished
statistically such as using IDF, which is a measure of how much information a word
provides, or employing the use of existing knowledge like ontological hierarchies. We
have used a combination of the IDF values for individual concepts calculated over the
entire corpus and the concept’s position within the MeSH ontology.
Quantitative Study: Our results are essentially a ranked order of intermediate
concepts/paths, thus the quantitative results of the retrospective studies are shown as
precision-recall curves. The use of citations expands the potential number of paths within
the results, how does this affect the precision-recall curves? Our citationally enhanced
studies have a better precision-recall curve. This is attributed to two cases. The first, and
most important, case is due to new paths being generated from the addition of citations.
The second case is caused by an increase in the IDF concept threshold.

1.6 Barriers and Issues
The potential of Swanson’s research has been widely acknowledged, but so has
the depth and complexity of the field when considering the expansive quantity of source
documents and the potential numbers of interconnections (Hearst 1999; Weeber et al.
2001). There have been three large research challenges within LBD. The first is the
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scalability of algorithms in dealing with very large volumes of information. The second is
the heavy reliance on subject matter experts or domain-specific knowledge sources.
Typically their help, whether automatic or manual, better refines a search for the
researcher or helps filter the results. For example, every concept within the
Metathesaurus has been assigned one or more semantic types (“Cell function”,
“molecular function”, etc.). Thus a researcher could make use of this by only wanting to
look at connecting concepts that match these additional criteria (Weeber et al. 2001). The
utilization of domain-specific sources helps natural language processing (NLP) to tackle
the variation and intricacies of natural language. Finally, the third difficulty is the lack of
a standard means of comparing the successfulness of LBD approaches. By its very
definition LBD attempts to uncover previously unknown details. This lack of a true gold
standard has caused many to simply qualitatively compare results to a select few original
studies (Yetisgen-Yildiz and Pratt 2008).

1.7 Summary
This expanding sphere of human knowledge has precipitated the need for
researchers to narrow their focus as it is infeasible for an individual to keep abreast of the
swelling volume of information. LBD is an attempt to help solve these challenges dedicated to building tools to discover, visualize, and traverse the hidden connections of
knowledge across many disciplines.
Semantic-based LBD techniques attempt to expand this by not only uncovering
connections, but illustrating the meaning of those connections. Stating that Fish Oils are
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related to Raynaud’s disease is useful, but not as useful as the statement: Fish Oils are
related to Raynaud’s disease due to their effect on blood viscosity.
Research into summarization techniques, discussed in chapter 2, has shown that
there are semantic correlations between a document and another references that cite it.
This dissertation explores the usefulness of incorporating bibliographic citations into
implementations of semantic LBD.
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Chapter 2
Review of the Literature

2.1 Introduction
Hypothesis generation is a key step in the process of making scientific discoveries
as much time and effort can be wasted just to disprove an initial hypothesis only to repeat
the cycle again. Traditionally, this step relies on prior knowledge, experience, and even
intuition (Srinivasan 2004). Much of what was involved with Swanson’s work was
reading and assimilating the literature and then using good judgment to explore related
topics until finally happening upon a plausible discovery. Automating this knowledge
discovery needs to focus on extracting useful patterns or relationships within large data
sets.
Literature-Based Discovery, is, in essence, a field focused on a blend of text
mining, information retrieval, and summarization in an attempt to answer questions
regarding the relationship between two concepts. Much of the work in these areas is
relevant and is covered within this chapter first, followed by a review of current research
within the field of LBD.
2.2 Text Mining
The process of discovering patterns in large data sets is termed data mining. Data
mining typically focuses on structured data stored within a database - looking for trends,
identifying clusters, frequently occurring sets, and so forth. A subtopic, text mining,
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makes use of many data mining techniques but instead looks for patterns among the
unstructured raw text of document collections.
In the simplest form a document collection, or corpus, can be any grouping of
text-based documents from a few to millions. An example of a well-used document
collection suitable for text mining is PubMed – the National Library of Medicine’s online
repository of biomedical research papers. To date PubMed contains over 28 million
document abstracts and is widely used by computer scientists in employing text mining
(Feldman and Sanger 2007).
As a research area, text mining incorporates techniques from other areas such as
information retrieval (IR) systems, natural language processing (NLP), and machine
learning combined into three different tasks: Information Retrieval, Question Answering,
and Text Summarization.

2.3 Information Retrieval
Information Retrieval can be defined as “finding material (usually documents) of
an unstructured nature (usually text) that satisfies an information need from within large
collections (usually stored on computers)” (Manning, Raghavan, and Schütze 2008). The
task itself is to find a subset of a larger collection which contains the desired information.
Most IR systems commonly extract meaningful words, concepts, or text fragments and
index the entire corpus in advance to avoid having to linearly scan all text in response to
a query.
The IR system also provides a search system containing a user interface or query
language. A user can express their needs by means of search primitives that can be
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understood by the system. The user query is then translated into a query that can be
executed by the underlying system. For example, a user may request information about
Fish Oils via the provided interface. If the IR system makes use of a Relational Database
Management System (RDBMS) this might be converted into a SQL query that
specifically looks for the given text within both the titles and abstract fields: SELECT
DocumentIds From SomeTable WHERE (Title LIKE ‘%Fish Oils%’ OR Abstract
LIKE ‘%Fish Oils%’).

A second example that is frequently utilized for text processing

is Apache Solr coupled with Apache Lucene. A similar query using a solr-based system
might look like: Title:“Fish Oils” OR Abstract:”Fish Oils”.
Once the system queries are executed against the indexed corpus, matching results
are returned to the user ordered by relevancy. Despite the power of such systems one
drawback is that users must look through potentially large volumes of results to find
relevant information. The combination of document indexing and search engines can
quickly find you documents whose content best matches your query - if the information is
all contained within a single document. This can be problematic when the information
desired is spread across multiple documents. A user must therefore already know exactly
what they are looking for and sift through the multitudes of results or continually
reformulate their queries in an ad hoc fashion to search for all the pieces to the puzzle. An
area of research known as Question Answering has techniques to help address these
limitations.
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2.4 Question Answering
Unlike the traditional Information Retrieval approaches, Question Answering
(QA) attempts to provide users with precise answers to their questions instead of
providing a large number of documents that are potentially relevant. To do so, QA
systems consist of three distinct phases: question processing, document processing, and
answer processing. These phases use a combination of Information Extraction and
Natural Language Processing techniques (Athenikos and Han 2010).
The question processing phase works much like Information Retrieval systems in
that they interpret the user’s input and translate it into an internal query. However, there
may be additional linguistic processing of the user query to determine the type of
question being asked and the expected answer type. Additional steps may also include
Named Entity Recognition (NER) to identify keywords or concepts.
In the second phase, Document Processing, the internal query is used to fetch a set
of resulting documents. The system attempts to select specific sections from the resulting
documents (termed candidate answer passages) that are most relevant to the query. To
accomplish this many QA systems make use of semantic knowledge in a combination of
named entity recognition and word/query disambiguation.
Named entities can be identified via the use of domain specific ontologies such as
Medical Subject Headings (MeSH) which is the National Library of Medicine’s (NLM)
controlled vocabulary thesaurus used with PubMed, and will be described in more detail
later. Systems like this are useful to both identify key terms for indexing articles but also
to identify when there may be more than one name for the same thing, such as
Epoprostenol and Prostacyclin.
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Another type of useful semantic source is WordNet, a large lexical database of
English. Within WordNet different parts of speech are grouped into sets of cognitive
synonyms (Athenikos and Han 2010). Consider an information retrieval search of the
word “iron”, here, possible results may include metals, golf clubs, and laundry services.
Identifying how a word is being used (noun vs verb) and the words with which it keeps
company (context) can help determine relevancy of search results.
Inclusion of semantic information can ensure that when a user searches for
Epoprostenol that the results also include documents that talk about Prostacyclin, or that
a search about Magnesium deficiency, might also include results with hypomagnesaemia.
In addition, a search of “iron oxide” likely means a user is not interested in oxides and
their use within laundry.
In the answer processing phase the candidate answers are then matched against
the expected answer types specified and then ranked according to matching scores as
determined by the search.
As a whole, Question Answering is considered an effective, but more challenging
task than information retrieval. It necessitates additional processing during corpus
indexing and processing of user queries. Furthermore, semantic knowledge systems tend
to be domain specific and thus cannot necessarily be applied across diverse texts. When
considering complex problems it can be challenging for a user to identify the best queries
to use, these techniques attempt to do some of that work for the user.
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2.5 Text Summarization
Text summarization is designed to combat the problem of large result sets by
providing a concise overview of the information from one or multiple documents in
either a textual or graphical summary (Mishra et al. 2014; Mani 1999). In general,
automatic text summarization can be categorized into several different types, each
described based on its input type (single or multi document), the output type (extraction
or abstraction), and the approach (Statistical, Latent semantic analysis, Natural Language
Processing, and others) (Yogan 2016).
Most of the initial research in this area focused on single document extractive
summarization (Aliguliyev 2009; Ko and Seo 2008). Extractive summarization works by
identifying the most important sections of the original text and compiling them together.
With the alternative, abstractive summarization, the system attempts to paraphrase the
content by means of natural language processing (Ganesan et al., 2010; Khan et al., 2015;
Allahyari et al. 2017). There has been less work in this area due to its complexity, but
there has been a growing interest in multi-document summarization. This is likely due to
the volume of information available and that relevant information is often scattered
among multiple sources (Mishra et al. 2014).

2.5.1 Statistical Text Summarization
Statistical implementations are typically based on the early works of Luhn, Spärck
Jones, and Edmundson. Luhn proposed that more important words will be repeated
within a document more often than others - this measurement became known as Term
Frequency (Luhn 1958). Karen Spärck Jones later created a second measure called
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Inverse Document Frequency (IDF) to account for the idea that if a word shows up
repeatedly in many documents then it loses meaning by being too general (Spärck Jones
1972). A common approach is to use the combination of both, entitled Term Frequency
Inverse Document Frequency (TF-IDF). Consider a single document that contains
“Hypomagnesemia” many times. In this case, it is likely that it is a central point of that
document. Whereas the word “patients”, which despite appearing in large numbers across
many documents, has far less useful meaning.
TF-IDF(w,d):= TermFrequency(w,d) x InverseDocFrequency(w)

(2.1)

|Corpus |
)
DocFrequency(w)

TF-IDF(w,d):= TermFrequency(w,d) x log(

Although there are multiple variations, a simple form of the TF-IDF is shown in Equation
2.1. The first variable, TermFrequency, is a function of term w and document d. For a
given term and document, it is the number of times that w appears within d divided by the
total number of terms contained within d. The second variable, InverseDocFrequency, is
the log of the total number of documents within the corpus divided by the number of
documents that contain the term w.
As an example, suppose our corpus consists of two documents (Table 1). The first
document, d1, contains the text “example: this is an example” and the second, d2, “this is
a second sample”. The term frequency of a term is calculated for a given document, and
is equal to the number of times that particular term appears within that document divided
by the total number of terms for the document.
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Table 1. Example term counts for two documents
d1
Term

d2
Term Count

Term

Term Count

this

1

this

1

is

1

is

1

an

1

a

1

example

2

second

1

sample

1

The term frequency of the term “example” for each document is calculated as follows:
term count("example", d1) 2
= = 0.4
5
total terms(d1)
term count("example", d2) 0
tf("example", d2) =
= = 0
5
total terms(d2)

tf("example", d1) =

The inverse document frequency is calculated once for the entire corpus and represents
the ratio of documents that include that particular term. For the term “example”, it would
calculated as follows:
# of documents
2
idf("example") = log(
) = 𝑙𝑙𝑙𝑙𝑙𝑙( ) = 0.301
1
# of documents with term

If we examine the idf of the term “this” we find that since every document in our corpus
contains this word, thus the idf equates to zero:
# of documents
2
idf("this") = log(
) = 𝑙𝑙𝑙𝑙𝑙𝑙 ( ) = 0
2
# of documents with term
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This implies that the word is not very informative as it appears in all documents. The
measure of tf-idf appears often within statistical text mining when considering individual
terms, but doesn’t account for sentence level constructs.
An intuitive approach to determine the importance of a sentence is to first identify
the characteristics that highlight the relevance of the sentence. In 1969, Edmundson
defined features which reflect the relevance of a sentence such as the sentence position
and the presence of title or cue words (Edmundson 1969). For title words, the idea is
simple: as the title is the most succinct summary of the document by its authors,
sentences that contain words that also occur within the title are likely to be more
important. This is in contrast to cue words, which are not important by themselves but
rather signify that something else is more likely to be important. Adjectives and adverbs
like “significant”, “irrelevant”, “impossible”, and others are applied in text to highlight
the neighboring word or phrase to the reader. Thus, if a list of such words is provided to a
summarization system it can be used within the scoring process. Each sentence is then
ranked based upon some scoring algorithm such as in Equation 2.2.
𝑛𝑛

Score = � 𝑤𝑤𝑤𝑤 × 𝑓𝑓𝑖𝑖

(2.2)

𝑖𝑖 = 1

where wi is the weight of a particular feature and fi is the score of that feature. Each
sentence will receive a score based upon all of its features, and the document summary is
produced from the highest valued content. Note that although specific words may be
called out (such as cue words, stop words, title words, etc.) only statistical properties,
relative positioning, and existence are examined in those methods.
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2.5.2 Latent Semantic Analysis
Latent Semantic Analysis (LSA) is a method that attempts to identify the
underlying meaning of a document. In other words, it extracts the relationships between a
set of documents and the terms they contain. This might be simple if a given term
described only a single concept, and a concept could always be described by a single
term. But natural languages have many situations where this is not the case. Thus the idea
behind LSA is that “the aggregate of all the word contexts in which a given word does
and does not appear provides a set of mutual constraints that largely determines the
similarity of meaning of words and sets of words to each other” (Landauer, Foltz, and
Laham 1998). For example, the word “bank” in English can refer either to a financial
institution or to the land alongside a river. If a document contains the word along with
other words such as loans and interest then it likely refers to a financial institution, but if
the document also contains terms such as fishing and rivers then it refers to the second.
The algorithm first constructs an m x n matrix whose m rows represent each
unique term and n columns represent each document. Each entry within the matrix, ai,j is
the weight of the term i within sentence j, computed by TF-IDF. The next step applies a
linear algebra technique to the matrix called single value decomposition (SVD) which
factors the original matrix into several derived from its eigenvectors. If desired,
dimensionality reduction can also be applied during the SVD to retain only the k principal
eigenvectors. The result of this produces three new matrices U, Σ, and VT (See Eq. 2.3).
M = U Σ VT

(2.3)

If the original matrix, M, is m x n then U will be an m x m matrix, 𝛴𝛴 will be an m x n

diagonal matrix, and VT is an n x n matrix. The U matrix contains the representation of
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each term within a concept space, the VT matrix contains the representation of each
document within the concept space, and the 𝛴𝛴 matrix represents the overall weight of
each concept.

Although LSA has been mainly used in the context of Information Retrieval,
returning answers that contain the concept of a user’s query if not the exact terms, it has
also been used within document summarization. Initially proposed by Gong and Liu,
instead of applying the LSA algorithm to terms within documents, it can instead be
applied to individual sentences within a document (Gong and Liu 2001). In their work
the matrix D = Σ VT describes how much any given sentence represents a topic where di,j

is the weight of concept i within sentence j.

2.5.3 Natural Language Processing
Natural Language Processing (NLP) attempts to recreate a more human-like
understanding of language. Each NLP implementation typically focuses on one or more
levels of language processing such as Phonology, Morphology, Lexical, Syntactic,
Semantic, Discourse, and Pragmatic (Liddy 2001). When applied to text processing
generally only lexical, syntactic, and semantic techniques are considered. This is mainly
due to the fact that phonology studies audible sounds, morphology analyzes the
compositions of individual words, discourse examines text at a multi-sentence
granularity, and pragmatic levels require a level of world knowledge to interpret the
context of words.
Lexical and syntactic parsing allows for the identification of words and phrases,
parts of speech tagging, and the ability to perform disambiguation tasks. In many cases
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approaches frequently make use of domain-specific knowledge sources to help in this
regard such as using controlled vocabularies to generate index terms or to produce a
summary. For example, within the biomedical area the UMLS Metathesaurus (Lindberg
et al. 1993) is used to link similar names for the same concept from nearly 200 different
vocabularies allowing systems to recognize that two papers might be talking about the
same subject (e.g. one document using the term “dyspnea” while another states
“shortness of breath”) (Verma et al. 2007).
Semantic NLP approaches can be more challenging as they attempt to discern the
meaning of the text. Not only does this leverage vocabularies to identify known terms but
also requires some understanding of the relationships between them. One tool of note,
SemRep, extracts semantic predications (subject-predicate-object triples) from raw text
(Rindflesch and Fiszman, 2003). SemRep was developed within the biomedical research
domain and uses domain knowledge provided by the UMLS, where its generated
predications contain “textual content with semantic predications consisting of UMLS
Metathesaurus concepts as arguments and UMLS Semantic Network relations as
predicates” (Kilicoglu et al. 2008). With the use of the tool, sentences are transformed
into any number of assertitional predications. These predications have been subsequently
used to build abstractive summarizations in the forms of graphs (Fiszman, Rindflesch,
and Kilicoglu 2004). Within the graphs, each vertex represents a concept while the edges
represent the relationships between two concepts.
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2.6 Literature Based Discovery
LBD is considered a more complex aspect of text mining or information retrieval
(Berry and Castellanos 2004; Smalheiser 2012). Not only does it involve identification
and extraction of salient information from text but seeks to uncover novel crossdocument associations that have never been publicly published (Ganiz et al. 2005;
Swanson 2008).
2.6.1 Literature Based Discovery Modes
The majority of LBD approaches are built upon a paradigm now referred to as the
ABC discovery model (Swanson 1987; Weeber et al. 2005; Smalheiser 2012). This
model states that new knowledge can be discovered between two concepts (A, C) from
non-interacting literatures, if hidden associations involving some intermediate concept
(B) can be uncovered (Swanson 1986). This is simply the transitive property of relations;
in other words, if an object A is associated with a second object B and that object B is
associated with a third object C, then it can be inferred that first object, A, is associated
with object C in some manner (Figure 3). These “B” concepts are frequently called
intermediate terms.

Figure 3. ABC Model

Figure 4. AnC Model
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The ABC model was later generalized by Wilkowski et al. where they proposed
an extension where several intermediate concepts may be required to connect the A and C
concepts (Wilkowski et al. 2011). This extension of Swanson’s ABC model is referred to
as the AnC model wherein n = {B1, B2, ... , Bm} (Figure 4). The work of this dissertation,
and the work by Cameron et al. (Cameron et al. 2015), are based off Wilkowski’s AnC
model.
Although Swanson’s work provided an explanation for his observations it did not
propose any framework for finding such connections. As such, subsequent LBD research
has begun to investigate better, and more automated, techniques and tools.
The ABC and AnC models have been implemented within LBD research in two
modes: open and closed discovery. Open discovery is the embodiment of hypothesis
generation and has been implemented in various approaches (Srinivasan 2004; Pratt and
Yetisgen-Yildiz 2003; Weeber et al. 2001; Wren et al. 2004; Frijters et al. 2010). It
assumes that the user begins with only a single concept (A) from their research questions
and they propagate outward via associations to an unknown target concept C by means of
one or more intermediate objects (Figure 5).
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Figure 5. Open Discovery Mode

Closed discovery, in comparison, is characterized by testing one’s hypothesis and
has also been widely implemented (Smalheiser, Torvik, and Zhou 2009; Srinivasan 2004;
Hristovski et al. 2006; Hu et al. 2005; Gordon, and Dumais 1998; Ahlers et al. 2007;
Cameron et al. 2013; Cameron et al. 2014; Lindsay and Gordon 1999; Weeber et al.
2001). Within a closed discovery approach, typically both the source concept A and
target concept C are known, but not necessarily the intermediate(s). These are instead
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discovered via an exploration from both ends to determine potential interesting
intermediates (Figure 6).

Figure 6. Closed Discovery Mode
Regardless whether an LBD implementation is designed for open or closed
discovery the algorithms used to determine intermediate candidates have included a
variety of approaches including statistical, knowledge-based, semantic-based, citationbased, and others.

2.6.2 Statistical Literature Based Discovery
The earliest LBD approaches established links between disjoint knowledge by
looking for the most frequently co-occurring intermediate terms across documents
utilizing statistical frequencies or distributions (Gordon and Lindsay, 1996; Lindsay and
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Gordon, 1999; Gordon, Lindsay, and Fan 2002). The conventional wisdom was that
discoveries are likely to arise from logical connections between terms or concepts that
frequently (co)occur within literature. The intermediate terms are then ranked based on
some relative frequency and presented to a researcher. While many of these techniques
have been used to successfully discover (Swanson 1986; Swanson 1988), or recover
previously discovered ones using a different approach (Gordon et al. 2002; Gordon &
Dumais 1998; Gordon and Lindsay 1996; Lindsay and Gordon 1999), several problems
exist. The reliance on statistical measures from text will favor co-occurring terms and
potentially miss associations from less frequent terms (Kostoff et al. 2009). Furthermore,
the statistics will be flawed in regards to Biomedical and Chemical entities that can be
expressed in a variety of forms such as chemical names (Krallinger, Rabal, Lourenço,
Oyarzabal, and Valencia 2017). In addition, these approaches rely on the researcher’s
domain expertise and their ability to eliminate noise (terms that are too general or
irrelevant) and refine their parameters.
Most existing approaches for LBD use feature extraction to determine what a
document is “about”. For example, a common approach for this type of textual analysis
makes use of counts and frequencies of tokens (words or phrases) as they appear. If a
particular token appears frequently within a particular document, it likely signifies
importance to the overall meaning of that document. Furthermore, understanding the
frequency across a collection of documents is also key. These relative frequencies give an
indication of a term’s statistical importance (Gordon and Lindsay 1996). A typical metric
used is TF-IDF (Sparck Jones 1972). Secondarily, the statistical approach can establish
links between different papers by looking for the most frequently co-occurring terms or
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concepts in those documents. This is achieved by computing the statistical distributions
and frequencies of the terms without consideration of their semantics (Lindsay and
Gordon 1999).
Understanding the contextual information of a document may also illustrate an
implicit association of concepts. If there is a large number of sources that associate two
topics A and B together, and also a great number of sources that associate two topics B
and C together. Then, it is plausible there is some association between A and C as well.
Some developed strategies and tools to generate semantic associations between terms or
compiled manual annotations. (Srinivasan 2004; Yetisgen-Yildiz and Pratt 2006; Ahlers
2007; Frijters et al. 2010) Other work has utilized some of those strategies and direct
mining to formulate testable hypotheses in specific areas through a series of manual
steps. (Weeber et al. 2003)
The primary limitation of approaches using term co-occurrence is that although it
can find intermediate concepts, it does not provide the relationship of those concepts. For
example, the concepts of Reynaud Syndrome and platelet aggregation might be found,
but not that platelet aggregation causes Reynaud Syndrome. In addition, these approaches
break down if there is more than one level of separation between the initial and final set
of concepts. That is to say that there might be relevant information that exists in longer
chains of concepts that are semantically connected.

2.6.3 Knowledge Based Literature Based Discovery
A criticism of purely statistical approaches is that domain expertise is necessary to
help refine a search, filter datasets, or extract plausible final results. In many cases it is
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entirely left up to the researcher to employ such knowledge when interpreting results.
However, within domain-specific knowledge repositories some of this expertise is “baked
in” ahead of time so to speak.
The knowledge-based approach gains its strength from the usage of additional
knowledge-based resources such as vocabularies, databases, and ontologies. It is also
quite common to find the usage of natural language processing as a basis of extraction
(Weeber, Kors, and Mons 2005).
Knowledge-based approaches can prioritize terms according to specific semantic
types, removing very general ones and targeting others (Hu, Yoo, Song, Zhang, and Song
2005). Thus a more refined set of potential intermediate terms are generated which satisfy
a set of researcher’s provided predefined semantic types.
An additional benefit that arises from these techniques is that variations in
terminology and nomenclature can be recognized - that is to say, synonyms (different
terms to designate the same concept) and homonyms (the use of words/phrases with
multiple meanings). “For instance, IL-12, IL12, interleukin 12, CLMF, cytotoxic
lymphocyte maturation factor, and natural killer cell stimulatory factor all refer to the
same concept: Interleukin-12” (Weeber et al. 2003). Purely statistical approaches won’t
draw connections between the variations, but normalizing extracted terms by means of a
thesaurus or ontology allow them to be treated as a single term.
Fundamentally, knowledge sources can be subdivided into two broad categories
based on the type of knowledge they contain. These two categories are: 1) definitional
knowledge and 2) assertional knowledge.
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2.6.3.1 Definitional Knowledge
Definitional knowledge refers to information that can be considered facts within a
particular domain. In many cases these sources exist in the form as vocabularies,
ontologies, or a database of facts. One such example within the biomedical domain is the
UMLS Metathesaurus.
The UMLS Metathesaurus is a large biomedical thesaurus from the National
Institute of Health that is organized by concept and links similar names for the same
concept from nearly 200 different vocabularies and is comprised of close to 3 million
unique concepts.
Figure 7 shows a small portion from this dataset. In this snippet the first segment
is the unique UMLS Concept identifier (C#) while other portions provide the
corresponding identifier in other vocabularies such as MeSH, represented in these
examples as D#. For example, in the figure Raynaud Disease is identified by C0034734
and Raynaud Phenomenon is identified by C0034735 within the MetaThesaurus but are
both associated with the same MeSH concept D011928.
C0034734|ENG|S|L1446659|PF|S0974677|N|A3500400||M0018534|D011928|MSH|MH|D011928|Raynaud Disease|0|N||
C0034735|ENG|P|L1970983|PF|S0974685|N|A3486562||M0449202|D011928|MSH|PEN|D011928|Raynaud Phenomenon|0|N||

Figure 7. Sample entries from the UMLS Metathesaurus
A second frequently used source is Medical Subject Headings (MeSH), which is a
controlled vocabulary of biomedical terms from over 5000 biomedical journals organized
into 16 hierarchical structures - each belonging to a different category such as Anatomy,
Organisms, Diseases, Chemicals, and others. MeSH has been utilized within LBD
research to map text to known structured knowledge and to provide implicit context
between co-occurring concepts. It also has been widely used to index, catalog, and search

31

MEDLINE articles. To accomplish this, MeSH descriptors are manually assigned to
scientific articles by domain experts. “The quality of these assignments is considered
high and relatively good indicators of the semantics of the content of the article to which
they are assigned” (Cameron 2014).

2.6.3.2 Assertional (Semantic) Knowledge
Assertional knowledge refers to statements, predicates, and assertions that have
been mined from scientific literature. Within the biomedical domain, processes are
“inherently composed of interactions between various types of entities” (Bakal, Talari,
Kakani, and Kavuluru 2018). Usually these statements are captured by an NLP tool, such
SemRep from the National Institute of Health, as binary interactions connecting a subject
entity to an object entity by means of some relation or predicate (subject-relation-object).
SemRep matches subject and object terms with UMLS Metathesaurus concepts and the
predicates from a list of types within the UMLS Semantic Network. An example, shown
in Table 2, where the tool extracts a list of predicates from the given source text.
Table 2. SemRep generated predicates from example source text
Source Text:
“We used hemofiltration to treat a patient with digoxin overdose that was complicated by
refractory hyperkalemia”
Extracted predicates:
●
●
●
●

Hemofiltration-TREATS-Patients
Digoxin overdose-PROCESS_OF-Patients
hyperkalemia-COMPLICATES-Digoxin overdose
Hemofiltration-TREATS(INFER)-Digoxin overdose
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SemMedDB is a repository by the NIH consisting of semantic predications extracted
from the titles and abstracts of Medline documents by the SemRep tool.

2.6.4 Semantic Based Literature Based Discovery
Traditional knowledge-based implementations that utilize definitional knowledge
can provide improvements over standard statistical approaches, but they do not provide
insights into the meaning of these associations. For example, in regards to the treatment
of diseases, “drug therapies are often used effectively, even though the exact cause of
action may be either poorly understood or unknown” (Ahlers, Hristovski, Kilicoglu, and
Rindflesch 2007). Although providing a new novel association is ‘better than nothing’,
LBD systems should strive to offer insight into the meaning of relationships as well.
Several attempts have been made to employ semantic predicates to perform
automatic abstractive summarization (Fiszman and Rindflesch 2004; Plaza, Díaz, and
Gervás 2011). These approaches have chosen to represent their summaries using concepts
rather than words and presenting the result as an interconnected graph. Traditionally
graph-based summarization methods usually represent the documents as graphs where the
vertices correspond to text units such as words, phrases, or sentences, and the edges
represent a form of similarity (Plaza, Díaz, and Gervás 2011).
In 2015, Cameron et al. devised a context-driven LBD approach based upon the
earlier graph-based semantic summarization methods. Their method was a closeddiscovery approach: given a pair of concepts as user input their system automatically
generates a graph representing the semantic associations between the two concepts. These
graphs are then used to find semantically related pathways from one concept to another.

33

One of the main strengths of this technique is the ability to automatically extract
subgraphs that allow researchers to interpret the meaning of the displayed predication
pathways. In the study by Cameron et al. subgraphs were constructed with the use of a
hierarchical agglomerative clustering algorithm to group edges based upon their
similarity. For example one subgraph might illustrate how Fish Oils is connected to
Raynaud’s Disease by way of Blood Viscosity effects, while a second subgraph illustrates
this connection via Platelet Aggregation (Cameron et al. 2015).

2.6.5 Citation Based Literature Based Discovery
Bibliometric analyses in the field of scientometrics have shown that “the most
productive authors are the ones engaged in the most innovative and varied research [and]
in addition, these researchers draw from a larger pool of knowledge, indicating that they
may be moving more often from topic to topic.” (Milojevic 2012).
Studying the structure of how documents are interrelated is usually is focused on
citations. Several examples of which include direct citations, bibliographic coupling, and
co-citations. A direct citation is the simplest case where paper A cites paper B.
Bibliographic coupling link exists between two papers A and B when each cites a
common paper C. Lastly a co-citation link exists between two papers A and B when a
third paper C cites both of them. Additionally, there are other possible ways to consider
two references to have some type of link either involving citations or by other factors
such as having authors in common.
Kostoff was the first to explore bibliographic coupling within the field of LBD.
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Kostoff’s approach begins like many other LBD algorithms using a pair of terms (A,C)
and retrieving all the documents related to each. He then augments the list of records to
include additional bibliographically coupled documents before performing some
statistical based LBD algorithms. Results of his research indicate that shared references
between two disjoint literatures could harbor many useful linking terms. The primary
drawback of the technique is the labor intensive procedure and lack of automation
(Kostoff 2014).

2.7 Citational Coupling
Zhang, Ding, and Milojević state that it “has become a convention for scientists
and researchers to refer to earlier work that relates to, inspires or is used by their own
work” (Zhang, Ding, and Milojević 2013). This is in reference to an earlier document by
Nicolaisen wherein certain basic assumptions are made about citations. That is, the
citation of a document (1) implies the use of that document and (2) reflects the merit of
that document (Nicolaisen 2007).
Sentences that contain a citation to another document are typically referred to as
citation sentences, or citances. These sentences typically highlight the most important
aspects of the paper being cited. This includes the research problem it addresses, a
methodology, or the results. (Abu-Jbara and Radev 2011). The author of an article writes
their abstract as a summarization to convey the central ideas from their perspective.
Research has shown that citing sentences are a “collaborative summary that indicates
what other researchers found relevant, interesting, or novel about the article” (Elkiss et al.
2008). In bioscience literature it is common for the text around citations to state known
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biological facts with reference to the original papers that discovered them (Nakov,
Schwartz, and Hearst 2004).
Some studies have shown that the “information contained in the abstract and in
the citances overlap to a large extent” (Divoli 2012). To that end efforts have been put
into creating automatic summarization by using the citation sentences to build a second
“abstract” for a given document constructed from all the papers that have cited it. This
overlap between the meaning of the citation sentences and the abstracts of the cited
articles goes both directions. Many times full-text is not necessarily available, and only
titles and abstracts can be utilized. In these situations, it stands that the abstracts of cited
references can be used as an indicator of a document’s body.

2.8 Summary
Regardless of their implementation (i.e. statistical, semantic, etc.), LBD
approaches are a blend of text processing techniques including text mining, information
retrieval, question answering, and text summarization. Each seeking to understand and
extract salient details about documents to present the most likely connected information.
Studies into summarization techniques have shown that strong connections between
documents and those they cite such that they are semantically related. This paper
therefore theorizes that bibliographic citations can improve LBD implementations when
incorporated.
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Chapter 3
Methodology

3.1 System Design
The foundation for the proposed work relies on replicating the research performed
by Cameron and then incorporating citationally related documents to improve the results.
The foundation portion was completed first going so far as to produce a single graph of
all uncovered predicates between two concepts focusing on the Fish Oils - Raynaud
Disease study. This work was further extended wherein cited documents were added to
the corpus and citational information was included as an initial study to determine if the
hypothesis had merit. Due to the positive initial results subsequent retrospective
experiments were conducted.
A standard three tier architecture is utilized to process the requests (Figure 8).
Upon receiving the request from the client, the web tier constructs an appropriate internal
query for our in house search engine. The distributed search engine executes the queries
(Apache Solr and otherwise) across multiple instances over an HDFS cluster and returns
the query results.

Figure 8. Three tier architecture
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Chemical Abstracts, a division of the American Chemical Society, has multiple
software products that allow researchers to search patents, journals, and other sources for
chemically related information, including MEDLINE. Forms were added in an existing
product’s user interface where a researcher simply types in the concept(s) of interest.

3.2 Query Specification
Users need some method of querying the LBD system. For closed discovery
approaches they will need to specify at least one ‘A’ concept and at least one ‘C’ concept
for the AnC methodology described earlier. Whereas for open discovery only a single
concept is needed as a starting point to explore.

3.2.1 Query Specification (Open)
For open discovery, our interface allows the user to select a single concept from
within the corpus and the initial predicate type of interest such as affects, causes, treats,
and others (Figure 9).
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Figure 9. Example open subgraph query

3.2.2 Query Specification (Closed)
Following the AnC pattern the design of our closed discovery system requires a
query in the form of two sets of concepts. Our user interface for the closed query
specification can be seen in Figure 10. The first set (Source) corresponds to the “A” set,
and the second (Destination) to the “C” set. There are also additional configuration
options to specify the desired path length, if citational information should be used, and if
the user wishes to only return paths that pass through a particular intermediate.
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Figure 10. Example closed subgraph query

3.3 Preprocessing
Cameron’s closed discovery implementation (Cameron et al. 2015) is the basis for
our approach, where the essential idea is to search all documents within the corpus that
contain at least one of the terms provided (MeSH or UMLS) and to use semantic
predications from those documents to build graphs. To accomplish this we need to have
several distinct types of data: 1) we need to process a collection of MEDLINE documents
and identify what concepts are contained within those documents, 2) we need to process
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document citations to expand our document results, and 3) we need to identify what
predicates are contained within those documents.
All MEDLINE (currently over 29 million) documents along with their basic
information were already available at Chemical Abstracts in the form of xml files
available via HDFS. This includes the title, abstract, authors, and indexed MeSH
concepts as defined within PubMed. Documents within PubMed are only abstracts and,
in general, do not contain information on their references. According to the National
Institute of Health 37% of records added in the last five years contain full text (stored in
PubMed Central) that is freely available. In these cases, the cited references were also
available within the xml records, unfortunately, for our studies we found that less than
one in ten fit this category. As such, when citational associations were not available this
information was added manually for each study. Additionally, in a small number of cases
the PubMed record was also missing an abstract - for these, the abstracts were gathered
from Publisher websites. This is indicated appropriately for each document within the
appendix corresponding to each research study.
The predicate information was acquired from the National Institute of Health as
an export of the SemRep tool. It is periodically run against the entire MEDLINE database
which contains titles and abstracts, and the download is provided via their website. The
export can be placed into the form of csv text files for processing. In cases where the
abstract was missing from the MEDLINE database, the tool was run manually on the
abstract/introduction when found and the information added. Figure 11 shows a small
portion from this dataset, where each entry identifies a unique relationship between two
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concepts from the UMLS Metathesaurus and which document and sentence it was
derived from.

"5306041","32399885","1","1296760","STIMULATES","C0024467","Magnesium","bacs","true","C
0033567","Epoprostenol","bacs","true"
Field
Field
Field
Field
Field
Field
Field
Field
Field
Field
Field
Field
Field

1: "5306041" - Auto-generated primary key for each unique predication
2: "32399885" - Foreign Key to a table of sentence information
3: "1" - The number of times the predication is extracted from the sentence
4: "1296760" - Medline Document ID
5: "STIMULATES" - Predicate Semantics
6: "C0024467" - Subject UMLS Concept ID
7: "Magnesium" - Subject Concept Name
8: "bacs" - Subject Semantic Type
9: "true" - Subject Novelty based on distance from root in UMLS Metathesaurus
10: "C0033567" - Object UMLS Concept ID
11: "Epoprostenol" - Object Concept Name
12: "bacs" - Object Semantic Type
13: "true" - Object Novelty based on distance from root in UMLS Metathesaurus

Figure 11. Sample entry from the SemRep DB export

In our implementation, as is typical in search engines, we make use of an offline
compilation process to pre-process our data (Figure 12). Using Hadoop/Cascading we
extract data from the formatted text (XML or CSV), parse the information, and then treat
individual records as tuples. To be able to execute our queries, we then need to identify
the classifications of data and how they are associated with each other. Thus, we need to
identify documents, MeSH concepts, UMLS concepts, predicates, and their underlying
relationships. By constructing this information during offline compilation we can build
necessary solr indexes for searching and pre-defined mapping relationships such as
“Document A cites Document B” which allow the queries to project from a given result
set to another. Later, using our internal syntax we can perform an online solr query for a
particular concept identifier then cross reference for all documents related to the results
of the query.

42
// Extracts Tuples from source files
Pipe referencePipe = new ReferenceExtraction(referenceInput);
Pipe predicatePipe = new PredicateExtraction(predicateInput);
Pipe meshPipe = new MeshExtraction(meshInput);
Pipe umlsPipe = new UmlsExtraction(metaThesaurusInput);

//each
//each
//each
//each

Reference
Predication
MeSH Concept
UMLS Concept

/* Calculates the Context for each Reference. That is, the MeSH Tree #s of all MeSH
terms for that reference.*/
Pipe referenceContextPipe = new ReferenceContext(referencePipe, meshPipe);
/* Each UMLS Concept already has its MeSH Concept ID from the MetaThesaurus entry where
it was extracted if it exists. However, here we merge in the corresponding MeSH
TreeNumbers.*/
umlsPipe = new UmlsMeshMergeAssembly(umlsPipe, umlsPipe);
//Calculate the IDF for each UMLS Concept as they appear from predications.
umlsPipe = new CalculatePredicateIDF(umlsPipe, predicatePipe);
/* Determine the context of a predicate as the summation of the reference contexts from
all references where that predicate has been extracted.*/
predicatePipe = new PredicateContextAssembly(predicatePipe, referenceContextPipe);
//For each predicate merge in the MeSH TreeNumbers and UMLS Concept IDF scores.
predicatePipe = new PredicateMeshAssembly(predicatePipe, umlsPipe);
//Construct solr Searchable/Indexed objects for query-time searching later.
Pipe predicateIndexedEntry = new ConstructPredicateEntity(predicatePipe);
Pipe referenceIndexedEntry = new ConstructReferenceEntity(referencePipe);
Pipe umlsIndexedEntry = new ConstructUmlsEntity(umlsPipe);
Pipe meshIndexedEntry = new ConstructMeshEntity(meshPipe);
//Construct relationships to allow projections between object types.
Pipe umlsToMeshRelationshipPipe = new ConstructUmlsToMeshRelationship(umlsPipe);
Pipe predToDocRelationshipPipe = new ConstructDocToPredRelationship(predicatePipe);
Pipe predToUmlsRelationshipPipe = new ConstructUmlsToPredRelationship(predicatePipe);
Pipe meshToDocRelationshipPipe = new ConstructMeshToDocRelationship(referencePipe);
Pipe DocToDocRelationshipPipe = new ConstructCitationRelationship(referencePipe);

Figure 12. Example Hadoop code to prepare searchable digest

3.4 Closed Search Algorithm
Closed search is the most common among LBD implementations (Ahlers,
Hristovski, Kilicoglu, and Rindflesch 2007; Cameron et al. 2013; Gordon and Dumais
1998; Hristovski, Friedman, Rindflesch, and Peterlin 2006; Lindsay and Gordon 1999;
Smalheiser, Torvik and Zhou 2009; Srinivasan 2004), namely because it applies the most
constraints and, as such, makes the results more narrow and meaningful. Our general
approach follows the same basis as described by Cameron et al in their paper (2015).
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● Step 1 - User specifies “A” and “C” sets of concepts, a maximum path length k,
and a date Dt.
● Step 2 - Define the set D as all pubmed IDs published before Dt which contain
any concept from set A or set C.
● Step 3 - Define G and R as an empty graphs and the set S as empty.
● Step 4 - For each pubmed id d ∊ D, add all predicates from d as edges into the
graph G.

● Step 5 - For all pairs of concepts (a,c) ∊ A x C, determine all possible paths

between concept a and concept c of maximum length k inside G. All these to R.

● Step 6 - Divide the graph R into smaller subgraphs, adding each into S.
● Step 7 - Sort the collection S of subgraphs by ranking.

Next we discuss our approach to the closed query formulation, leaving a discussion
regarding subgraph generation and scoring algorithms for later in the chapter.

3.4.1 System Query Construction
Our query process is summarized in the steps below, diverging from a
generalization of Cameron’s algorithm only by adding steps 3 and 4 where the list of
documents may optionally be expanded to also include any additional references that the
initial set has cited. For each resulting document in step 5, we want to collect all defined
semantic predicates.
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● Step 1 - User specifies “A” and “C” sets of concepts.
● Step 2 - Define the set S as the set of all documents within the corpus that contain
at least one of the terms.
● Step 3 - (Optional) Define the set S’ as the set of all documents cited by
documents within the set S.
● Step 4 - Define the resulting set of documents S’’ = S ∪ S’

● Step 5 - Define the set of predicates P as the set of all predicates defined for each
document in S’’
● Step 6 - Create resulting graphs from the predicates within P.

Steps one through five are formulated within a system query. Using the Fish Oil-Raynaud
Syndrome study as an example, Figure 13 shows the portion of the system query which
searches for the UMLS and MeSH concepts.
query = 'UMLS_CONCEPT_NAME: "Fish Oils" | UMLS_CONCEPT_NAME: "Eicosapentaenoic Acid" |
UMLS_CONCEPT_NAME: "Raynaud Disease" | UMLS_CONCEPT_NAME: "Raynaud Phenomenon" '
exploreQuery("subgraphTextQueryId") { solr(q: query) }
//Search UMLS Concepts for the above query terms
entity("umlsconcept") {
identifier 'UMLS_QUERY_ID'
search("solr") { queryId subgraphTextQueryId" }
}
//Find corresponding MeSH terms for the provided search concepts (UMLS)
entity("mesh") {
identifier 'MESH_QUERY_ID'
constraint {
type "PROJECTION"
projection {
relationshipName "umls_to_mesh"
sourceIdentifier "UMLS_QUERY_ID"
}
}
}

Figure 13. Step 1 – Search for concepts

When executed, the results return a total of four UMLS concepts, and three MeSH
concepts. This is because both Raynaud Disease (C0034734) and Raynaud Phenomenon
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(C0034735) within the UMLS are mapped to the single MeSH concept Raynaud Disease
(D011928) (Figure 14).
Retrieved umlsconcept results: (4)
[UMLS_CONCEPT_ID:[C0000545], UMLS_CONCEPT_NAME:[Eicosapentaenoic Acid],
MESH_ID:[D015118], INV_DOCUMENT_FREQ:[8.333311917991818]]
[UMLS_CONCEPT_ID:[C0016157], UMLS_CONCEPT_NAME:[Fish Oils], MESH_ID:[D005395],
INV_DOCUMENT_FREQ:[8.119986372349722]]
[UMLS_CONCEPT_ID:[C0034734], UMLS_CONCEPT_NAME:[Raynaud Disease], MESH_ID:[D011928],
INV_DOCUMENT_FREQ:[9.758878686545028]]
[UMLS_CONCEPT_ID:[C0034735], UMLS_CONCEPT_NAME:[Raynaud Phenomenon], MESH_ID:[D011928],
INV_DOCUMENT_FREQ:[8.87448928343275]]
Retrieved mesh results: (3)
[DESCRIPTOR_IDENTIFIER:[D005395], DESCRIPTOR_NAME:[Fish Oils],
MESH_TREE_NUMBER:[D10.627.430]]
[DESCRIPTOR_IDENTIFIER:[D011928], DESCRIPTOR_NAME:[Raynaud Disease],
MESH_TREE_NUMBER:[C14.907.617.812]]
[DESCRIPTOR_IDENTIFIER:[D015118], DESCRIPTOR_NAME:[Eicosapentaenoic Acid],
MESH_TREE_NUMBER:[D10.212.302.380.410.385
D10.251.355.255.200
D10.251.355.337.290
D10.627.430.450.390]]

Figure 14. Results of step 1 system query

Although MEDLINE documents have MeSH concepts assigned to them directly,
content curators will only mark those concepts which are deemed significant. This is in
contrast to SemRep predications that use UMLS concepts, which are extracted via NLP.
As either approach might miss the presence of a topic, the second step requires fetching
the appropriate references for our search terms from either of these initial sets. The query
is a simple projection (Figure 15).
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//Find which predicates contain the given UMLS Concepts
entity("predicate") {
identifier 'PREDICATE_QUERY_ID'
constraint {
type "PROJECTION"
projection {
relationshipName "predicate_to_umls"
sourceIdentifier "UMLS_QUERY_ID"
}
}
}
//Find set of references S which contain EITHER the MeSH term or a predicate
//which contained the UMLS Concept.
entity("reference") {
identifier 'REFERENCE_QUERY_ID'
constraint {
type "PROJECTION"
projection {
relationshipName "reference_to_mesh"
sourceIdentifier "MESH_QUERY_ID"
}
}
constraint {
type "PROJECTION"
projection {
relationshipName "predicate_to_document"
sourceIdentifier "PREDICATE_QUERY_ID"
}
}
or()
}

Figure 15. Step 2 – Search for the set S of references

For each retrospective study we collected together the MEDLINE articles cited by the
original LBD paper. We will refer to these as core papers as they were directly cited by
the LBD researcher. Then, for each core paper, all cited MEDLINE papers were also
added to our corpus. Although each of the studies focused on different areas, some
overlap was found. This is due to both the inherent interconnectedness of biomedical
science as well as later LBD papers citing earlier work.
Our example query results in a total of 193 documents from our corpus (Figure
16). Those marked in red are from the Fish Oils-Raynaud Disease study and comprise the
majority of the hits as expected. Those in blue come from a study around MagnesiumMigraine Disorders, those in green come from a study about the Obesity Paradox, and
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those in yellow are from the Somatomedins-Arginine papers. Additionally, bold pubmed
id numbers are from a core paper and those in italics were cited from a core paper but are
directly hit by the search terms.
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Figure 16. Results of step 2 system query

Later, in chapter four, when we discuss each retrospective study we will examine the
effectiveness of closed discovery and ensure that no results are skewed to this overlap.
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The next step of our process gathers all of the cited references from these 193
documents. The query is shown in Figure 17 and yields a total of 520 documents within
our corpus.
entity("reference") { //The set of references S’ = cited by the set of references S.
identifier 'CITED_REF_QUERY_ID'
constraint {
type "PROJECTION"
projection {
relationshipName "reference_to_cited_reference"
sourceIdentifier "REFERENCE_QUERY_ID"
}
}
}

Figure 17. Step 3 – Search for the set S’ of cited references

In total this makes 561 unique references as many papers have overlapping references.
The fifth step of the query takes this list of references and collects the predicates that
were extracted from those documents via SemRep (Figure 18). For our example study
this amounted to 2097 predicates.

entity("predicate") { //Find the set of unique predicates that come from either S or S’
identifier 'SUBGRAPH-QUERY-RESULTS'
constraint {
type "PROJECTION"
projection {
relationshipName "predicate_to_document"
sourceIdentifier "REFERENCE_QUERY_ID"
}
}
constraint {
type "PROJECTION"
projection {
relationshipName "predicate_to_document"
sourceIdentifier "CITED_REF_QUERY_ID"
}
}
or()
}

Figure 18. Steps 4 and 5 – Search for predicates from the union of S and S’
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3.4.2 Closed Graph Generation and Display
Our system query results will be a list of all predicates that have been derived
from the documents related to the original query. For closed discovery, graph algorithms
are then applied to distill all possible paths up to the specified length between the
concepts of the A set and the concepts of the C set. Then, one or more directed
predications graphs are created in which nodes are UMLS concepts and edges are UMLS
predicates. An example graph can be seen in Figure 19.

Figure 19. All paths of length two between Magnesium and Migraine Disorders

For ease of implementation, the points of the graph are distributed randomly in a
three dimensional box with edges drawn between their corresponding vertices. This was
accomplished using the THREE.js JavaScript framework. The image can be rotated,
zoomed, and navigated to help fully understand all of the predicate relationships. This
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particular graph is a candidate graph containing all possible paths between the two sets.
Each graph edge represents one or more predicates that associate two concepts. The blue
dots along the edge represent each type of connection such as treats, causes, isa, etc.
Clicking on one of the blue dots navigates to a new page with every document that
generated the predicate in question. Additionally when there are multiple predicate types
that connect two concepts, multiple blue dots may appear.
It should be obvious that representing all of the resulting paths within a single
graph will quickly become unusable with larger numbers of concepts and graph edges. As
such, it is necessary to divide this resulting graph into multiple subgraphs and impose
criteria to rank the results. This will be discussed later in this chapter.

3.5 Open Search Algorithm
The closed discovery process is based around having some hypothesis to be
explored. This creates the initial search concepts which generate the resulting connection
graphs. At that point the user is left to explore the concepts which appear and the listings
of references which produced the predicate graph edges. An open discovery approach
needs to be more dynamic and flowing as its purpose is to help uncover possibilities. As
such we find that there needs to be a difference between the initial search starting the
open discovery and the subsequent exploratory queries.

3.5.1 Initial Open Discovery System Query Construction
Our exploratory approach, or open discovery, is started where a user specifies a
single concept. However, this could prove to be intractable by itself as there are likely to
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be a large number of other concepts that appear in a predication with the selected
concept. Thus, the user must also specify an initial relationship of interest, such as treats
or causes. The initial search is described as follows:

● Step 1 - User specifies a single concept C and relationship R.
● Step 2 - Define the set of predicates P as the set of all predicates that have the
relationship R and where one of the concepts is C.
● Step 3 - Create resulting display graph from the predicates within P.

Here, as we are interested in predicates that specifically contain the provided concept and
relationship there is no need to include additional documents via citational association or
to gather up other predicates within the documents. Using the same example as before,
perhaps we wish to start our exploration for things that are known to treat the condition
known as Raynaud Disease. The query for this is simple and is shown in Figure 20.

query = '(SUBJECT_NAME: "Raynaud Disease" | OBJECT_NAME: "Raynaud Disease") &
(PREDICATE_DESCRIPTOR: "TREATS") '
exploreQuery("subgraphTextQueryId") { solr(q: query) }
//Search Predicates directly for the above query terms
entity("predicate") {
identifier 'SUBGRAPH-QUERY-RESULTS'
search("solr") { queryId subgraphTextQueryId" }
}

Figure 20. Open search query for predicates

The results of the query will be a series of predicates, each with one of the concepts as
the specified search concept, Raynaud Disease.
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3.5.2 Open Graph Generation and Display
The resulting predicates are shown directly connected to the user’s single search
concept (Figure 21).

Figure 21. Example open discovery for Raynaud Disease

Unlike the closed discovery graphs, here, concepts can also be selected to further
exploration. If the user starts their open discovery with Raynaud Disease, they can then
select Epoprostenol as an exploration target. It then makes sense that the system will then
display Epoprostenol in the center along with a new arrangement of related concepts
(Figure 22). A breadcrumb trail is displayed showing the user their exploration path, also
providing a quick method to return back to a previous concept or conduct a closed
discovery search between their initial search concept and the current one.
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Figure 22. Open discovery for Raynaud Disease –> Epoprostenol

3.5.3 Subsequent Open Discovery System Query Construction
Subsequent exploration queries could continue to search for “all” predicates
containing a single concept each time. However, this will be little coherence between the
results from one search to the next subsequent search. By selecting a subsequent concept
the user is essentially exploring the connection to that concept, not just the concept. Thus,
it is important to take into consideration the result context when performing the next
search. Our algorithm is as follows:
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● Step 1 - Define the concept C’ as the previously selected concept within this open
discovery exploration.
● Step 2 - User selects concept C within results of an open discovery search.
● Step 3 - Define the set S as the set of all documents within the corpus that contain
a predicate that associates C with C’.
● Step 4 - Define the set S’ as the set of all documents cited by documents within
the set S.
● Step 5 - Define the resulting set of documents S’’ = S ∪ S’

● Step 6 - Define the set of predicates P as the set of all predicates defined for each
document in S’’.
● Step 7 - Define the set of predicates P’ as the set of all predicates within P where
one of the concepts is the selected concept C.
● Step 8 - Create resulting display graph from the predicates within P’.

The initial search (Figure 23) looks for predicates that connect concept C and C’ together.
query = '(SUBJECT_NAME: ""Epoprostenol" & OBJECT_NAME: "Raynaud Disease") |
(SUBJECT_NAME: "Raynaud Disease" & OBJECT_NAME: "Epoprostenol") '
exploreQuery("subgraphTextQueryId") { solr(q: query) }
//Search predicates for the above query terms
entity("predicate") {
identifier 'BASE_PREDICATE_QUERY_ID'
search("solr") { queryId subgraphTextQueryId" }
}

Figure 23. Steps 1-2 – Search for predicates that connect concept C’ and C
The rest of the query steps follow a similar series of steps to our closed discovery
implementation, collecting the predicates from the documents and cited documents.
These can be seen together in Figure 24.
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//Find the set of documents S that contain the predicates
entity("reference") {
identifier 'REFERENCE_QUERY_ID'
constraint {
type "PROJECTION"
projection {
relationshipName "predicate_to_document"
sourceIdentifier "BASE_PREDICATE_QUERY_ID"
}
}
}
//Find the set of references S’ which are cited by the set of references S.
entity("reference") {
identifier 'CITED_REF_QUERY_ID'
constraint {
type "PROJECTION"
projection {
relationshipName "reference_to_cited_reference"
sourceIdentifier "REFERENCE_QUERY_ID"
}
}
}
//Find the set of unique predicates that come from either S or S’
entity("predicate") {
identifier 'SUBGRAPH-QUERY-RESULTS'
constraint {
type "PROJECTION"
projection {
relationshipName "predicate_to_document"
sourceIdentifier "REFERENCE_QUERY_ID"
}
}
constraint {
type "PROJECTION"
projection {
relationshipName "predicate_to_document"
sourceIdentifier "CITED_REF_QUERY_ID"
}
}
or()
}

Figure 24. Rest of predicate query for subsequent open discovery

3.6 System Query Post-Processing
During the execution of our retrospective studies, it was noticed that a number of
concepts and predicates would appear within the results that had little to no value. The
SemRep tool produces a large variety of predications, each with a semantic type that
associates the two concepts. Some types such as treats, stimulates, or causes provide
useful meaning, while others such as administered_to, diagnoses, and location_of are of
less usefulness for our purposes. Additionally, concepts such as Patients or Human which
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are so pervasive within the literature also provide little to no meaning. Two types of
filters were placed during post-processing to account for these situations: one for
predicates and one for concepts.

3.6.1 Concept Filtering
The standard approach for examining the “value” of concepts/words is to start by
calculating the Inverse-Document Frequency (IDF) of each concept. This is normally
computed during the compilation of the corpus. The difficulty for our study arises from
two aspects. The first is the smaller total number of documents within our corpus
(thousands of documents rather than millions). The second comes from the challenge of
using NLP to associate words from titles and abstracts to the UMLS concepts within our
results. Due to these restrictions the IDF was instead calculated based upon the
predications data from SemRep for all of MEDLINE – consisting of 85.7 million
predicates extracted from 16 million documents. For a given UMLS concept, if it exists
within a predicate, then it is counted as existing within that document.
From Equation 2.1, the more times a particular term shows up across the corpus,
the smaller the IDF value will be. For a given closed search, each predicate returned from
a system query contains two concepts. The set of unique concepts returned can then be
examined. An examination of the IDF scores for the Magnesium – Migraine Disorders
study is illustrated in Figure 25. Table 3 then shows the lowest ten concepts, all with little
semantic meaning.
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Figure 25. Histogram for concepts returned for Magnesium – Migraine Disorders

Table 3. Lowest concepts by IDF score returned for Magnesium – Migraine Disorders
Concept

IDF score

Patients

1.449559652

Therapeutic procedure

2.345444877

Human

2.821365442

Cells

2.903629008

Rattus norvegicus

2.996794117

Disease

3.147157075

Child

3.273016623

Woman

3.545474848

Mus

3.584664126

Pharmaceutical Preparations

3.64006119
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The web tier can cull any predicates that contain a concept with a score lower than a
given threshold. For experimental purposes we utilized a value that was two standard
deviations below the mean score.
A second approach to remove uninformative relationships involves MeSH tree
numbers. Each MeSH concept is organized into a hierarchy consisting of sixteen root
categories listed in Appendix F. Category A contains anatomic terms, B is for organisms,
C for diseases, D for drugs/chemicals, etc. With each category descriptors are arranged
hierarchically from most general to most specific. As an example, the MeSH tree number
for Raynaud Disease is C14.907.617.812, laying in category C because it is classified as
a disease. Above it in the hierarchy is C14.907.617 for peripheral vascular diseases,
C14.907 for vascular diseases, and C14 is for Cardiovascular diseases (Figure 26). A
concept’s tree number can help identify how general or specific it is, and some LBD
studies have made use of this to remove suggestions that were too general (Zhang,
Fiszman, Shin, Wilkowski, and Rindflesch 2013; Fiszman, Rindflesch, and Kilicoglu
2004; Swanson, Smalheiser, and Torvik, V. I. 2006).
C - Diseases
C14 - Cardiovascular Diseases

C2 - Virus Diseases

C14.907 - Vascular Diseases

C14.280 - Heart Diseases

C14.280.358 - Heart Aneurysm

C14.907.617 - Peripheral Vascular Diseases

C14.907.617.500 - Erythromelalgia

C14.907.617.812 - Raynaud Disease

Figure 26. Sample MeSH Tree
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Our primary results rely on semantic predications which relate two UMLS
concepts. As not all UMLS concepts have an associated MeSH descriptor, they will also
not have a corresponding MeSH Tree number. For those that do, having a shorter tree
number indicates a more general concept and potentially is less useful. An examination of
the average IDF values as a function of the MeSH tree depth shows just this. For the three
studies Fish Oils-Raynaud Disease, Magnesium-Migraine Disorders, and SomatomedinsArginine the list of predicates resulting from the search query was captured. For each
study the list of unique concepts was extracted and divided into groups by MeSH tree
number length. If a concept had more than one tree number, the closest integer average
length was used.

Figure 27. Average IDF value of concepts as a function of MeSH tree depth

As can be seen in Figure 27, more general concepts (i.e. shorter tree number
length) have a smaller average IDF score than more specific terms. A closer examination
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of the concepts shows us more concrete examples to determine an appropriate cutoff.
Table 4 shows a listing of concepts with a tree depth of one for the same three studies
along with their UMLS concept identifier and the MeSH Tree Number.
Table 4. Concepts with MeSH tree depth of one for three studies
C0043250 Injury wounds

Pharmaceutical
[C26] C0013227 Preparations

[D26]

C0007613 Cell physiology

[G04] C0007634 Cells

[A11]

C0007222 Cardiovascular Diseases

[C14] C0087111 Therapeutic procedure

[E02]

C0023779 Lipids

Macromolecular
[D10] C0751282 Complexes

[D05]

C0040300 Body tissue

[A10] C0005515 Biological Factors

[D23]

C0027361 Persons

[M01] C0021053 Immune System Diseases [C20]

Operative Surgical
C0543467 Procedures

[E04] C0007004 Carbohydrates

[D09]

Pharmaceutical
C0013227 Preparations

[D26] C0007613 Cell physiology

[G04]

C0007634 Cells

[A11] C0043251 Wounds and Injuries

[C26]

C0087111 Therapeutic procedure

[E02] C0023779 Lipids

[D10]

C0029224 Organic Chemicals

[D02] C0004611 Bacteria

[B03]

Endocrine System
C0014130 Diseases

[C19] C0011900 Diagnosis

[E01]

C0027765 nervous system disorder

[C10] C0040300 Body tissue

[A10]

C0007004 Carbohydrates

[D09] C0027361 Persons

[M01]

C0007613 Cell physiology

[G04] C0006826 Malignant Neoplasms

[C04]

C0007222 Cardiovascular Diseases

Operative Surgical
[C14] C0543467 Procedures

[E04]

C0023779 Lipids

Pharmaceutical
[D10] C0013227 Preparations

[D26]

C0006826 Malignant Neoplasms

[C04] C0007634 Cells

[A11]

Operative Surgical
C0543467 Procedures

[E04] C0087111 Therapeutic procedure

[E02]
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As before, those in red are from the query results of the Fish Oils-Raynaud
Disease study, those in blue come from a study around Magnesium-Migraine Disorders,
and those in yellow are from the Somatomedins-Arginine papers. A glance over these
concepts shows that all of them are too general to be useful as potential intermediates as
we are interested in more specific biochemical connections. The same is also true for
those concepts with a depth of two. At a depth of three we find a mixture of useful
concepts such as Hypertension (C0020542) [C08.381.423] and less useful like Human
Volunteers (C0020155) [M01.774.500]. The above analysis led to the culling of any
predicates that contain a concept with either a tree depth of one or two.

3.6.2 Predicate Filtering
Most of the post-processing is accomplished via an examination of the concepts
within each predicate. However, each predicate also has one of thirty semantic types
which characterizes the relationship between the two concepts (Table 5). In addition, all
but three of the types can appear in a negated form that have the prefix “NEG_”. The
semantic meaning of these connections may not be applicable for all studies attempting to
uncover hidden knowledge.
The types administered_to, location_of, process_of, method_of, part_of, and uses
consistently appear at the bottom of IDF scoring of predicates by group. This is caused by
the prevalence of more generic concepts within such groupings: such as “water administered_to - patients”, “heart - location_of - fatty acids”, “anemia - process_of patients”, and so on. In addition, some types such as diagnoses and occurs_in are less
useful to us because such relations discuss procedures, in the case of diagnoses, and

62

population groups in the other. For our studies, where we wish to examine biochemical
interactions, we filter out predicates with these eight semantic types.

Table 5. Predicate Semantic Types
Clinical

Biologic

General

ADMINISTERED_TO

ASSOCIATED_WITH

AFFECTS

COMPLICATES

AUGMENTS

CAUSES

DIAGNOSES

CONVERTS_TO

COEXISTS_WITH

MANIFESTATION_OF

DISRUPTS

COMPARED_WITH

OCCURS_IN

INHIBITS

HIGHER_THAN

PREDISPOSES

INTERACTS_WITH

ISA

PREVENTS

STIMULATES

LOCATION_OF

PROCESS_OF

LOWER_THAN

TREATS

METHOD_OF
PART_OF
PRECEDES
PRODUCES
SAME_AS
USES

For closed discovery, the remaining predicates are then used to form a graph
which can be very large and challenging to explore. Paths are computed from any source
concept within (A set) to any target concept (C set), for path lengths up to the specified
length.
Recall the earlier description of document sets S and S’ (Figure 2). By definition
the document set S contains all documents which contain at least one concept from the
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union of the sets A and C. Therefore, all predicates that contain either an A or C concept
must also come from those documents in S.

Figure 28. Predicates within document sets S and S’

A revisualization of this is shown in Figure 28. Predicates containing either an A or C
concept must be within S, but past that there are no restrictions (i.e. all other possible
concepts and predicates that connect those concepts may be in S, S’, both, or neither).
When we consider paths of length two with a single intermediate concept [A-B1-C], then
predicates will originate from papers containing the original search terms as each of the
two predicates contain at least one search concept (Figure 29).

64

Figure 29. Paths of length two within document sets S and S’

Once you consider paths of length three [A-Bm-Bn-C], you allow for one predicate that
does not contain a search term [Bm-Bn]. By observation the starting predicate [A-Bm] and
the ending predicate [Bn-C] must be found within S, and therefore all four concepts must
also be found within S. However, the connecting predicate [Bm-Bn] can also be found
outside S – which in our case, will be S’ (Figure 30).

Figure 30. Paths of length three within document sets S and S’
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We can further extend this analogy to paths of lengths four [A-Bm-Bn-Bo-C]
which can be seen in Figure 31. It is at this point possible for a path to be formed that
includes a concept that is not present within any of the documents of S. This analogy can
be continued to further increase the possible number paths found, however, increasing
path lengths will, at some point, cause each pair of concepts in the graph database to be
connected as greater and greater numbers of predicates are included. As such, there is an
expectation that the number of paths will grow quickly and the average value of those
paths to decrease.

Figure 31. Paths of length four within document sets S and S’

Using the Fish Oil-Raynaud Disease study as an example, the total number of
paths found and the average path IDF score were calculated as the maximum path length
was varied from two to five. The average IDF score for a given path was calculated as the
average of the IDF scores of each of the concepts that comprised the path. The average
was then computed across all paths returned (Figure 32).
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Figure 32. Paths found and average path IDF varying with maximum path length

From this it can be seen that the graph complexity (number of paths) grows quickly as a
function of path length. Additionally, the average IDF value for those paths declines as
additional ‘low value’ connections are made. These two facts match the intuitive idea that
a more direct connection has more meaning.
The studies detailed in the next chapter are based upon previous work within the
field. The seminal papers from which the discoveries were originally made tend to
provide supporting evidence in the form of citations. Considering the ABC model for
simplicity, in many cases the authors point out those documents supporting where either
‘half’ of the connection is derived (e.g. [A-B] or [B-C]). If a perfect set of semantic
predicates were to be generated from all of those documents, then merely examining
paths of length two would be sufficient to recover the connections. However, if our
predicates are not a perfect representation of the semantic knowledge contained within
those documents, then we want to make use of their citations as an alternative means of
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summarization. As a compromise between graph complexity and desiring the information
gain from citations, our trials are conducted utilizing path lengths of three by default, two
when possible.
3.7 Subgraph Generation
As we’ve seen, even with a small corpus a search may result in hundreds or
thousands of possible paths. This has caused researchers to explore approaches to filter,
compare, and organize their concepts or predicates.

3.7.1.1 Degree Centrality
Graph theory defines degree centrality as a measure of connectedness of the
vertices within a graph. By definition, a vertex with more edges than other vertices has
higher degree centrality. Researchers have hypothesized that this equates to the
importance of the corresponding concepts (Wilkowski et al. 2011; Zhang et al. 2011;
Zhang, Fiszman, Shin, Wilkowski, and Rindflesch 2013). In their 2011 study “Degree
centrality for semantic abstraction summarization of therapeutic studies” Zhang et al.
used this method on SemRep predications to summarize the most important information
from a collection of documents. They achieved better results when compared to term
frequencies. Wilkowski et al. also used degree centrality when comparing possible paths,
reducing large graphs by retaining only paths which contained highly connected
concepts.
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3.7.1.2 Fact Checking
When considering knowledge in general, statements of facts are in the same form
as our predications: (subject, predicate, object) triples. If these then existed within a
perfect knowledge graph, fact checking would be as trivial as checking for the existence
of an edge. Unfortunately, our graphs of knowledge not only have limited information
but also suffer from missing or incorrect assertions (Shi and Weninger 2016). When
considering the knowledge contained within a large body of scientific papers there will
exist duplicate or even contradictory assertions, not to mention that what can be regarded
as true in one moment may change over time.
The frequency in which a given piece of knowledge appears within a corpus has
been used as a measure of its validity for information retrieval (Kan, McKeown, and
Klavans 2001; Zhang et al. 2013). In a newer study, NLP has been used to attempt to
extract a factuality measure along with the predications Kilicoglu, H., Rosemblat, G., &
Rindflesch, T. C. (2017). The basis of their work is formed on the idea that most
biomedical knowledge claims are expressed in the form of hypotheses or speculation
rather than explicit statements of fact. Additional linguistic analysis examine the words
used (e.g. “Nifedipine increase blood flow”, “our findings support the hypothesis”, “may
benefit”, “does not support”, etc.) and attempts to assign a factuality score: Fact,
Probable, Possible, Counterfact, Conditional, etc.). These approaches attempt to order
possible results by the degree of measured or implied factuality.

3.7.1.3 Concept Similarity
One of the strengths of utilizing predicates is the inherent semantic meaning
contained with a path relating two concepts. A reasonable goal would be to cluster
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together predicates that are more closely related to that higher level concept. For
example, in the Fish Oils-Raynaud Disease study we could expect one grouping around
the topic of Platelet Aggregation and a different one around the topic of Blood Viscosity
– similar to how latent semantic analysis attempts to produce collections of terms around
higher order themes.
One of the simplest measures to compare concepts is a technique based on the
reciprocal of the shortest path length between a pair of concepts within an ontology
(Rada, Mili, Bicknell, and Blettner 1989; Lee, Kim, and Lee 1993). For instance, in
Figure 26 the similarity score between Raynaud Disease and Vascular Disease is the
same as between Erythromelalgia and Vascular Disease because the distance is the same.
A weakness of this approach lies in the assumption that the link or association
between a concept and its parent are uniform distances. In 1995, Resnik introduced an
equally simply but alternative measure based upon the concept of information content.
Resnik stated that “one key to the similarity of two concepts is the extent to which they
share information in common” (Resnik 1995). That is the connecting path between the
concepts must go through a concept that is abstract enough to contain them both. For our
earlier example (Figure 26) Erythromelalgia and Raynaud Disease are connected through
Peripheral Vascular Diseases while Virus Diseases and Raynaud Disease are only
connected through the root Diseases.
Resnik also suggested the association of probabilities with the concepts to avoid
the unreliability of edge distances. Each concept was assigned a value that equates to the
probability of encountering an instance of that concept. In information theory,
information content is defined as the amount of information gained when a random
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variable or signal is sampled (Ross 2014). In this case, the information gained for a
concept (E) with probability P is simply:
I(C) := -log(P)

(3.1)

This should make intuitive sense: as the probability increases (the more abstract the
concept), the lower its potential information content (Figure 33).

Figure 33. Information Content as a function of probability

Resnik, taking into account multiple inheritance, defined his similarity as the information
content of the least common subsumer of both concepts. In a more general sense, the
semantic similarity between two concepts is proportional to the amount of information
they share (Resnik 1995; Jiang and Conrath 1997; Lin 1998).

3.7.2 Path Relatedness
A fundamental requirement for clustering paths based upon semantic meaning is
the ability to define how similar two paths are to each other. According to Cameron,
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assertions in scientific literature which are related will usually occur in similar contexts,
and that the context of a path is the aggregation of the context of each assertion or
predication within the path (Cameron 2014).
To define the context of a single semantic predication Cameron made two
assumptions. The first is that as MEDLINE articles are manually assigned a list of MeSH
descriptors, these form a semantic summary of the full text of the article comprised of
concepts. In addition, the predications themselves form a relational semantic summary by
associating one concept to another. As both capture the implicit context of the reference,
the concept-level semantic summary (MeSH descriptors) and relational semantic
summary (predications) are interchangeable, albeit not equal, perspectives.
The essence of the second assumption is succinctly stated by the English linguist
John Rupert Firth: “You shall know a word by the company it keeps” (Firth 1957). In
other words, that the “context of an individual predication across the entire corpus could
be represented more comprehensively, as the aggregation of the MeSH descriptors
assigned to each document in which it occurs” (Cameron 2014).
Cameron continued this reasoning to define the context of a path as the
summation of the contexts of its predicates. While standard distributional approaches
would assign frequency vectors as the context of each predicate and then to use cosine
similarity to compare paths, this is a poor fit as the goal is to cluster paths based upon
relatedness and not similarity. Additionally, because the concept descriptors are arranged
in a hierarchical structure, concepts will have one or more tree numbers that indicate their
relative positioning within the tree. If two different concepts share some common parents
they will share some semantic meaning. For example, the MeSH term Fish Oils
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(D005395) has a tree number of D10.627.430. The D signifies Chemicals and Drugs,
D10 is the identifier for lipids, and D10.627 identifies oils. Thus, another concept such as
Fatty Acids, Omega-3 with a tree number of D10.627.430.450 signifies that it is closely
related to the concept of Fish Oils.
The Sørensen–Dice coefficient, or Dice similarity, is a statistic used to measure
the similarity between two sets (Eq 3.2).
(3.2)

(3.3)

This measure has long been applied to terms within a taxonomy leveraging information
measures and the least common parent that subsumes both terms (Lin 1998). Cameron’s
suggestion was that the dice similarity between two MeSH descriptors mi and mj could be
computed based upon the sets A(mi) and A(mj) respectively where A(m) is the set of all
ancestors of the MeSH descriptors m (Eq 3.3). For example, the dice similarity between
Fish Oils (D10.627.430) and Fatty Acids, Omega-3 (D10.627.430.450) is calculated as
follows:
A(Fish Oils) = {D10.627.430,

D10.627, D10}

A(Fatty Acids, Omega-3) = {D10.627.430.450,

D10.627.430, D10.627, D10}

A(Fish Oils) ∩ A(Fatty Acids, Omega-3) = {D10.627.430,

D10.627, D10}

dice (Fish Oils, Fatty Acids, Omega-3) = (2 x 3) / (4 + 3) = 6/7
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The range of similarity values is [0,1] where the maximum similarity occurs when the
two descriptors are equal. Cameron further defines a normalized dice similarity score by
using a similarity threshold (𝜏𝜏 sim = 0.75) in an effort to maximize the weight of in-context
descriptors and minimize the weight of out-of-context descriptors (Eq 3.4).

(3.4)

(3.5)

The semantic relatedness sr’’(pi,pj) between two paths pi and pj, is then computed as the
sum of the pairwise normalized dice similarity between the context sets C(pi) and C(pj)
(Eq 3.5). Take the following two paths from our results explained later as an example:

pi

Eicosapentaenoic Acid

INTERACTS_WITH

Epoprostenol

TREATS

Raynaud
Phenomenon

pj

Eicosapentaenoic Acid

STIMULATES

Epoprostenol

TREATS

Raynaud
Disease

The first predicate (pred1), Eicosapentaenoic Acid - INTERACTS_WITH - Epoprostenol
appears only in [PMID6252872] which is in our corpus because it is cited by three core
references [PMID6302714, PMID6318123, PMID6321621]. The second predicate (pred2),
Epoprostenol - TREATS - Raynaud Phenomenon appears in three core papers
[PMID3883365, PMID6788326, PMID7037038]. The third predicate (pred3),
Eicosapentaenoic Acid - STIMULATES - Epoprostenol comes from [PMID6098049]. The
last predicate (pred4), Epoprostenol - TREATS - Raynaud Disease appears in the core
reference [PMID3883365] and one of the papers it cites [PMID7025341].
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The context set for each of these predicates is simply the aggregate of the MeSH
descriptors of all the documents from which it is present. Table 6 shows the context sets
for these four predicates along with the document identifiers where each concept
originated. The context set for each path is then simply the unique set of MeSH
descriptors aggregated from its predicates. For pi, this is the 27 unique terms resulting
from the union of C(pred1) and C(pred2), and for pj, this is the 26 unique terms resulting
from the union of C(pred3) and C(pred4).
For the 702 pairs only 32 cross the similarity threshold (Table 7). Of these 18 are
self matches, leaving only 14 that are more interesting. An example calculation of one
pair is as follows for the case mi = Epoprostenol [D10.251.355.255.550.550.500] and
mj = Prostaglandins [D10.251.355.255.550]:

A(Epoprostenol) = {D10.251.355.255.550.550.500,

D10.251.355.255.550.550,

D10.251.355.255.550, D10.251.355.255, D10.251.355, D10.251, D10}

A(Prostaglandins) = {D10.251.355.255.550,

D10.251.355.255, D10.251.355, D10.251,

D10}

A(Epoprostenol) ∩ A(Prostaglandins) = A(Prostaglandins)
dice (Epoprostenol, Prostaglandins) = (2 x 5) / (7 + 5) = 10/12 = 0.833
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Table 6. Context set for example predicates
C(pred1)

C(pred2)

C(pred3)

C(pred4)

Arachidonic Acids
(PMID6252872)

6-Ketoprostaglandin F1 alpha
(PMID3883365)

Arachidonic Acids
(PMID6098049)

6-Ketoprostaglandin F1 alpha
(PMID3883365)

Blood Vessels
(PMID6252872)

Adult
(PMID3883365,PMID7037038)

Eicosapentaenoic Acid
(PMID6098049)

Adult
(PMID3883365)

Eicosanoic Acids
(PMID6252872)

Aged
(PMID7037038)

Endothelium
(PMID6098049)

Ambulatory Care
(PMID7025341)

Eicosapentaenoic Acid
(PMID6252872)

Epoprostenol
(PMID3883365, PMID6788326,
PMID7037038)

Epoprostenol
(PMID6098049)

Buffers
(PMID7025341)

Epoprostenol
(PMID6252872)

Erythrocyte Deformability
(PMID3883365)

Fatty Acids, Unsaturated
(PMID6098049)

Clinical Trials
(PMID7025341)

Humans
(PMID6098049)

Epoprostenol (PMID3883365,
PMID7025341)

Fatty Acids, Unsaturated Erythrocytes
(PMID6252872)
(PMID6788326)
Humans
(PMID6252872)

Female
(PMID3883365, PMID6788326,
PMID7037038)

Indomethacin
(PMID6098049)

Erythrocyte Deformability
(PMID3883365)

Platelet Aggregation
(PMID6252872)

Humans
(PMID3883365, PMID6788326,
PMID7037038)

Platelet Aggregation
(PMID6098049)

Female
(PMID3883365, PMID7025341)

Prostaglandins
(PMID6252872)

Infrared Rays
(PMID7037038)

Umbilical Veins
(PMID6098049)

Fingers
(PMID7025341)

Thromboxanes
(PMID6252872)

Infusions, Parenteral
(PMID7037038)

Hand
(PMID7025341)

Umbilicus
(PMID6252872)

Male
(PMID3883365, PMID6788326,
PMID7037038)

Humans
(PMID3883365, PMID7025341)

Middle Aged
(PMID7037038)

Injections, Intravenous
(PMID7025341)

Prostaglandins
(PMID6788326, PMID7037038)

Lupus Erythematosus, Systemic
(PMID7025341)

Prostaglandins E
(PMID6788326)

Male
(PMID3883365)

Radiometry
(PMID7037038)

Prostaglandins
(PMID7025341)

Raynaud Disease
(PMID3883365, PMID6788326,
PMID7037038)

Raynaud Disease
(PMID3883365, PMID7025341)

Scleroderma, Systemic
(PMID3883365, PMID6788326)

Scleroderma, Systemic
(PMID3883365)

Thermography
(PMID7037038)

Thermography (PMID7025341)

Time Factors
(PMID7037038)

Time Factors (PMID7025341)
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mi

Table 7. MeSH descriptors pairs mi x mj that exceed 𝜏𝜏sim
mj

∑(diceN(mi,mj
))

Epoprostenol

Epoprostenol, Prostaglandins

2

Eicosapentaenoic Acid

Eicosapentaenoic Acid, Arachidonic Acids,
Prostaglandins

3

Thromboxanes

Arachidonic Acids

1

Fatty Acids, Unsaturated

Fatty Acids, Unsaturated

1

Humans

Humans

1

Arachidonic Acids

Eicosapentaenoic Acid, Arachidonic Acids,
Prostaglandins

3

Platelet Aggregation

Platelet Aggregation

1

Prostaglandins

Eicosapentaenoic Acid, Arachidonic Acids,
Prostaglandins, Epoprostenol,
6-Ketoprostaglandin F1 alpha

5

Erythrocyte Deformability

Erythrocyte Deformability

1

Female

Female

1

Raynaud Disease

Raynaud Disease

1

Male

Male

1

6-Ketoprostaglandin F1

6-Ketoprostaglandin F1, Prostaglandins

2

Scleroderma, Systemic

Scleroderma, Systemic

1

Adult

Adult

1

Time Factors

Time Factors

1

Middle Aged

Adult

1

Thermography

Thermography

1

Aged

Adult

1

Prostaglandins E

Prostaglandins, Epoprostenol,
6-Ketoprostaglandin F1 alpha

3
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Cameron noted that a broad range of scores may exist for this approach and
additionally suggested using a log reduction in addition to the normalized dice similarity
scores. This was accomplished by adding an additional step to compute the relatedness
between a single MeSH descriptor to the context set of descriptors for a path (Eq 3.6).
(3.6)

(3.7)

Using this new equation for the semantic relatedness between two paths (Eq 3.7), and
data calculated in Table 7, for our example we see that:

3.7.3 Cluster Similarity
If the desired goal is to achieve one or more result graphs with semantically
related paths, then there is an additional measure we require. Equation 3.7 measures how
much two single paths are related to each other, but another statistic is required when
comparing one cluster to another. Hierarchical clustering algorithms measure this
similarity in one of four ways (Manning, Raghavan, and Schütze 2008).
The first, single-link similarity, simply uses the similarity between the pair most
similar between the two clusters. The second, complete-link similarity, uses the pair most
dissimilar. The third is centroid, or average inter-similarity across all pairs between the
two clusters. Lastly, the fourth is the average of all similarities between all pairs
including those pairs from the same cluster. Cameron noted that centroid similarity is
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ideal for the merging of two groups of paths as it will maintain the greatest amount of
relatedness. As such he defines the inter-cluster similarity between two buckets Ba and Bb
each containing one or more paths:
(3.8)

3.7.4 Subgraph Clustering
Cameron used a hierarchical agglomerative clustering (HAC) algorithm to
construct coherent subgraphs based on the context relatedness of the individual paths
(Cameron 2014). Initially starting with a number of buckets equal to the total number of
possible paths, they iteratively calculate the relatedness between a set of paths from one
bucket to each other. If the score exceeds a threshold the buckets are combined.
Repeating the process until no more buckets are merged. This can result in one or more
subgraphs whose paths share greater semantic meaning, and thus should appear less
cluttered. The steps for Cameron’s algorithm are shown in Table 8.
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Table 8. Hierarchical Agglomerative Clustering algorithm used by Cameron et al.
Step 1: For each path generate an empty bucket and place the path within. Call this
collection buckets
Step 2: Compute path relatedness threshold as two standard deviations above the mean
of the path relatedness scores.
Step 3: Computer the inter-cluster similarity score between each pair of buckets b1 and
b2 in buckets compute the similarity score (Equation 3.8). For each pair whose
similarity score exceeds the threshold, mark the two buckets for merging.
Step 4: For each pair marked for merging, create a new bucket consisting of all paths
from the two buckets. Place this new bucket in mergedBuckets. If a bucket has
not been marked for deletion or merging, add it to mergedBuckets by itself.
Step 5: Repeat this algorithm until number of buckets in the previous iteration is equal
to the number of buckets from the current one - that is, there are no more
changes.

As noted by Cameron et al. (2015) the time to complete this step could take from minutes
to hours and produced between one and two hundred graphs and singleton paths for each
of their studies. Although this can produce more semantically meaningful results, this is
problematic for two reasons. One, there are two sets of results: subgraphs consisting of
more than one path and singletons. If we wish to ascertain quantifiable measurements
about the efficacy of the system in terms of precision and recall then only a single
ordered list of the results should be returned to the researcher.
Secondly, there may be many paths that are extremely similar. This can arise from
several different cases: differences in predicate semantic types only, differences only in

80

the starting and/or ending concepts, and paths that are a longer version of an existing
path. Despite their similarities, they will have slightly different contexts which could
cause them to not be combined together during clustering. But to the user viewing the end
results, the extra graphs will seem redundant and of little use.
When searching the Fish Oils-Raynaud Disease study with a path length of two,
there are eleven paths found (Table 9). The first case can be seen when comparing the
first and third listed paths. The paths differ only in that with one Epoprostenol TREATS
Raynaud Phenomenon and in the other, it is ASSOCIATED_WITH.
If we consider these cases as similar and treat them as a single merged path, then
after combining a single path is left as a placeholder for the grouping, and for our Fish
Oils example this leaves only three paths remaining (Table 10).
Zhang et al. describes a similar approach, where at a higher level, a predicatation
can be considered as a metapredication in the form {Semantic Concept Group - Predicate
Group - Semantic Concept Group} (Zhang et al. 2013). In their study predicate types are
grouped together (e.g. INHIBITS, STIMULATES, and INTERACTS_WITH into an
“Interaction” group). They use these grouping to form graph clusters.
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Table 9. Fish Oils – Raynaud Disease paths with max length two
Eicosapentaenoic Acid

INTERACTS_WITH Epoprostenol

TREATS

Raynaud
Phenomenon

Eicosapentaenoic Acid

INTERACTS_WITH Epoprostenol

TREATS

Raynaud Disease

Eicosapentaenoic Acid

INTERACTS_WITH Epoprostenol

Raynaud
ASSOCIATED_WITH Phenomenon

Eicosapentaenoic Acid

NEG_INHIBITS

Epoprostenol

TREATS

Raynaud
Phenomenon

Eicosapentaenoic Acid

NEG_INHIBITS

Epoprostenol

TREATS

Raynaud Disease

Eicosapentaenoic Acid

NEG_INHIBITS

Epoprostenol

Eicosapentaenoic Acid

INHIBITS

Eicosapentaenoic Acid

Raynaud
ASSOCIATED_WITH Phenomenon

Thromboxane A2

CAUSES

Raynaud
Phenomenon

INTERACTS_WITH Thromboxane A2

CAUSES

Raynaud
Phenomenon

Eicosapentaenoic Acid

STIMULATES

Epoprostenol

TREATS

Raynaud
Phenomenon

Eicosapentaenoic Acid

STIMULATES

Epoprostenol

TREATS

Raynaud Disease

Eicosapentaenoic Acid

STIMULATES

Epoprostenol

Raynaud
ASSOCIATED_WITH Phenomenon

Table 10. Condensed Fish Oils – Raynaud Disease paths with max length two
Eicosapentaenoic Acid

*

Epoprostenol

*

Raynaud
Phenomenon

Eicosapentaenoic Acid

*

Epoprostenol

*

Raynaud Disease

Eicosapentaenoic Acid

*

Thromboxane A2

CAUSES

Raynaud
Phenomenon

The second case can be seen in the first and second lines of Table 10. Here, an
assumption is made that the researcher using the system considers the starting set of
concepts together conceptually and the same for the target set of concepts. In other
words, as long as the “core” of the path (everything not including the start and end) is
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identical, we can consider the paths the same and plot them together. Figure 34 shows an
illustration of these eleven paths being condensed into two aggregate groupings.

Figure 34. Example combined predicates for Fish Oils – Raynaud Disease

The third case arises with longer path lengths. For example, take the following
two paths (Table 11). The first path is just a longer version of the second path. As such,
we use the shorter path for subgraph creation and add the longer path into whatever
results include the shorter.

Table 11. Sample of Fish Oils – Raynaud Disease paths with max length three
Eicosapentaenoic
Acid

INHIBITS

Arachidonic Acid

Thromboxane
STIMULATES A2

Eicosapentaenoic
Acid

INHIBITS

Thromboxane A2

CAUSES

Raynaud
CAUSES Phenomenon

Raynaud
Phenomenon

Using these three checks as additional post-processing we then can form the subgraphs
with the resulting paths (Table 12):
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Table 12. Clustering algorithm
Step 1: For each path generate an empty bucket and place the path within. Call this
collection buckets
Step 2: Compute path relatedness threshold as two standard deviations above the mean
of the path relatedness scores.
Step 3: Remove the first bucket, b1, from buckets. Compare b1 with the remaining
buckets in buckets by computing their similarity score. For each bucket b2 whose
similarity score with b1 exceeds the threshold, add all paths contained within b2
to listToCombine.
Step 4: Create a new bucket consisting of all paths contained within b1 and from
listToCombine. Place this new bucket in listsToAdd. If a bucket has not been
marked for merging, add it to leftOvers by itself.
Step 5: If buckets is not empty go back to step three.
Step 6: Add all buckets within listToAdd to buckets.
Step 7: If any buckets were combined, go back to step three.

The results of this algorithm consists of an unordered set of subgraph results. Each result
will consist of one or more paths as some will have been combined semantically.
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3.8 Result Ordering
With many possible subgraph results it is highly important to determine a sort
order. Paths with the shortest length are likely to be of primary importance to the
researcher using an LBD system. As such, the primary sorting criteria of the resulting
subgraphs is the minimum path length contained. If there is a more direct relation
between two concepts, a researcher is more likely to be interested in this than a path that
goes through several intermediate concepts.
The second sorting criteria is an ordering based upon the average frequency of
occurrence of the found path predications. The more documents a predication has
appeared within, generally implies a greater accepted belief of that statement. (Kan,
McKeown, and Klavans 2001; Zhang, Fiszman, Shin, Wilkowski, and Rindflesch 2013)

3.9 Result Evaluation
Put succinctly, evaluating LBD systems is a “fundamentally challenging task
because if they are successful, by definition they are capturing new knowledge that has
yet to be proven useful” (Yetisgen-Yildiz and Pratt 2008). This difficulty has been
overcome by many researchers by replicating the historical discoveries to evaluate the
performance of their systems (Lindsay and Gordon 1999; Weeber, Klein, de Jong‐van
den Berg, and Vos 2001; Srinivasan 2004; Hristovski, Friedman, Rindflesch, and Peterlin
2006; Cameron et al. 2015; Song, Heo, and Ding 2015). These historical studies have
become known as the gold-standard for LBD systems and include many from Swanson
and Smalheiser including Fish Oils – Raynaud Disease, Magnesium – Migraine
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Disorders, Alzehimer’s Disease – Estrogen, Somatomedin C – Arginine, Alzeimer’s
Disease – Indomethacin, and others.
In general, these systems have reported qualitative success based solely upon the
presence of the original connections within their results - usually claiming to have
recovered some number of the intermediate concepts found in the original paper. This
approach ignores the fact that in some cases these results are a few out of potentially
hundreds of results (ignoring the rest), nor does it give a quantitative measure of the
information retrieval (Yetisgen-Yildiz and Pratt 2008).

3.9.1 Information Retrieval Metrics
At its heart LBD is a blend of summarization and information retrieval. A
standard measure of IR system performance is not only the ability to return information
relevant to the search, but also to not return non-relevant information. This has been
quantized in two popular metrics: precision and recall (Baeza-Yates and Ribeiro-Neto
1999).
For a standard document-based information retrieval system, precision is defined
as the proportion of the relevant documents returned compared with the total number
returned (i.e. what % of the returned results are correct). Recall is defined as the
proportion of relevant documents returned compared with the total number of relevant
documents in the system (i.e. what percentage of the correct results are returned). In
contrast to these, LBD systems return terms instead of documents. As such, precision and
recall for the evaluation of an LBD system are calculated with the following formulas:
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(3.9)

(3.10)

Here, Ti is the set of intermediate terms generated by the LBD system for a given starting
term(s) i, and Gi is the set of intermediate terms as defined by the gold standard
(Yetisgen-Yildiz and Pratt 2008).
Within information retrieval systems a well-known challenge is the trade-off
between the two metrics. A system designed for high precision can result in low recall,
and vice versa. An additional measure was created to help address this issue, F-measure,
which is a combined version of the two:
(3.11)

For F-measure, R is the recall, P is the precision, and β is a weighting factor between the
two. The most commonly used case sets this to one, assigning equal value to precision
and recall.

3.9.2 Ranked Retrieval
Precision, recall, and the F-measure are all set-based measures calculated using a
complete unordered set of results. With ordered (ranked) result sets, subsets of retrieved
documents can be examined using the top k retrieved documents. For example, if a search
had a total of seven ordered results (d0 through d6) and a maximum of three relevant
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results, we can calculate both precision and recall after considering each result. These
figures are shown in Table 13.
Table 13. Example Ranked Retrieval Data
Ranked Result

Precision

Recall

d0

Relevant

1.0

0.333

d1

Relevant

1.0

0.667

d2

Not Relevant

0.667

0.667

d3

Not Relevant

0.5

0.667

d4

Not Relevant

0.4

0.667

d5

Not Relevant

0.333

0.667

d6

Relevant

0.429

1.0

For each of these, the values of precision and recall can be plotted to
provide a precision-recall curve. These curves have a distinctive saw-tooth shape due to
the fact that if the (k+1)th result retrieved is non-relevant then recall is the same as for the
top k documents, but precision has dropped. And if it is relevant, then both precision and
recall increase causing the curve to increase up and to the right (Figure 35).

Figure 35. Sample Precision – Recall Curve
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A common combination of precision and recall is the F1 measure, defined as the
harmonic mean of precision and recall (Eq. 3.12).
𝐹𝐹1 =
𝐹𝐹1@𝑘𝑘 =

2 ∗ 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 ∗ 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟
𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 + 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟

2 ∗ 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝@𝑘𝑘 ∗ 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟@𝑘𝑘
𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝@𝑘𝑘 + 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟@𝑘𝑘

(3.12)

(3.13)

This can then be further extrapolated for ranked recall to a measure of “F1 at k” (Eq 3.13)
which is a calculation of the F1 score as a function of the top k returned results.

3.9.3 Natural Language Challenges
Suppose we try to strictly apply our measures of precision and recall. Using the
Magnesium-Migraine Disorders study as an example, we run into an inherent problem.
The usefulness of any term or predicate depends ultimately on the context of the articles
within which it occurs. “Interpreting that context and its usefulness requires, in general,
expert knowledge and human judgment” (Swanson, Smalheiser, and Torvik 2006). For
example, magnesium acts like a Calcium antagonist, having been compared to both
Verapamil and Nifedipine - two calcium channel blockers known to help treat migraines
(Figure 36).
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Figure 36. Magnesium as a Calcium antagonist

Although our gold standard LBD studies identify a list of intermediates, such as Calcium
Channel Blockers between Magnesium and Migraine Disorders, these are usually meant
to identify “higher-level” concepts that relate the two. And here two classic problems
arise in natural languages: synonymy and polysemy. Synonymy refers to a case where two
different words (say Calcium Channel Blockers and Verapamil) have the same meaning.
Polysemy, on the other hand, refers to the situation where a term has multiple meanings
(e.g. bank). To account for this in our calculations of precision and recall the following
rules are used:

1. Multiple terms that are associated with a “gold-standard” intermediate are all
counted as a single hit/true positive. (i.e. If the results contain Calcium Channel
Blockers, Verapamil, Nifedipine, etc. then these all count as a single true positive
for the idea of Calcium Channel Blockers).
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2. If no terms are found to associate with a “gold-standard” intermediate, this is
counted as a single miss/false negative.
3. Each term appearing in the answers that cannot be associated with a “goldstandard” intermediate will count as a false positive.
Yet another difficulty that may arise is that the semantics of terms may evolve over
time. For example, the term “virus” which initially only referred to an infectious
biological agent now also is used to refer to those of a digital origin with similar
properties (Xun, Jha, Gopalakrishnan, Li, & Zhang 2017). When creating associations the
context of the surrounding words can matter to better identify the semantic meaning of
the term.

3.10 Summary
This chapter presents the system design of a performant LBD system and
semantic-based search algorithms for both closed and open discovery approaches. A key
contribution of this dissertation is the inclusion of citations within these algorithms. This
is followed by a discussion on several filters based upon concept IDF scores and the
MeSH term hierarchy that must be applied to cull terms which are too common or too
general. Lastly we discuss how to generate subgraph results along with an evaluation
approach to qualitatively compare the results with and without the use of citational
references.
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Chapter 4
Results

Knowledge rediscovery, or retrospective analysis, is the standard for evaluating
LBD systems. Initially the goal was to construct a LBD framework with an
implementation of Cameron’s algorithms using the Fish Oils – Raynaud Disease study as
a testbed. This was then expanded to make use of citational links between documents.
Because these had positive results, additional studies were performed with the same
algorithms to test the results to see if they were truly indicative of better results. To date,
we have performed five projects using retrospective studies. These projects were based
on the original studies: the Magnesium – Migraine Disorders discovery by Swanson, the
connections between Somatomedins and Arginine also by Swanson, the association
between Testosterone and Sleep by Miller, and Kostoff’s research on the common factors
of Parkinson’s disease and Crohn’s disease.

4.1 Retrospective Study: Fish Oils and Raynaud Disease
In this retrospective study the corpus consisted only of the papers that Swanson
cited in his paper (Table A-1) as well as documents that those papers cited. A listing of
the key predicates along with their corresponding sentences are recorded by document
identifier within Table A-2. Appendix A also includes the topmost results of the search,
first using citations and then again without.
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We seeded our search with two concepts as sources: Fish Oils (C0016157) and
Eicosapentaenoic Acid (C0000545), and two concepts as targets: Raynaud Disease
(C0034734) and Raynaud Phenomenon (C0034735). This is analogous to the search
criteria as made by Cameron et al.
In the original study it was stated that dietary fish oil might prevent Raynaud’s
syndrome. “This is because dietary fish oils (1) inhibit Platelet Aggregation, (2) increase
the flow of blood (by reducing Blood Viscosity), and (3) have a regulatory effect on
muscle (thereby preventing vasoconstriction and stimulating vasodilation)” (Cameron
2015). As such, rediscovery approaches consider these to be the primary three
intermediate topics that should be found.

4.1.1 Platelet Aggregation
It is unsurprising that within our top results, the topic of Platelet Aggregation
appeared several times under the guise of different MeSH terms, namely Figure A-2,
Figure A-3, and Figure A-5. Particularly within biochemistry many things will be closely
interrelated, and we can examine these connections via separate paths. The first two
connect Fish Oils and Eicosapentaenoic Acid via Prostaglandins to Epoprostenol to
Raynaud Phenomenon (Figure A-2 and Figure A-3). A third then connects
Eicosapentaenoic Acid to Platelet aggregation to Alprostadil to Raynaud Phenomenon
(Figure A-5).
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4.1.2 Fish Oils to Raynaud Phenomenon Path via Prostaglandins
As shown in Figure 37, this path is present within our results. The stronger
predicate [Fish Oils INHIBITS Prostaglandins] reported within Cameron’s results,
does not exist within the export of SemRepDB and thus must be derived from the fulltext.

Figure 37. Prostaglandins Subgraph

In fact, none of the core papers have a predicate relating the two. However,
multiple papers [PMID6302714, PMID6303363, PMID6301111] cite Culp et al.
[PMID7208950] whose abstract states “The effect of altering the abundance of precursors
and inhibitors of prostaglandin formation by dietary supplements of fish oil…” (Culp
1980). This generates a lesser version of the predicate [Fish Oils INTERACTS_WITH
Prostaglandins],

connecting the two concepts with INTERACTS_WITH rather than

INHIBITS.
The second predicate [Prostaglandins ISA Epoprostenol] also does not exist
in the core non full-text documents - nor does any predicate relating the two. A core
paper [PMID6301111] cites both [PMID378308] by Bayer et al. and [PMID6773615] by
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Pickard et al. In the abstract of the first paper, the authors state “due to the formation of
platelet aggregates it is concluded that PGI2 is a most potent anti-aggregatory
prostaglandin” (Bayer 1979), while in the abstract of the second paper the authors state
“These results support our suggestion that a prostaglandin, in particular PGI2, is required
for hypercapnia to produce full cerebral vasodilatation” (Pickard 1980). In both cases, the
predicate [Prostaglandins ISA Epoprostenol] is derived, as Epoprostenol is also
known as PGI2 or prostacyclin.
The next predicate, [Epoprostenol TREATS Raynaud Phenomenon] has multiple
predicates within the non full-text core documents. It is present in [PMID6788326,
PMID7037038, and PMID3883365].

The analysis indicates that this particular path would not be found using only non
full-text versions of the core documents, but is present in our results because our
algorithm included the cited references.

4.1.3 Eicosapentaenoic Acid to Raynaud Phenomenon Path via Prostaglandins
This path is largely the same as the previously described one, aside from the
difference of the first graph edge (Figure 37). Here, the predicate [Eicosapentaenoic
Acid CONVERTS_TO Prostaglandins]

is found in two non full-text core documents

[PMID6314583 and PMID6821892]. Despite this, because this path also utilizes the
[Prostaglandins ISA Epoprostenol] step, this path would also not be found using
only non full-text versions of the core documents, but is present in ours because
bibliographic associations included the additional references.
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4.1.4 Eicosapentaenoic Acid to Raynaud Disease Path via Platelet Aggregation
We can see a more obvious interaction using the MeSH concept Platelet
Aggregation directly in our fourth graph result (Figure 38). The predicate
[Eicosapentaenoic Acid DISRUPTS Platelet Aggregation] appears in the abstract
of one core document [PMID6303363] where it was said that Eicosapentaenoic acid “has
been reported to be a potent antagonist of platelet aggregation and also to reduce the
incidence of cardiovascular disorders” (Terano et al. 1983).

Figure 38. Platelet Aggregation Subgraph
From there, there are associations between Platelet Aggregation and both
Epoprostenol and Alprostadil. Although the path between Epoprostenol and Raynaud’s
Disease was previously discussed, the predicates [Epoprostenol DISRUPTS Platelet
Aggregation]

and [Epoprostenol AFFECTS Platelet Aggregation] are new. These
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are generated from one core paper and over ten cited articles. The title of the 1985 core
paper [PMID2408588], “Inhibition of platelet aggregation by a new stable prostacyclin
introduced in therapy of patients with progressive scleroderma”, produces the first
predicate (Keller, J., Kaltenecker, A., Schricker, K. T., Neidhardt, B., & Hornstein, O. P.
(1985).
The second [Alprostadil DISRUPTS Platelet Aggregation] does not appear
in the non full-text version of any core document. Core documents [PMID6301111 and
PMID6302714]

cite four different papers [PMID190267, PMID364545, PMID7003784,

and PMID7427564]

which generate this predicate, and one of which [PMID7427564] is hit

on the search terms. As an example, Minkes et al. [PMID190267] state in their abstract
“Furthermore, dBcAMP and PGE1 both inhibit platelet aggregation” (Minkes 1977)
while Whittle et al. [PMID364545] state “The activity of prostacyclin (PGI2), PGE1 or
PGD2 as inhibitors of platelet aggregation” in theirs (Whittle 1978). As Prostaglandin E1
(PGE1), is also known as Alprostadil, these yield the predicate in question.
The final predicate that has not been discussed, [Alprostadil TREATS
Raynaud’s Disease],

appears in two core references [PMID3977414, PMID7259326].

The 1981 paper [PMID7259326] by Martin et al. concludes that Alprostadil “may
therefore be suitable treatment for Raynaud's phenomenon and the vascular insufficiency
of systemic sclerosis and other connective tissue diseases” (Martin et al. 1981)

4.1.5 Blood Viscosity
The second intermediate Blood Viscosity was found by Cameron et al. (2015) via
the following predicates: [Eicosapentaenoic Acid DISRUPTS Blood Viscosity],
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[Fish Oils AFFECTS Blood Viscosity], [Ketanserin DISRUPTS Blood
Viscosity],

and [Ketanserin TREATS Raynaud Phenomenon]. This shows up in our

15th result (Figure 39).

Figure 39. Blood Viscosity Path

The predicates are mostly found directly within the titles and abstracts of core
documents. The predicate [Eicosapentaenoic Acid DISRUPTS Blood Viscosity] is
from [PMID6303363] where Terano et al. state that “We recently reported that EPA also
reduces whole blood viscosity” (Terano 1983). Similarly, the predicate [Fish Oils
AFFECTS Blood Viscosity]

is contained within the title of Woodcock et al.’s paper

[PMID6320945]: “Beneficial effect of fish oil on blood viscosity in peripheral vascular
disease” (Woodcock 1984). [Ketanserin TREATS Raynaud Phenomenon] is lastly found
in multiple core documents [PMID6812750, PMID6365102, PMID6432198].
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The one exception, [Ketanserin DISRUPTS Blood Viscosity] is not found
within any of the non full-text documents. Instead, only a weaker relation [Ketanserin
AFFECTS Blood Viscosity]

exists within Walker et al.’s paper [PMID2412054] where

they state “Ketanserin given intravenously for seven days to patients with very severe leg
ischaemia, significantly improves whole blood viscosity...” (Walker 1985).
For this path, there is no additional benefit from utilizing bibliographic citations
and the only change from not using full-text is the weaker relation between Ketanserin
and Blood Viscosity.

4.1.6 Vascular Reactivity
Cameron et al. reported that they were unable to retrieve the intermediate concept
of Vascular Reactivity directly. They later observed that SemRep erroneously parsed the
phrase Vascular Reactivity (C1660757) into two tokens: Vascular (Blood VesselsC0005847) and Reactivity (Reactive-C0205332) (Cameron 2016). Only after adjusting
the predicates manually were they able to achieve the results in Figure 40.

Epoprostenol

AFFECTS_MAN

TREATS

INHIBITS_MAN
EPA
AFFECTS_MAN

Vascular
Reactivity

RD/RP
CAUSES

Figure 40. Vascular Reactivity Path from Cameron et al.
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In their results, multiple predicates had to be manually adjusted, indicated with
the suffix notation of “_MAN” in the graph. Here, these are from [Eicosapentaenoic
Acid AFFECTS_MAN Vascular constriction], [Epoprostenol INHIBITS_MAN
Vascular constriction]

and [Epoprostenol TREATS Raynaud Syndrome].

However, our results (Figure 41) generated a path without any modification to the
predicates or utilizing full-text. A particular predicate, [Epoprostenol ISA
Vasodilator Agents]
PMID114606].

can be found within two documents [PMID7003784 and

The first states that “Prostaglandins E1 (PGE1) and I2 (prostacyclin, PGI2)

are potent vasodilators and inhibitors of platelet aggregation “, while the second states
“As PGI2 is the most potent cerebral vasodilator drug tested”. Both of these are cited by
one of the core documents [PMID6301111].
The second predicate [Vasodilator Agents TREATS Raynaud Disease] is also
only included via citation. The core document by Belch et al. [PMID3883365] cites an
earlier paper by Belch et al. [PMID7025341] where they measured the effects of
“prostacyclin (PGI2) a potent antiplatelet and vasodilator agent in 5 female patients with
Raynaud's syndrome” with positive results (Belch et al. 1981). Thus, the entire path is
generated due to the inclusion of bibliographic citations.
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Figure 41. Vascular Reactivity Path

4.1.7 Retrospective Study: Fish Oils and Raynaud Disease - Conclusions
In work later performed by Cameron as part of his dissertation, he attempted to
rediscover Swanson’s Raynaud Syndrome–Dietary Fish Oils hypothesis without the use
of full-text. Through a similar predicate analysis he noted that “these results collectively
suggest that titles and abstracts alone, might NOT be sufficient” (Cameron et al. 2016).
As such, this matches the results of this project in that several of his resulting paths were
only available due to the usage of predicates generated from full-text. This project,
however, shows that it is possible to reproduce the results of Swanson’s Raynaud
Syndrome–Dietary Fish Oils hypothesis (using a similar corpus) without the use of fulltext by modifying Cameron et al.’s approach by incorporating bibliographically related
documents.
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In Appendix A, Table A-3 details the precision and recall at each ranked result
when using citations. Table A-4 does the same when not using citations but otherwise
follows the same algorithm. A graph of the results can be seen here in Figure 42.

Figure 42. Precision Recall Curve for Fish Oils – Raynaud Disease Study

The shape of this graph departs from the typical sawtooth shape of precision-recall
curves. When considering standard document relevancy, a document result is unique and
can be considered relevant or not. Here, each result is a subgraph which may contain
more than one possible path, and each path could contain several concepts. For example,
the very first result using citations was shown in Figure 41. In this graph paths may go
through Epoprostenol, Alprostadil, Vasodilator Agents, and Systemic Scleroderma, the
precise meaning of which may vary: Epoprostenol and Alprostadil generally imply an
association with Platelet Aggregation, Vasodilator Agents refers to Vascular Reactivity,
and Systemic Scleroderma, although related to Raynaud’s Disease isn’t a direct
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connection. This implies that the first search result has a recall of 0.667 having two of the
three intermediate topics, and a precision of 0.667 for having two relevant and one nonrelevant topics.
A second factor that is different from standard document information retrieval
approaches is that a subgraph result may technically contain new information but no new
relevancy information. Consider the first (Figure 41) and the second (Figure 37) returned
results. The second result has a new concept, Prostaglandins, when compared to the first
result, but semantically this is still referring to the topic of Platelet Aggregation. It
provides additional information into the interconnectedness between the concepts but at
the same time does not demonstrate increased recall.
An alternative is to examine the F1 measure as a function of the top k results
(Figure 43). The search without citations only returned a total of eight results, but up to
that point using citational information produced a better F1 score.

Figure 43. F1 @ K measure for Fish Oils – Raynaud Disease Study
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Beyond the behavior of the graphs themselves, the most noticeable difference is
that without using citations, one of the three intermediate concepts (Vascular Reactivity)
was unable to be recovered.

4.2 Retrospective Study: Magnesium and Migraine Disorders
In his 1987 paper, “Migraine and Magnesium: Eleven Neglected Connections”
Swanson described his discovery of how Magnesium deficiency might exacerbate
Migraines via eleven different interrelated mechanisms (Swanson 1988). These are listed
below in Table 14. We attempted to reproduce these results via the approach described
previously.
Table 14. Swanson’s Eleven Intermediates for Magnesium-Migraine Disorders
Calcium Channel Blockers
Vascular Mechanisms
Prostaglandins
Epilepsy
Serotonin
Inflammation
Spreading Cortical Depression
Hypoxia
Platelet Aggregation
Stress/Type A personality
Substance P
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Our corpus consisted of 131 of the original MEDLINE documents cited by
Swanson (Table B-1) along with the other MEDLINE documents they cited, totaling
approximately 2,900 references. Some documents were missing abstracts (and thusly
missing SemRep abstract-generated predicates), for these abstracts/introductions were
located and added manually along with any generated predicates. A listing of the
predicates along and their corresponding sentences are recorded by document identifier
within Table B-2.
Unless specified otherwise, each search was performed with a source concept of
Magnesium (C0024467) and a destination of Migraine Disorders (C0149931). Even
today the exact nature of migraine hasn’t been completely solved and there is debate if it
is primarily a vascular (pertaining to blood vessels), neurological (pertaining to neurons),
or a mixture of the two. We examined each of the eleven intermediates that Swanson
discovered to determine if our system has recovered the discovery. In addition, we will
discuss a twelfth intermediate concept, Diabetes, not identified by either Swanson or
Cameron.

4.2.1 Calcium Channel Blockers
It stands that if the source of pain is caused by vasoconstriction, then a vasodilator
should provide relief. Peroutka explained that “calcium channel antagonists are a
recently developed class of vasodilators that prevent the influx of calcium into vascular
smooth muscle. The unique pharmacologic effects of these agents provide a theoretical
basis for their use in the treatment of migraine” (Peroutka 1983).
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Figure 44. Calcium Channel Blockers

Our second search result using citations are shown in Figure 44. Known calcium
channel blockers, Verapamil and Nifedipine, both treat Migraine as suggested by
multiple articles. The article by Markley, Cheronis, and Piepho [PMID6539877] entitled
“Verapamil in prophylactic therapy of migraine” states “Verapamil significantly reduced
both headache frequency and duration with few side effects” (Markley, Cheronis, and
Piepho 1984). The article by Meyer and Hardenberg [PMID6358126] indicates that
“Nifedipine and verapamil provided equivalent relief for cluster but produced more side
effects, and were less effective, than nimodipine in control of migraine” (Meyer and
Hardenberg 1983). Similar statements to the use of Verapamil and Nifedipine in the use
of migraines can be found in other documents. [PMID2425960, PMID6339937,
PMID2425960]

All of these produce at least one of the two predicates

106

[C0042523|Verapamil - TREATS - C0149931|Migraine Disorders] and
[C0028066|Nifedipine - TREATS - C0149931|Migraine Disorders].
The presence of Magnesium acts like a Calcium antagonist, having been
compared to both Verapamil and Nifedipine. The predicates connecting
Magnesium(C0024467) to Verapamil(C0042523) and Nifedipine(C0028066) can be
found in two documents [PMID7297597, PMID3458981]. In the paper by Sjögren A. and
Edvinsson L. [PMID3458981] it was indicated that “the order of potency for eliciting
relaxation was: nifedipine greater than verapamil greater than magnesium” (Sjögren and
Edvinsson 1986). While in the second reference by Turlapaty, Weiner, and Altura
[PMID7297597] it is noted that a deficiency of magnesium induces vascular constriction:
“Previous studies on isolated blood vessels indicate that [a] withdrawal of magnesium
([Mg2+]0) induces calcium-dependent contractile responses” (Turlapaty, Weiner, and
Altura 1981).
In Andersson’s 1986 paper [PMID2424267] he calls out several calcium channel
blockers in his statement: “The cardiovascular effects of different calcium channel
blockers (CCB), exemplified by nifedipine, verapamil and diltiazem, are not identical”
(Andersson 1986). Other papers also illustrate this relationship [PMID2981405,
PMID6202853, PMID6708731, PMID6869560, PMID7195070]

(Figure 45).
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Figure 45. Calcium Channel Blockers Subgraph

Multiple documents associate Calcium Channel Blockers with Migraine
Disorders, including the paper by Peroutka mentioned earlier [PMID6358127,
PMID3521194, PMID6715160].

Taken together these explicitly show that both Nifedipine

and Verapamil are Calcium Channel Blockers and that the blockers as a whole are used
as treatment for migraines.

4.2.2 Vascular Mechanisms
Multiple subgraphs were examined connecting Magnesium and Migraine
Disorders via vascular mechanisms. In the following sections we examine Dilatation,
Blood Vessels, Contraction, and Vasospasm to understand the underlying connections.
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4.2.2.1 Dilatation
The 1977 paper by Hachinski et al. [PMID597797] attempted to examine regional
cerebral blood flow (rCBF) and dilation during migraines. One theory of migraine at the
time conjectured that the primary mechanism consists of a series of events initiated by
vasospasm of the cerebral arteries followed by a reactive vasodilation. The distension of
the vessels was assumed to be the source of the headache pain. Although their findings
did not support the speculation, it did not discount distention of the intracranial arteries
during migraine headache (Hachinski et al. 1977). The predicate seen in the fourth search
result (Figure 46), [C0012359|Pathological Dilatation - COEXISTS_WITH C0149931|Migraine Disorders],

was extracted from Hachinski’s paper, signifying one

of the underlying possibilities for migraines.

Figure 46. Vascular Mechanisms (Dilatation) Subgraph
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The interaction along calcium channels has already been discussed, both in terms of
Verapamil and Magnesium acting as a vasodilator, or in the case of Magnesium
deficiency, acting as a vasoconstrictor.

4.2.2.2 Vascular Mechanisms - Summary
Our resulting subgraphs have shown vascular connections between Magnesium
and Migraine Disorders using a path length of three using our constrained corpus. If we
were to extend our corpus to include the additional documents that Cameron utilized
within his study then several additional predicates would have appeared and allowed a
connection at a path length of two. The 1972 article [PMID4260015] “Magnesium
metabolism from the viewpoint of cardioangiology. II. Findings in magnesium
metabolism in vascular diseases” by Wustenberg et al. generates the predicate
[C0024467|Magnesium - ASSOCIATED_WITH - C0042373|Vascular Diseases].
Although ASSOCIATED_WITH is not as strong of a direct implication as INHIBITS,
implied by Swanson, its existence would have been sufficient reason to investigate paths
of length three. Additionally, the predicate [C0149931|Migraine Disorders - ISA C0042373|Vascular Diseases]

would have been generated from Domzal’s 1975 article

[PMID1153064], wherein he states “EEG changes suggest--according to the author--that
migraine is a primary cerebral and only secondarily a vascular disorder” (Domzal 1975).

4.2.3 Prostaglandins
As is common with many biochemical systems, a particular chemical can have
one effect in larger concentrations, while a deficiency will provoke the opposite response
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as a means of regulation. As Horrobin’s experimental results showed this was the case for
prostaglandins - indicating that higher concentrations can cause vascular dilation, while
the opposite was true in low concentrations (Horrobin 1977). Various experiments have
shown that the administration of Prostaglandins could cause migraine-like symptoms,
such as in Carlson’s study where Prostaglandin E1 was infused intravenously into eight
healthy male subjects with no prior history of migraine - all experienced symptoms with a
sufficient dosage (Carlson, Ekelund, and Orö 1968).

Figure 47. Prostaglandins Subgraph – Path Length of 2

The title of their article, “The effect of infused prostacyclin in migraine and
cluster headache”, by Peatfield et al. [PMID7026501] implies some relationship between
prostacyclin (Epoprostenol), a type of Prostaglandin, and migraines. They noted that “We
have assessed the role of prostacyclin by infusing it into eight patients with migraine and
eight with cluster headache. Most of the subjects developed a dull throbbing headache
during the infusion” (Peatfield, Gawel, and Rose 1981). The title itself generates two
different predicates: [C0033567|Epoprostenol - AFFECTS - C0009088|Cluster
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Headache]

and [C0033567|Epoprostenol - AFFECTS - C0149931|Migraine

Disorders].

Meanwhile, Prostacyclin was noted by Briel, Lippert, and Zahradnik
[PMID3898850] to be a “potent naturally occurring vasodilator and inhibitor of platelet
aggregation”, then continue to state that “Magnesium is known to exert an inhibitory
effect on coagulation and platelet function”, thus prompting them to investigate the
effects of “magnesium sulfate on vascular prostacyclin synthesis and platelet prostacyclin
interaction” (Briel, Lippert, and Zahradnik 1985). This last statement having generated
the predicate [C0024467|Magnesium - INTERACTS_WITH - C0033567|Epoprostenol]
in Figure 47.

Figure 48. Prostaglandins Subgraph – Path Length of 3

Using a path length of three we can see some of the additional details that we would
expect (Figure 48).
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The predicate [C0033567|Epoprostenol - ISA - C0033554|Prostaglandins]
is derived from the sentence “Prostacyclin appears to be the most active of the
vasodilating prostaglandins with inflammatory and hyperalgesic properties” in the article
by Peatfield et al. [PMID7026501] (Peatfield et al. 1981). Two documents [PMID4016946,
PMID89390]

also generate the predicate [C0033554|Prostaglandins -

ASSOCIATED_WITH - C0149931|Migraine Disorders].

Both articles make a claim that

“Prostaglandins (PG), particularly PGE, may be linked to the pathophysiology of
migraine”, namely because “PGEs cause vasodilation and hyperalgesia, both typical
reactions of inflammation”. This view that vascular headache is an "inflammatory
reaction" explains the “local role of PGs and the effectiveness of PG-inhibitors in the
treatment of migraine” (Parantainen, Vapaatalo, and Hokkanen 1985).
It has been shown that Magnesium Deficiency can increase prostaglandin
production. This was noted by Soma et al. in their 1988 paper [PMID3238000] wherein
their findings suggested “that the biosynthesis of eicosanoids, mainly PGI2, is stimulated
in Mg deficiency, and this may provide protection against intracellular Mg depletion and
Ca accumulation, so as to counteract to the constricted and hyperreactive state of the
vasculature in such a condition” (Soma et al. 1988.)

4.2.4 Epilepsy
Migraines have been a mystery for decades due to the mixture of vascular and
neurogenic symptoms. Swanson noted that “a connection between migraine and epilepsy
has been suspected for most of the past century” (Swanson 1988). In 1969, Basser wrote
his paper [PMID4978139] entitled “The Relation of Migraine and Epilepsy” which
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illustrated their study into a potential relationship between the two: “It is the purpose of
this paper to examine the question of the relation of migraine and epilepsy by an analysis
of 1,800 cases of migraine seen at the Northcott Neurological Centre since 1951 with
particular reference to those cases in which migraine and epilepsy were manifested in the
same individual” (Basser 1969). Our first search result (Figure 49) shows the predicate
[C0014544|Epilepsy - COEXISTS_WITH - C0149931|Migraine Disorders] derived
from this.

Figure 49. Epilepsy Subgraph – Path Length of 2

Canelas et al. wrote a paper in 1965 [PMID14338128] entitled “Disorders of
Magnesium Metabolism in Epilepsy”, from which the predicate [C0024467|Magnesium
- ASSOCIATED_WITH - C0014544|Epilepsy]

was derived. As an interesting note, in

their introductory paragraph they state that “The possibility that convulsions may occur in
Mg deficiency led some investigators to study the metabolism of this metal in the
epilepsies, and a trend to low blood concentrations was usually found” (Canelas, De
Assis, and De Jorge 1965). A second article, [PMID108361], also generated this predicate.
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4.2.5 Serotonin
Serotonin is present in both blood platelets and blood serum that acts as a
neurotransmitter and causes vascular constriction. Swanson noted that Hilton and
Cumings discovered “increased platelet aggregability and sensitivity to serotonin release
in headache-free migraine patients”, and that many researchers have also suggested that
platelets and serotonin have some association with migraines (Swanson 1988). Several
studies within our corpus have associated Serotonin to migraines [PMID6275679,
PMID5658323, PMID5297855, PMID1254466, PMID1146499].

Each producing a

predicate to connect the two concepts (Figure 50).
“Serotonin is released from platelets during a migraine attack, thus causing a
transient increase in plasma serotonin which, through its vasoconstrictive action, is then
thought to play a role in the development of the headache phase of the attack. Plasma
serotonin is rapidly metabolized, leading to a drop in blood levels of serotonin as a
consequence of a migraine episode” (Swanson 1988). It has been further suggested that a
serotonin releasing factor is present within the blood of migraine patients. Free fatty acids
(Figure 51) have been suggested for this (Anthony 1982).
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Figure 50. Mg - Migraine search result 14

Figure 51. Mg – Migraine search result 5

Our corpus contained six references that connected Serotonin to vasoconstriction
[PMID6948814, PMID6538269, PMID4814375, PMID379918, PMID7060640,
PMID1262918].

One example [PMID6948814] of which states that “In isolated human pial

arteries (diameter 0.4-0.5 mm), contractions were produced by potassium, noradrenaline,
serotonin, and prostaglandin F2 alpha” (Brandt, Andersson, Edvinsson, and Ljunggren
1981). Given that serotonin is a known vasoconstrictor this is no surprise. We have also
previously noted the vasodilator effects of Magnesium and Calcium Channel Blockers.
The predicate [C0036751|Serotonin - STIMULATES - C0042523|Verapamil] is
derived from [PMID7150872] in the sentence “The calcium channel blocking agent,
verapamil (10(-6)M), inhibited completely contractile responses to KCl; contractile
responses elicited by angiotensin II and 5-HT were attenuated by verapamil” (Altura and
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Turlapaty 1982). This matches our expectations (Figure B-5). The same is true for the
predicate [C0028066|Nifedipine - INHIBITS - C0036751|Serotonin] derived from
[PMID450213] and is seen in Figure B-3.
Our results (Figure 50 and Figure 51) have shown interconnections between
Magnesium and Migraine Disorders via Serotonin using a path length of three within our
constrained corpus. Cameron states that the 1987 article [PMID3629724] by Pertseva et al.
produces the predicate [Magnesium - INTERACTS_WITH - Serotonin] (Cameron 2014).
In this case, by extending our corpus to include the additional document that Cameron
utilized within his study then we gain an additional predicate that would have appeared
and allowed a connection at a path length of two. However, upon inspection, the abstract
of the article states “A stimulating effect of serotonin, guanine nucleotides and sodium
fluoride is found as well as a dependence of the catalytic activity of adenylate cyclase on
magnesium and manganese ions” (Pertseva and Soltitskaia 1987). This produces the
predicate [C0001492|Adenylate Cyclase - INTERACTS_WITH C0024467|Magnesium],

which is different than expected.

4.2.6 Inflammation
In his paper Swanson posits that “pain is a classic sign of inflammation, and
migraine has been described as a sterile inflammatory disease of cranial blood vessels”
(Swanson 1988). Acute inflammation is generally characterized by vasodilation,
increased permeability, and increased blood flow. In 1979 Moskowitz et al. [PMID90971]
proposed a mechanism for pain in headache based upon the abnormal release of
Substance P from trigeminal nerve terminal terminals. The trigeminal nerve is the largest
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of the cranial nerves and provides the primary pathway for the transmission of head pain.
Moskowitz also hypothesized that pain was the result of an induced release of
vasodilators such as Substance P from the nerve fibers (Moskowitz, Romero, Reinhard,
Melamed, and Pettibone 1979).

Figure 52. Inflammation Subgraph

The relationship between Pain and Migraine Disorders is fairly common as one
would expect. The titles of several articles indicate as such: [PMID3585352,
PMID6830162, PMID7310427, PMID20784580],

each generating the predicate

[C0030193|Pain - ASSOCIATED_WITH - C0149931|Migraine Disorders]. However,
given the complexity of migraine, the explanation is not as straightforward.
Sicuteri, Renzi, and Geppetti wrote an article in 1986 [PMID2433912] where they
construct the predicate [C0037659|Somatostatin - TREATS - C0030193|Pain] for
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headaches and further implicate the involvement of Substance P. “Opiates and
somatostatin inhibit the release of substance P from primary sensory neurones and relieve
both pain and autonomic symptoms of cluster headache attack” (Sicuteri, Renzi, and
Geppetti 1986).
To complete the association as shown in Figure 52, we have to determine the
relationship between Magnesium and Somatostatin. An article within our corpus sheds
some light onto this and provides the necessary predicate. Curry and Bennett’s article
[PMID6141690] “Magnesium requirement for somatostatin inhibition of insulin secretion”
suggests from the title alone that Magnesium is necessary for Somatostatin to function
properly - at least in certain capacities. The predicate relationship, INHIBITS, in this case
is misleading but upon examination fits into our expectations. As we’ve seen so far it is
the case of Magnesium deficiency which is in relation to Migraine conditions. Here, a
lack of Magnesium causes Somatostatin to not function properly.

4.2.7 Spreading Cortical Depression
Spreading Cortical Depression (SCD), or Spreading Depression of Leao is
described as a self-propagating wave of depolarization across the cerebral cortex.
Experimentally it could be induced by means of a stimulus applied to the cerebral cortex,
and results showed that it was accompanied by vasodilation of the arteries. SCD has also
been found to be induced by hypoxic conditions and has been implicated in migraines.
(Swanson 1988). Additional research into spreading depression has shown two different
types, one based upon glutamate and the other on potassium. The introduction of
Magnesium ions were able to block the potassium based SCD [PMID739264,
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PMID6150068] (Van

Harreveld 1978, 1984), while a deficiency induced spreading

depression in some situations [PMID3763042, PMID3801897] (Walther, Lambert, Jones,
Heinemann, and Hamon 1986; Anderson, Lewis, Swartzwelder, and Wilson 1986).
Unfortunately, our system was unable to produce a subgraph that could relate
Magnesium and Migraine Disorders via Spreading Cortical Depression using a path
length of 3 or less. It is expected that clinical verbiage used within abstracts did not use a
consistent terminology to be able to produce the necessary predicates, which is consistent
with the results of Cameron et al.

4.2.8 Brain Hypoxia
Hypoxia is defined as a deficiency in the amount of oxygen reaching a particular
section of tissue. In 1974, Bucking and Baumgartner suggested [PMID4842482] that
migraine and spreading depression might be initiated by cerebral hypoxia. They found
that experimentally induced hypoxia caused a burst of cerebral electrical activity that
resembled spreading depression (Bücking and Baumgartner 1974). It was later suggested
that the mechanisms of both SCD and brain hypoxia/anoxia are related in the ionic
permeability of brain cells (Hansen and Zeuthen 1981).
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Figure 53. Hypoxia Subgraph

As can be seen in Figure 53, the predicate [C0024467|Magnesium ASSOCIATED_WITH - C0151744|Myocardial Ischemia]

is generated by another article

by Altura and Altura [PMID6149922]. They note that “Mg++ ions are essential for
regulation of Na+ and K+ transport across cell membranes” and “under conditions where
cellular Mg++ is depleted (e.g. hypoxia, ischaemia, anoxia)” (Altura and Altura 1984).
Additionally of note, they state “A reduction in the extracellular Mg++ concentration can
produce hypertension, coronary vasospasm and potentiation of vasoconstrictor agents by
allowing excess entry of Ca++; concomitantly, the potency of vasodilator agents is
reduced” (Altura and Altura 1984). The predicate [C0151723|Hypomagnesemia PREDISPOSES - C0151744|Myocardial Ischemia]

[PMID527222].

comes from similar statements in
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Both Altura BM’s 1979 article [PMID390330] on ischemic heart disease and the
1976 reference by Hearse et al. [PMID939020] produce the associations between Ischemia
and Myocardial Ischemia. Of lesser interest, but related biochemically we see Cerebral
Vasospasm. Previously we have seen a connection between Magnesium and Cerebral
Vasospasm. For Figure 53, all three predicates [C0024467|Magnesium - DISRUPTS C0265110|Cerebral Vasospasm], [C0265110|Cerebral Vasospasm COEXISTS_WITH - C0151723|Hypomagnesemia],
- COEXISTS_WITH - C0022116|Ischemia]

and [C0265110|Cerebral Vasospasm

come from [PMID6680619] by Altura and

Altura.
The final link, [C0022116|Ischemia - CAUSES - C0149931|Migraine
Disorders],

can be found in two documents. The first by Skinhoj E and Paulson OB

[PMID5803690], comes from the following statement: “According to the classical theory
the first (prodromal) phase in migraine is caused by ischemia within the internal carotid
system and the second phase (headache) by a vasodilation, especially within the external
carotid system” (Skinhoj and Paulson 1969). The second from Welch et al. [PMID184066]
where they state that “Since biochemical abnormalities reported herein were common to
occlusive CVD and migraine headache, it seems probable that they are due to ischemia
associated with both conditions and possibly related to the resultant disorder of cerebral
energy metabolism” (Welch et al. 1976).

4.2.9 Platelet Aggregation
The hypothesis that migraine is a platelet disorder was proposed by Hanington
citing evidence in the difference in the behavior of platelets in migraine patients
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(Hanington, Jones, Amess, and Wachowicz 1981; Hannington 1986). Other research has
since disputed this (Steiner, Joseph, and Rose 1985; Joseph and Welch 1987), instead
suggesting that differences in platelet behavior is a consequence to other changes such as
stress, the release of catecholamines, FFAs, serotonin, and prostaglandins (Swanson
1988).
Previously we have seen that Prostacyclin (Epoprostenol) inhibits platelet
aggregation and that Magnesium can enhance this effect when present, or inhibit it during
the case of Magnesium deficiency (Figure 48).
A more direct connection to the concept Platelet Aggregation shows up at length
4 (Figure 54), but there are many paths of little value generated at this length. In his paper
Cameron mentions a 1987 article by Briel et al. [PMID2440758] that confirms the
predicate [Magnesium - INHIBITS - Platelet Aggregation]. However, this paper does not
generate the predicate with SemRep.
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Figure 54. Platelet Aggregation Subgraph – Path Length of 4

The other paths of note in Figure 54 connect Prostaglandins and Platelet
Aggregation. We can find the predicate [C0033567|Epoprostenol - DISRUPTS C0032176|Platelet aggregation]

from “Prostacyclin (PGI2), a strong vasodilator of

cerebral vessels and potent inhibitor of platelet aggregation” inside [PMID7048862]
(Quintana, Konda, Ishibashi, Yoshimoto, and Suzuki 1982) and other documents
[PMID7014260, PMID6992233, PMID6117893, PMID6110816, PMID6117893]. The
other predicate [C0033554|Prostaglandins - DISRUPTS - C0032176|Platelet
aggregation]

is derived from both [PMID372242] and [PMID361756].
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4.2.10 Stress / Type A Personality
Swanson noted that the “descriptions of migraine-associated personality in the
older literature bear a close resemblance to descriptions of what is now called the type A
personality” (Swanson 1988). Several studies have reported a correlation between those
of type A personality and frequency of headaches.

Figure 55. Stress Subgraph
Our study shows a meaningful path connecting Magnesium and Migraine
Disorders that related to Stress/Type A personality by means of Hypertensive disease.
In the 1954 article by Friedman et al. [PMID13214278] entitled “Migraine and tension
headaches; a clinical study of two thousand cases” the authors state “Among this group
are headaches associated with hypertension, arteriosclerosis, infection, brain tumor,
hematoma, allergy, and cranial trauma” which generates the predicate
[C0018681|Headache - ASSOCIATED_WITH - C0020538|Hypertensive disease] in
Figure 55 (Friedman, Von Storch, and Merritt 1954).
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Swanson explained that “stress causes an increases in blood levels of free fatty
acids, which in turns induces loss of blood magnesium”, or in other words, “type A
behavior in effect entails a virtual deficiency of Magnesium” (Swanson 1988). This is
backed up by McCarron [PMID6847018] who states that “Many studies suggest that
reduced consumption of calcium or magnesium is associated with an increased risk of
developing hypertension and cardiovascular disease” (McCarron 1983) which generates
the predicate [C0024467|Magnesium - PREDISPOSES - C0020538|Hypertensive
disease].

4.2.11 Substance P
During our prior analysis of a connection involving inflammation/pain, the
neuropeptide “Substance P” was referred to as another possible factor in the genesis of
migraines. Our study did not find a meaningful path connecting Magnesium and
Migraine Disorders that related to Substance P. However, an exploratory analysis did
find a connection utilizing the concept Cluster Headache.
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Figure 56. Substance P Subgraph – Path Length of 3

Two papers within our corpus related Substance P to Cluster Headache. The first,
was a 1983 paper by Sicuteri et al. [PMID6193886] where their title, “Substance P and
endogenous opioids: how and where they could play a role in cluster headache” generates
the graph predicate. They state that “Substance P appears to be involved in the
transmission of pain signals from the periphery to the spinal cord and brain stem” and
that “Substance P containing neurons are responsible for the neurogenic vasodilation”
(Sicuteri, Rainò, and Geppetti 1983). The second paper, “Substance P in the human iris:
possible involvement in echothiophate-induced miosis in cluster headache” by
Fanciullacci et al. [PMID2452018], also connects the two concepts by title alone
(Fanciullacci et al. 1988).
The predicate [C0038585|Substance P - CAUSES - C0019595|Histamine
Release]

are produced from the sentence “Substance P (SP) induces histamine release
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from isolated rat peritoneal mast cells at concentrations of 0.1-10 muM” written in an
article by Fewtrell et al. [PMID6184468] (Fewtrell et al. 1982). In the same avenue, the
connection between Substance P and Blood Vessels comes from sentence “Indirect
evidence has abundantly been presented to support the view that substance P (SP) is
involved in the vasodilatation following activation of fine calibre pain fibres”, by Rosell
et al. [PMID6171999] (Rosell et al. 1981). Both of these connections fit our earlier
reasoning that inflammation, pain, and Substance P are interrelated.
The one new connection in Figure 56 is [C0024467|Magnesium - DISRUPTS C0019595|Histamine Release].

This predicate also comes from Fewtrell et al.

[PMID6184468] where they state that “Extracellular calcium (0.1-1 mM), magnesium (110 mM) and cobalt (0.01-0.1 mM) all inhibit SP-induced histamine release when added
before the peptide” (Fewtrell et al. 1982). It therefore stands that if the presence of
Magnesium inhibits SP-induced histamine, then a magnesium deficiency would cause
help provoke headaches in this context.

4.2.12 Diabetes
In addition to the aforementioned eleven connections (Table 14) there was one
unexpected concept that showed up in our initial graph (Figure 57) of length two paths Insulin. The predicate [C0024467|Magnesium - COEXISTS_WITH C0021641|Insulin]

is derived from Flink et al. [PMID572225] where the authors note

that “FFA fell by a maximum of 65% or 0.44 meq/liter and Mg fell by a maximum of
0.31 meq/liter during the glucose-insulin infusions” (Flink, Shane, Scobbo, Blehschmidt,
and McDowell 1979). The other predicate [C0021641|Insulin - ASSOCIATED_WITH -
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C0149931|Migraine Disorders]

came from [PMID65562], a paper by Hsu et al. (Hsu et

al. 1977). In our result set for paths of length three this relationship appears in the third
answer, shown in Figure 58.

Figure 57. Insulin Subgraph

Figure 58. Insulin (Glucose) Subgraph

Performing a search between {Magnesium, Hypomagnesemia} and Migraine
Disorders yields Figure 59. Of primary interest is the predicate
[C0151723|Hypomagnesemia - COEXISTS_WITH - C0011849|Diabetes Mellitus]
which comes from four documents [PMID7068108, PMID6802656, PMID5682248,
PMID527222]

where each group of authors found a connection. Fujii et al. [PMID7068108]

state that “Hypomagnesemia has been reported to occur in diabetes mellitus in the course
of recovery from ketoacidoses, as well as during insulin maintenance therapy” (Fujii,
Takemura, Wada, Akai, and Okuda 1982). McNair et al. [PMID6802656] found that “net
tubular reabsorption of magnesium is decreased in diabetic patients in presence of
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hyperglycaemia, leading to hypermagnesiuria and hypomagnesaemia” (McNair,
Christensen, Christiansen, Madsbad, and Transbøl 1982). Jackson and Meier, in their
1968 paper [PMID5682248] “Routine serum magnesium analysis. Correlation with clinical
state in 5,100 patients”, show that “Diabetes mellitus was the most common condition
associated with hypomagnesemia” (Jackson and Meier 1968). If the conditions of
Diabetes as a disease make magnesium deficiency prevalent, then it is also likely that
migraines are also common for individuals with Diabetes.

Figure 59. Diabetes Subgraph

In the paper “Increased platelet aggregation in early diabetes mellitus” by Sagel et
al. [PMID1138583], they note a “tendency toward vascular disease in diabetes mellitus”
and conclude that “platelet aggregation may be increased early in diabetes mellitus”
(Sagel, Colwell, Crook, and Laimins 1975). Additionally. Rayssiguier notes in his 1984
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paper [PMID6399344] studying the role of magnesium in arteriosclerosis that “magnesium
and potassium depletion have also been reported in diabetes and the vascular implications
of this should be considered” (Rayssiguier 1984). More recent studies have started to
investigate the connections between Diabetes and headaches/migraines [Aamodt,
Stovner, Midthjell, Hagen, and Zwart 2007; Berge et al. 2013; Fagherazzi et al. 2019;
Haghighi et al. 2015; López-de-Andrés et al. 2018].
It should be noted that the connection [C0042373|Vascular Diseases COEXISTS_WITH - C0011849|Diabetes Mellitus]

which completes the path is only

found by including cited documents. This document [PMID1138583] does not have any of
the search MeSH terms, and is only included via the citation from a paper by Joseph and
Welch [PMID3308769], cited by Swanson which details a study on platelets and migraines
(Swanson 1988).

4.2.13 Retrospective Study: Magnesium and Migraine Disorders - Conclusions
The goal of this retrospective study and comparison with Cameron’s results is
twofold: 1) A further test of reproducibility - that is, in general, similar results can be
achieved, and 2) answer the question if the inclusion of citational information improves
upon the prior results. The results are summarized in Table 15. For the eleven
intermediate concepts, all of the seven that Cameron found were found in our reduced
corpus with path lengths less than or equal to three. For the four concepts (Hypoxia,
Stress, Substance P, Spreading Depression) noticed by Swanson that Cameron did not
find, we were able to discover three. Substance P was discovered via discovery browsing
of related concepts, so it is possible they could have been found within Cameron’s system
under a different search. Both Stress/Type A Personality and Hypoxia were found within
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our default search. This implies that overall the results were similar and differences are
likely due to the differences in datasets due to updates to documents, MeSH terms, and a
different version of the SemRep tool. Our results include a twelfth concept, Diabetes,
undiscovered by Swanson and Cameron, where some predicates could only be uncovered
via including cited documents.
Table 15. Comparison of rediscoveries with those of Cameron (Magnesium)
Intermediate

Fleig

Cameron

Calcium Channel Blockers

Found at 2

Found at 2

Prostaglandin

Found at 2

Found at 2

Epilepsy

Found at 2

Found via discovery browsing.

Serotonin

Found at 3

Found at 2

Vascular

Found at 3

Found at 2

Inflammation

Found at 3

Found via discovery browsing.

Hypoxia

Found at 3

Did not find

Platelet Aggregation

Found at 3

Found via discovery browsing?

Stress (Type A personality)

Found at 3.

Did not find

Found (at 3) via discovery browsing.

Did not find

Spreading Cortical
Depression

Not Found

Did not find

Diabetes

Found at 2

Did not find

Substance P

In Appendix B, Table B-3 details the precision and recall at each ranked result when
using citations. Table B-4 does the same when not using citations but otherwise follows
the same algorithm. A graph of the Precision-Recall curve can be seen here in Figure 60,
and the F1@K measure in Figure 61.

132

Figure 60. Precision – Recall Curve for Magnesium – Migraine Disorder Study

Figure 61. F1 @ K measure for Magnesium – Migraine Disorder Study
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Comparison results show that using citations in the initial search does not uncover
one of the expected intermediates that could not be found without their use as there was
sufficient justification for several of the terms to account for the discovery. But, the
inclusion of citations does cause the relevant results to appear higher in the ordered result
set, yield additional results with exploratory searches, and illuminate one new
intermediate concept. Analysis of the data indicates this stems from two factors. The first
is caused by additional predicates that although yield no new intermediates in this case,
may enhance the clustering. The second is caused by a higher IDF threshold.
The IDF threshold is calculated independently for each search, based upon the
unique concepts that are returned. Without citations the query result set contains 962
unique UMLS concepts with a mean of 8.11 and a calculated cutoff at 3.945. When using
citations the query result set contains 1943 unique UMLS concepts with a mean of 8.49
and calculated cutoff at 4.566. Several of the non-relevant concepts appearing within the
non-citation search fall below this higher value. This trend continues for all five of the
studies performed (Table 16).
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Table 16. Number of unique concepts and average IDF by study
Number of Unique Concepts

Avg IDF

Std Dev

Origin Study

449

7.872367037 2.164025258

Fish Oils (W/o Citations)

962

8.119543301 2.13191342

Magnesium (W/o Citations)

967

8.177050274 2.137530552

Fish Oils (With Citations)

1276

8.242275259 2.123573465

Arginine (W/o Citations)

1686

8.492098715 2.107634478 Testosterone (W/o Citations)

1943

8.489334596 2.011232172 Magnesium (With Citations)

2163

8.508816686 2.072720142

2260

8.628326503 2.091449369 Parkinson’s (W/o Citations)

2745

8.700485948 2.064198644 Testosterone (With Citations)

3077

8.73736814

2.06278992

Arginine (With Citations)

Parkinson’s (With Citations)

This behavior is to be expected given the nature of language. Zipf’s law states
that, when given a corpus comprised of natural language, the frequency of any word is
inversely proportional to its rank in the frequency table for that corpus. In other words,
that the most frequent word will occur about twice as often as the second most frequent
word, three times that of the next and so on and so forth (Zipf 1949). This distribution
follows that of a power law probability distribution. Previously we stated that IDF values
for each unique concept were calculated based upon the 85.7 million predicates generated
from Semrep. Plotting the document frequencies for each concept in rank order we find
that they behave as expected by Zipf’s law (Figure 62).
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Figure 62. Log – Log Plot of Concepts Illustrating Zipf’s Law

The probability density for the Zipf distribution has been defined as Equation 4.1, where
ζ(s) is the Riemann zeta function (Eq 4.2), k is the rank position, and s characterizes the
distribution.

𝑓𝑓(𝑘𝑘|𝑠𝑠) =

𝑘𝑘 −𝑠𝑠
𝜁𝜁(𝑠𝑠)
1

𝜁𝜁(𝑠𝑠) = ∑∞
𝑛𝑛=1 𝑛𝑛𝑠𝑠 , s > 1

(4.1)

(4.2)

The shape of this probability curve is known as a Pareto distribution and can be seen in
Figure 63.
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Figure 63. Example Pareto Distribution

When considering the set of unique concepts within a document set, such as our
search results without using citations, that set will contain some distribution of concepts
out of the entire corpus following Zipf’s law. That is to say we expect, on average, more
concepts with a lower IDF score. By expanding the search to include citationally related
documents a greater number of concepts are returned, thereby increasing the average IDF
score. Following the probability distribution selecting random sets shows us this behavior
and explaining the additional differences between results (Figure 64).
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Figure 64. Average IDF for Random Selection of Unique Concepts
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4.3 Retrospective Study: Somatomedin and Arginine
In his 1990 paper, “Somatomedin C and Arginine: Implicit Connections between
Mutually Isolated Literatures” Swanson described four connections between the protein
Somatomedin C, also termed Insulin-Like Growth Factor 1 IGF), and the dietary amino
acid Arginine. These were: stimulus of Growth Hormones, the promotion of Wound
Healing, recovery from malnutrition, and the general improvement of Body Mass/Weight
(Swanson 1990). We attempted to reproduce these results via the approach described
previously.
Our corpus consisted of 150 of the original MEDLINE documents cited by
Swanson (Table C-1) along with the other MEDLINE documents they cited, totaling
2,125 references. Some documents were missing abstracts (and thusly missing SemRep
abstract-generated predicates), for these abstracts/introductions were located and added
manually along with any generated predicates. A listing of the pertinent predicates along
and their corresponding sentences are recorded by document identifier within Table C-2.
Unless specified otherwise, each search was performed with source concepts of
Somatomedins (C0037657) and Insulin-Like Growth Factor I (C0021665), along with a
destination of Arginine (C0003765). As an example, Figure 65 shows a complete graph
of all paths of length two returned. Of the four intermediates we immediately see three of
them, along with a new intermediate, Diabetes.
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Figure 65. Somatomedin – Arginine paths of length 2

4.3.1 Growth Hormone
The first intermediate, Growth Hormone (GH), is also known as somatotropin or
human growth hormone (HGH). It stimulates both growth and the regeneration and
reproduction of cells. Arginine, Somatomedin, and IGF all have direct associations to
somatotropin as can be seen in Figure 66 where our results with a path length of two are
shown.
The article entitled “Effect of arginine on serum levels of insulin and growth
hormone in obese subjects” [PMID6027286] by Copinschi, Wegienka, Hane, and Forsham
(1967) suggests [C0037663|Somatotropin - INTERACTS_WITH -
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C0003765|Arginine]

by title alone. Three other articles also provide similar associations

[PMID4201417, PMID5571779, PMID3683183].

Figure 66. Growth Hormone Subgraph

Multiple sources provide the relationships between Somatotropin and IGF1.
Manson, Smith, and Wilmore wrote in their article “Growth hormone stimulates protein
synthesis during hypocaloric parenteral nutrition” [PMID2899993] that “GH was
associated with an increase in insulin and insulin-like growth factor-I concentrations”
(Manson, Smith, and Wilmore 1988). This sentence produces the predicate
[C0037663|Somatotropin - STIMULATES - C0021665|Insulin-Like Growth
Factor I].

This is similarly echoed in other references: “Levels of circulating IGF I and

IGF II are affected by growth hormone” [PMID3322823] (Hammerman 1987), “By
contrast, both GH and PL stimulate IGF-I synthesis” [PMID6338399] (Adams, Nissley,
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Handwerger, and Rechler 1983), and “There was also a significantly enhanced increase
of SM-C/IGF I in the presence of GH” [PMID6385593] (Stracke, Schulz, Moeller, Rossol,
and Schatz 1984).
The explicit relationship between Somatomedins to GH/Somatotropin is clear in
the article “Specific binding of a somatomedin-like polypeptide in rat serum depends on
growth hormone” [PMID967246] by Moses, Nissley, Cohen, and Rechler, where they
state that “Somatomedins are growth hormone-dependent polypeptides” (Moses, Nissley,
Cohen, and Rechler 1976). In addition to this, in 1980 Hintz et al. wrote in their article
“Interaction of somatomedin-C with an antibody directed against the synthetic C-peptide
region of insulin-like growth factor-I” [PMID6153391] that “Insulin-like growth factor-I
is a human plasma peptide with strong structural homology to human prosinsulin. This
peptide has been classified as a somatomedin on the basis of its biological actions and
growth hormone dependence” (Hintz, Liu, Marshall, and Chang 1980). Additional
references also produce the predicates relating Somatomedin and Somatotropin:
[PMID4506104, PMID3803997, PMID6639868].

4.3.2 Malnutrition
The second intermediate, Malnutrition, is discovered through Kwashiorkor which
is a type of severe form of protein malnutrition and Protein-Energy Malnutrition. The
subgraph illustrating these relationships is shown in Figure 67.
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Figure 67. Malnutrition Subgraph

Several predicates relating Arginine and Kwashiorkor, Marasmic Kwashiorkor,
and Protein-Energy Malnutrition were generated from the 1986 article entitled “Serum
insulin-like growth factors I and II concentrations and growth hormone and insulin
responses to arginine infusion in children with protein-energy malnutrition before and
after nutritional rehabilitation” by Soliman et al. [PMID3099250]. They stated that “GH
responses to arginine were depressed in the three malnourished groups and improved
significantly in marasmic-kwashiorkor and marasmic children after nutritional
rehabilitation” (Soliman et al. 1986). They then further state that “insulin responses to
arginine were impaired in kwashiorkor, and marasmic-kwashiorkor children and
improved significantly after refeeding”.
In “Effects of dietary composition on somatomedin activity in growing rats”
[PMID107298], Reeves et al. studied how diet affects somatomedin activity. The predicate
[C0037657|Somatomedins - ASSOCIATED_WITH - C0022806|Kwashiorkor] was
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produced by their conclusion that “these data suggest that dietary composition has a
direct effect on plasma somatomedin activity and that the severe growth retardation
associated with protein malnutrition may be related to its additional effect on serum
somatomedin” (Reeves et al. 1979). Three other references produce like predicates:
[PMID96201, PMID6792631, PMID467343].
Finally, two other papers [PMID412936, PMID105670] examined Somatomedins
in relation to malnutrition. As an example, in the first paper, Hintz et al. stated that their
“study was undertaken to define the interrelationships of somatomedin, growth hormone,
and an inhibitor of SM in protein-calorie malnutrition” (Hintz, Suskind, Amatayakul,
Thanangkul, and Olson 1978).

4.3.3 Wound Healing
Our results show that Wound Healing is directly connected to each of Arginine,
Somatomedins, and Insulin-Like Growth Factor I. Each of these is illustrated in Figure
68. The predicate [C0003765|Arginine - AFFECTS - C0043240|Wound Healing] is
derived from the 1985 article by Barbul et al [PMID3923266] where their conclusions
“indicate that high arginine levels in IVH solutions improve wound healing and thymic
immune function following injury” (Barbul et al. 1985).
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Figure 68. Wound Healing Subgraph

Spencer, Skover, and Hunt investigated the relationship between Wound Healing
and Somatomedins from which the predicate [C0037657|Somatomedins - AFFECTS C0043240|Wound Healing]

is derived. In their 1988 article “Somatomedins: do they

play a pivotal role in wound healing?” [PMID3380847] they state that “An understanding
of the role of somatomedins in normal wound healing might be able to help us understand
abnormalities of the repair process such as keloid formation” (Spencer, Skover, and Hunt
1988).
Although these two predicates are sufficient to prove the intermediate Wound
Healing, the additional predicate [C0021665|Insulin-Like Growth Factor I AFFECTS - C0043240|Wound Healing]

is also present within the subgraph. The

originating article “Regenerating endothelial cells express insulin-like growth factor-I
immunoreactivity after arterial injury” [PMID3690631] by Hansson, Jennische, and
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Skottner concludes that “IGF-I is likely to be involved in the repair of the intima in
injured arteries” (Hansson, Jennische, and Skottner 1987).

4.3.4 Diabetes
In addition to the aforementioned three connections there were a few unexpected
intermediate concepts that showed up: these include Insulin, Diabetic, and Diabetes
Mellitus (Figure 69). Although these were not called out as intermediates in Swanson’s
original paper (Swanson 1990) it should be noted that Cameron et al. also uncovered
Insulin.
In 1980 Binoux, Hossenlopp, Lassarre, and Seurin studied the production of
Somatomedin [PMID6986740]. Their findings suggested that “insulin plays an important
role in SM generation, as it itself is capable of both stimulating the release of SM and
amplifying the stimulatory effect of GH” (Binoux, Hossenlopp, Lassarre, and Seurin
1980). This conclusion produces the predicate [C0021641|Insulin - INTERACTS_WITH
- C0037657|Somatomedins].

This interplay is also backed up by the predicate

[C0021641|Insulin - COEXISTS_WITH - C0037657|Somatomedins] from Kogawa et
al. [PMID6751804] where “the addition of human growth hormone and/or insulin to the
perfusates caused a significant increase in somatomedin after 120 minutes of
recirculation” (Kogawa, Takano, Hizuka, Asakawa, and Shizume 1982). Other sources
also show relationships between the two concepts: [PMID6368579, PMID1261514,
PMID132381]
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Figure 69. Diabetes Subgraph

The predicate relating Arginine and Insulin, [C0003765|Arginine COEXISTS_WITH - C0021641|Insulin],

comes from “Sex-determined variation in

serum insulin and growth hormone response to amino acid stimulation” [PMID5917038], a
study by Merimee, Burgess, and Rabinowitz. They state that “during the course of
experience with subjects who were given infusions of arginine, we observed that female
subjects showed a greater rise in serum insulin and in serum HGH than did males of a
comparable age” (Merimee, Burgess, and Rabinowitz 1966). Three other studies
[PMID6027286, PMID4903729, PMID6754563] also generate predicates linking
Arginine and Insulin.
The relations between either Somatomedins or Arginine and Diabetic/Diabetes
Mellitus are generated from a few sources. The observation “of a growth hormone-
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resistant decrease in somatomedin activity associated with conditions of insulinopenia
suggest that somatomedin and growth might be related to metabolic control in diabetes
mellitus” from Phillips and Orawski [PMID142677] produces [C0037657|Somatomedins
- ASSOCIATED_WITH - C0011849|Diabetes Mellitus]

(Phillips and Orawski 1977).

The next, [C0037657|Somatomedins - AFFECTS - C0241863|Diabetic], is likewise
generated by the observation in [PMID2413420] that “diabetic children, treated
conventionally, have normal circulating IGF levels, but both growth rate and serum IGF
concentration may increase dramatically when diabetic control is optimized” (Hill and
Milner 1985). Finally, the 1979 study “Prolactin nonresponsiveness to arginine in
diabetes mellitus” examined the interaction of Arginine within diabetic patients (Le
Roith, Shapiro, Jabotinsky, and Spitz 1979).

4.3.5 Body Weight (Growth)
Performing a closed discovery yields a subgraph result that includes Growth
(Figure 70). Multiple studies generate predicates associating Arginine and Growth:
“Dietary arginine may play a critical role in growth of normal as well as neoplastic
tissue” [PMID430251] (Milner and Stepanovich 1979), “The diet supplemented with
arginine and glycine improved growth before and after trauma” [PMID430225] (Pui and
Fisher 1979), “The rôle of arginine in growth” [PMID20276173] (Borman et al. 1946), and
“Effect of arginine deficiency on growth and intermediary metabolism in rats”
[PMID4430939] (Milner, Wakeling, and Visek 1974).
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Figure 70. Growth (Body Weight) Subgraph

The inter-relationship between Growth and Somatotropin has been known for
over half a century as evident by the well-known study by Salmon and Daughaday where
they hypothesized the existence of a mediating factor (Salmon and Daughaday 1957).
Multiple documents generate predicates relating the two. The predicate
[C0037663|Somatotropin - AUGMENTS - C0018270|Growth] comes from
[PMID6243390] where the authors acknowledge the earlier work: “It is now over 20 years
since Salmon and Daughaday hypothesized that stimulation of growth by growth
hormone (somatotropin) was mediated by a circulating 'sulfation factor'” (Phillips,
Vassilopoulou-Sellin, and Reichard 1979). Similar quotes can be found in other
references: “Somatomedin (SM) is a growth hormone (GH)-dependent peptide,
circulating in normal serum, which directly causes skeletal growth” [PMID1128255]
(Daughaday, Phillips, and Herington 1975), “The significance of pituitary growth
hormone (GH) for the regulation of skeletal growth is uniformly recognized”
[PMID4538721] (Hall 1972), and “In the whole animal a major function of GH is to
stimulate the longitudinal growth of the skeleton, and GH acts by controlling the
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production of a second series of hormones, the somatomedins” [PMID1128683] (Francis
and Hill 1975).
The other predicates shown in Figure 70 have already been discussed in our
examination of previous intermediates. These include the association of Somatropin to
both Somatomedin and Insulin-Like Growth Factor I.

4.3.6 Retrospective Study: Somatomedin and Arginine - Conclusions
The goal of this retrospective study is the same as our previous ones and the
results are summarized in Table 17. We were able to successfully uncover all five of the
expected intermediate concepts. In comparison, Cameron’s study was not able to find
Wound Healing.

Table 17. Comparison of rediscoveries with those of Cameron (Somatomedins)
Intermediate

Fleig

Cameron

Growth Hormone

Found at 2

Found at 2

Body Weight

Found at 2

Found at 2

Malnutrition

Found at 2

Found via discovery browsing.

Wound Healing

Found at 2

Not Found

Diabetes

Found at 2

Found at 2

In Appendix C, Table C-3 details the precision and recall at each ranked result when
using citations. Table C-4 does the same when not using citations but otherwise follows
the same algorithm. A graph of the Precision-Recall can be seen here in Figure 71.
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Figure 71. Precision – Recall Curve for Somatomedins – Arginine Study

As we were able to uncover all of the expected intermediates with just a path
length of two, the slight improvement in our Precision-Recall curve when using citations
is purely due to the higher IDF threshold which we discussed previously. Figure 72
shows the F1@K graphs for each approach and their expected similarity.

Figure 72. F1 @ K measure for Somatomedins – Arginine Study
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4.4 Retrospective Study: Testosterone and Sleep
In their 2012 paper, “A Closed Literature-Based Discovery Technique Finds a
Mechanistic Link Between Hypogonadism and Diminished Sleep Quality in Aging Men”
Miller et al. described their insights into the associations between Hyogonadism and
diminishing sleep quality in men. It had been known that the process of aging in healthy
adults causes a reduction in sleep quality due to decreased REM sleep, more frequent
awakenings, and total sleep duration (Espiritu 2008). It had also been previously
suggested that hormonal changes could be responsible for a shorter sleep duration
(Trenell, Marshall, and Rogers 2007), though no mechanism was known.
Miller et al. stated that a consequence of hypoganism is high levels of Cortisol,
and therefore theorized that as men age and testosterone levels decrease their cortisol
levels increase due to the onset of hypogonadism. (Miller et al. 2012). As such we expect
to find the intermediate Cortisol/Hydrocortisone. We attempted to reproduce these results
via the approach described previously.
Our corpus consisted of 52 of the original MEDLINE documents cited by Miller
et al. (Table D-1) along with the other MEDLINE documents they cited, totaling 2,039
references. A listing of the pertinent predicates along and their corresponding sentences
are recorded by document identifier within Table D-2. Our search was performed with
the source concept Testosterone (C0039601) and the destination of Sleep (C0037313,
C0037322, C0234451), finding results at path lengths of one and two.
Multiple papers call out the direct association between Testosterone and Sleep
directly. Andersen and Tufik’s 2008 paper [PMID18519168] states it directly in their title
“The effects of testosterone on sleep and sleep-disordered breathing in men: its
bidirectional interaction with erectile function” (Andersen and Tufik 2008). In the 1997
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paper [PMID9329339] by Leibenluft et al. they claim that their results indicated that
“testosterone has relatively specific and discrete effects on sleep and hormonal rhythms
in men” (Leibenluft et al. 1997). Lastly Axelsson et al. wrote in their 2005 paper
[PMID15914523] that “testosterone increased during sleep and fell during waking,
whereas circadian effects seemed marginal” (Axelsson, Ingre, Åkerstedt, and Holmbäck
2005). Our first search result illustrates this (Figure 73).

Figure 73. Direction relationship between Testosterone and Sleep

Several results also appear which continue to emphasize that a relationship exists,
but does not provide a deeper semantic meaning. These include Gonadal Steroid
Hormones (Figure D-3), Hormones (Figure D-5), Aging (Figure D-7), Growth Hormone
Secretion (Figure D-8), Circadian Rhythms (Figure D-9), and Estrogens (Figure D-13).

4.4.1 Hydrocortisone (Cortisol)
Hydrocortisone does show up in our ninth search result (Figure 74), the
association having been generated from multiple source references. Cortisol is a
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glucocorticoid secreted by the adrenal cortex in response the physical and psychological
stress. Glucocorticoids are involved in the metabolism of carbohydrates, proteins, and
fats and have anti-inflammatory properties. The release of Cortisol affects the
metabolism by attempting to help maintain blood glucose levels during physical exercise.
Testosterone is an anabolic hormone important in the growth and maintenances of
muscle, bone, and red blood cells. Similar to Cortisol, Testosterone levels increase in
response to exercise and stress.

Figure 74. Relationship between Testosterone and Sleep via Hydrocortisone

Previous research has established that under particular circumstances Cortisol and
Testosterone exhibit a negative relationship. In the paper [PMID15724043] “Fetal plasma
testosterone correlates positively with cortisol” Gitau et al. noted that “unlike the norm in
the adult, where testosterone production is often inhibited by cortisol, in the fetus there is
a positive link between the two” (Gitau, Adams, Fisk, and Glover 2005). Doerr and Pirke
concluded that the “administration of cortisol leading to plasma levels as seen under
treatment with ACTH suppresses testosterone by abolishing or flattening the nocturnal
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rise” in their paper [PMID956348] “Cortisol-induced suppression of plasma testosterone
in normal adult males” (Doerr and Pirke 1976). Two additional papers also discuss the
relationship: [PMID15886244, PMID15841103].
The paper [PMID10841212] "Sleep impairments in healthy seniors: roles of
stress, cortisol, and interleukin-1 beta” by Prinz, Bailey, and Woods noted that “healthy
older women and men with higher levels of free cortisol under a mild stress condition had
impaired sleep” (Prinz, Bailey, and Woods 2000). The researchers Kern, Dodt, Born, and
Fehm also corroborates this [PMID8548511] in the results where “changes in sleepdependent secretion of GH and cortisol correlated significantly with an age-dependent
decrease in slow wave sleep” (Kern, Dodt, Born, and Fehm 1996). Five other papers also
discuss the relationship between Cortisol and Sleep: [PMID3790626, PMID3661052,
PMID2541159, PMID8077308, PMID6822642].

4.4.2 Alzheimer’s Disease
One of our results indicated a potential connection via the intermediate
Alzheimer’s Disease (Figure 75). Upon inspection this path exists due to two cited papers
included within the corpus. The first [PMID16344336], entitled “Effects of testosterone
on cognition and mood in male patients with mild Alzheimer disease and healthy elderly
men”, by Lu et al. concluded that “testosterone replacement therapy improved overall
quality of life in patients with AD” but had “minimal effects on cognition” (Lu et al.
2006).
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Figure 75. Relationship between Testosterone and Sleep via Alzheimer’s disease

The second was a paper [PMID12531038] by McCurry et al. titled “Treatment of sleep
disturbance in Alzheimer's disease” only suggested that “sleep problems in AD are multifactorial, and influenced by a variety of demographic, physical, psychiatric and
situational factors” (McCurry, Reynolds, Ancoli-Israel, Teri, and Vitiello 2000). The
predicates in question were generated from very general relationships and thus are
inconclusive, but does leave open the possibility that sleep problems in some Alzheimer’s
patients could be due to decreased Testosterone.

4.4.3 Interleukin-1 Beta
Interleukin-1 beta is a cytokine protein and is a pro-inflammatory cytokine
involved in the body’s inflammatory response to infections or conditions associated with
an inflammatory state. From [PMID15240608], Testosterone has been shown to have
“immune-modulating properties” and evidence suggests that it “may suppress the
expression of the pro-inflammatory cytokines” (Malkin et al. 2004). Previously we noted
the relationship between reduced testosterone and greater amounts of cortisol, a known
glucocorticoid. This is further evidenced by a paper by Chang and Opp [PMID
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10956236] entitled “IL-1 is a mediator of increases in slow-wave sleep induced by CRH
receptor blockade”. Therein they describe that “IL-1 promotes sleep, and glucocorticoids
inhibit IL-1 synthesis” (Chang and Opp 2000).

Figure 76. Relationship between Testosterone and Sleep via IL-1 beta

Several other papers provide support for the role of IL-1 in sleep. In [PMID
9781819] Taishi et al. state that “much evidence implicates interleukin-1beta (IL-1beta)
in sleep regulation” (Taishi et al. 1998). In the same year Fang, Wang, and Krueger
[PMID9530230] wrote that “Interleukin-1 beta (IL-1 beta) is a well characterized sleep
regulatory substance” (Fang, Wang, and Krueger 1998). A later study [PMID12000022].
in 2001 by some of the same individuals continued to support the earlier work (Krueger,
Obál, Fang, Kubota, and Taishi 2001).
The original paper by Miller et al. did not state IL-1 (or any other cytokine) as a
potential intermediate. However, given the papers just mentioned, it seems likely that
these proteins could be potentially involved within the biochemical interactions involving
sleep and the role of testosterone (Figure 76).

4.4.4 Parkinson’s Disease
Within our results, one answer showed Parkinson’s Disease as an intermediate
(Figure D-6). This path is due entirely to ten papers which studied the effects of
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Parkinson’s Disease with either Testosterone or Sleep. These are documents included in
our local corpus that were cited from core papers in our final study involving the
connections between Parkinson’s Disease and Crohn’s Disease. It should be noted that, as
such, we would not have this result from just the corpus constructed from Miller et al.’s
work. The paper by Okun et al. [PMID16682542] indicates that “testosterone deficiency
has been reported in patients with Parkinson disease (PD), Alzheimer disease, and
Huntington disease” (Okun et al. 2006). And numerous papers illustrate the relationship
between sleep disorders and PD: [PMID2259351, PMID18591114, PMID17942122,
PMID15389999, PMID12621636, PMID12438461, PMID11798367, PMID10752568].

4.4.5 Retrospective Study: Testosterone and Sleep - Conclusions
We were able to successfully uncover the single expected intermediate concept,
Cortisol/Hydrocortisone. As we were able to recover the concept with a path length of
two, as expected, Cameron’s study was also able to recover the concept. Additionally,
because we found the solutions at path lengths of two and less we expect there to be little
difference between the citational and non-citational approaches. In fact, the resulting
subgraphs were identical between the two trials, yielding the same P-R (Figure 77) and
F1@K (Figure 78) curves.
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Figure 77. Precision – Recall Curve for Testosterone – Sleep Study

Figure 78. F1 @ K measure for Testosterone – Sleep Study
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4.5 Retrospective Study: Parkinson’s Disease and Crohn’s Disease
Parkinson’s disease (PD) is a neurodegenerative disorder that affects dopamineproducing neurons within the brain. In turn, dopamine activates the nerve cells that
coordinate normal muscle activity. In patients with PD, there is a reduction in the supply
of dopamine which impairs their ability to control movement.
Crohn’s disease (CD) is a type of chronic inflammatory bowel disease (IBD) that
affects the lining of the digestive tract. CD is also considered an autoimmune disease as
the immune system attacks the gastrointestinal tract causing abdominal pain, diarrhea,
vomiting, and other complications.
In 2014 Kostoff published a study titled “Literature-related discovery: common
factors for Parkinson’s Disease and Crohn’s Disease” where in the interconnections
between these two diseases were explored via LBD. Kostoff concluded that there were
three major themes that unified the PD and CD literatures: these were Genetics,
Neuroimmunology, and Cell Death. Additionally, he noted that these three themes are not
independent from each other. In one example Kostoff states “there are genetic
determinants of the inflammatory response” which are immunological in nature, and that
“naturally occurring genetic variants in important inflammatory mediators such as TNFalpha appear to alter inflammatory responses” (Kostoff 2014).
Reproducing Kostoff’s study, our corpus consisted of 32 of the original
MEDLINE documents cited by Miller et al. (Table E-1) along with the other MEDLINE
documents they cited, totaling 1,974 references. A listing of the pertinent predicates
along and their corresponding sentences are recorded by document identifier within Table
E-2. Our search was performed with the source concept Parkinson Disease (C0030567)
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and the destination of Crohn’s Disease (C0010346), finding results at path lengths of two
and three.
4.5.1 Immunology
Inflammation is a normal response for the body’s immune system when tissues
are injured by trauma, toxins, bacteria, or other causes. Chemicals such as histamine are
released by the damaged cells which lead into the surrounding area causing swelling.
This is a signal to the body’s white blood cells to help protect the area from foreign
substances.
Performing a closed search with a max path length of two we find that four of the
eight results match this case: Inflammation (Figure E-2), Chronic Inflammation (Figure
E-5), Immune Response (Figure E-6), and Anti-Inflammatory Agents (Figure E-8). Past
research has well documented this generalized connection. Whitton’s paper
“Inflammation as a causative factor in the aetiology of Parkinson's disease”
[PMID17339843] considers the “possible use of anti-inflammatory drugs in PD”
(Whitton 2007). Additionally, “accumulating evidence has suggested that inflammation
in the brain participates in the pathogenesis of Parkinson's disease” (Li, Wang, Pei, Liu,
and Hong 2005). Similar statements connect PD to Inflammation in [PMID19221310,
PMID15869932, PMID15109580, and PMID17156147].
Crohn’s disease is, by definition, an inflammatory bowel disease “characterized
by transmural inflammation” (Vallance et al. 2005) and Burke et al. noted
[PMID17156147] that the “pathogenesis of inflammation in CD has been extensively
investigated” (Burke et al. 2007). Additional statements that connect Inflammation to CD
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can be found in [PMID12474223, PMID15058528, PMID11052175, and
PMID11743591].
Another result (Figure E-7), Cytokine, connects PD to CD and yields more direct
information. Cytokines are a broad category of proteins important to cell signaling. More
directly for our study, they can be involved with immune responses and inflammation.
Wahner et al. noted in 2007 [PMID17984451] that “markers of neuroinflammation,
including activated microglia and increased levels of circulating proinflammatory
cytokines, have been observed in the brains and CSF of patients with Parkinson disease”
(Wahner, Bronstein, Bordelon, & Ritz 2007). Mogi et al. also noticed the connection
[PMID10400088]: “the levels of proinflammatory cytokines such as tumor necrosis
factor (TNF)-alpha are increased in the striatum and cerebrospinal fluid from patients
with Parkinson's disease (PD)” (Mogi et al. 1999). Similar observations were made in
[PMID9550432] connecting cytokines in the pathogenesis of Crohn’s Disease.
Performing a closed search with a path length of three, and limiting paths that go
through one of these intermediates (Figure E-10), we can see additional details to these
associations. The first result of the search (Figure 79) shows a number of new potential
intermediate terms of interest: Peroxisome Proliferator-Activated Receptors (PPAR),
Inflammatory Bowel Diseases (IBD), Interleukin-1 beta, Ulcerative Colitis (UC), Tumor
Necrosis Factor-alpha (TNF alpha), and the TNF gene.
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Figure 79. Relationship between PD and CD (Inflammation)

Although these concepts seem like a good fit, and many are associated with
Inflammation and Crohn’s Disease, none are directly linked to Parkinson’s disease in the
graph. Thankfully, however, the subsequent results provide more detail.

Figure 80. Relationship between PD and CD – TNF protein
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While Tumor Necrosis Factor-alpha and TNF gene both appeared in Figure 79,
we find TNF protein (Figure 80) in the second search result. The predicate
[C1448177|TNF protein – ASSOCIATED_WITH – C0030567|Parkinson Disease]
comes from [PMID12205053], a paper by Sriram. Therein they studied the potential role
for TNF-alpha in PD, stating that “the proinflammatory cytokine TNF-alpha is an
obligatory component of dopaminergic neurodegeneration” and that “enhanced
expression of the proinflammatory cytokine, tumor necrosis factor (TNF)-alpha, has been
found in association with glial cells in the substantia nigra of patients with PD” (Sriram
2002). Similar predicates come from other documents [PMID14724828,
PMID17483119].

Figure 81. Relationship between PD and CD – IL-10

Another related result from the search (Figure 81) shows the intermediate
Interleukin-10. The predicate [Interleukin-10 – ISA – cytokine] was extracted
from a 2005 paper [PMID15879017] (Chevrier et al. 2005). The subsequent association
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with Crohn’s Disease stems from [PMID16461743] where they conclude “the NOD2fs
mutation results in a loss-of-function phenotype in human myeloid DC and imply
decreased immune regulation by IL-10 as a possible mechanism for this mutation in CD”
(Kramer, Netea, De Jong, Kullberg, and Adema 2006). Of note, their paper associates
this immune regulating cytokine with Crohn’s Disease, but it is also within the context of
a genetic variation.

4.5.2 Cell Death
The last two results of the Inflammation search (Figure E-19 and Figure E-21)
show a relation with the concept of Cell Death via Immunology – specifically Cytokine or
Inflammation. The first of the two, shown here as Figure 82, indicated that Parkinson’s
Disease is related to Apoptosis. Apoptosis is a regulated form of pre-programmed cell
death which can occur either because it senses some amount of stress (internal) or
because it of external signals from other cells.

Figure 82. Relationship between PD and CD – Apoptosis
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In 2005, Maraganore et al. performed a genetic study of Parkinson’s Disease, in
their paper [PMID16252231] “High-resolution whole-genome association study of
Parkinson disease”, where we extracted [C0030567|Parkinson Disease – AFFECTS –
C0162638|Apoptosis].

They identified eleven single nucleotide polymorphisms

(variation in a single nucleotide that occurs at a specific position) associated with PD and
discovered that “the protein encoded by this gene plays an important role in neurogenesis
and in neuronal apoptosis, which is consistent with existing hypotheses regarding PD
pathogenesis” (Maraganore et al. 2005). TNF-alpha is a cytokine known to be a large
mediator of apoptosis, and three additional papers in our corpus then further relate
Cytokine to Apoptosis: [PMID16493072, PMID11922776, PMID9422513].

Figure 83. Relationship between PD and CD – Cell Death (Inflam)

Figure 83 shows Cell Death explicitly as a connection. This is derived from two
references. The first, [C0030567|Parkinson Disease -

AFFECTS - C0007587|Cell
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is from a paper [PMID17908040] by Tweedie, Sambamurti, and Greig who detail

that “TNF-alpha has been demonstrated to play a major role in central nervous system
(CNS) neuroinflammation-mediated cell death in AD, PD and amyotrophic lateral
sclerosis (ALS) as well as several other CNS complications” (Tweedie, Sambamurti, and
Greig 2007). The same predicate is also extracted from a second paper [PMID8196673].
The predicates connecting Cell Death to Inflammation/Anti-inflammatory Agents
is supported by two studies [PMID15109580, PMID17984451]. One of which indicates
that “antiinflammatory agents inhibit dopaminergic cell death in animal models of PD,
and there is one epidemiological report that their use significantly diminishes the risk of
PD” (McGeer and McGeer 2004).
Further evidence of Cell Death being a common factor lies hidden in one of
results from the original search (Figure E-3), shown in Figure 84 below. When the
connections are examined, the listed concept Anti-Anxiety Agents (C0040616) is found
to be a misnomer. The predicate [C0040616|Anti-Anxiety Agents – TREATS –
C0030567|Parkinson Disease]

is extracted from Olanow’s 2006 paper

[PMID16717254], stemming from the sentence “this raises the possibility that antiapoptotic agents might be neuroprotective in PD” (Olanow 2006).
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Figure 84. Relationship between PD and CD – Cell Death (apoptosis)

A similar problem occurred in two documents making the connection with
Crohn’s Disease: [C0040616|Anti-Anxiety Agents – TREATS – C0010346|Crohn’s
disease].

Hanauer summarized [PMID15580149] that “the past decade has brought

forth a series of novel biologic agents targeting tumor necrosis factor (TNF) for the
treatment of Crohn's disease” and his review discussed “the results of controlled clinical
trials of anti-TNF agents for Crohn's disease” (Hanauer 2004). In this case, “anti-TNF”
was interpreted by SemRep as Anti-Anxiety Agents by mistake, and we’ve already noted
how TNF is associated with apoptosis. The second article, [PMID17470824] by
Sandborn also encountered the same issue with SemRep where “anti-TNF” was picked
up as Anti-Anxiety Agents (Sandborn 2007).
With a better understanding of the connections found in Figure 84, this shows a
more direct connection between Parkinson’s Disease and Crohn’s Disease via the higher
order concept Cell Death.
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4.5.3 Genetics
Previously we referenced a paper by Maraganore et al. [PMID16252231] in
regards to the intermediate Apoptosis, wherein the authors stated they “identified 11
Single Nucleotide Polymorphisms that were associated with Parkinson’s Disease”
(Maraganore et al. 2005), generating the predicate [C0752046|Single Nucleotide
Polymorphism – ASSOCIATED_WITH – C0030567|Parkinson Disease].

This same

concept also appeared as one of the original search results (Figure 85). A large scale
international study [PMID17052658] the next year by Elbaz et al. further corroborated
this by identifying “13 single-nucleotide polymorphisms (SNPs) significantly associated
with Parkinson's disease” (Elbaz et al. 2006).

Figure 85. Relationship between PD and CD – Single Nucleotide Polymorphism

The predicate [C0752046|Single Nucleotide Polymorphism –
NEG_ASSOCIATED_WITH – C0010346|Crohn’s disease]

which connects Crohn’s

Disease is extracted from [PMID15685540] where the authors wrote that “the G2677T
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SNP was not associated with UC or CD” (Ho et al. 2005). This, unfortunately, is a weak
association. Like before, we can dig for additional meaning by attempting a deeper
search. A different search performed (Figure E-23) focused around Single Nucleotide
Polymorphism between PD and CD, we find several genetic intermediates (Figure 86).

Figure 86. Relationship between PD and CD, PL3 – Single Nucleotide Polymorphism

From the figure we find that ABCB1 gene connects to all three: Parkinson’s
Disease, Crohn’s Disease, and Single Nucleotide Polymorphism. This is not a surprise as
the last result of our original search connected PD and CD via ABCB1 gene (Figure E-9).
Additionally P-Glycoprotein, also known as Multidrug Resistance Protein 1 (MDR1), is
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encoded by the ABCB1 gene. Ishikawa et al. reported in [PMID15256718] that “genetic
variations of the human ABCB1 (P-glycoprotein/MDR1) gene have been most
extensively studied” and “more than fifty single nucleotide polymorphisms (SNPs) and
insertion/deletion polymorphisms in the ABCB1 gene have been reported” (Ishikawa et
al. 2004).
Other research has further connected the gene to each of the two diseases. In their
paper “Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical
relevance” [PMID14749689] Marzolini, Paus, Buclin, and Kim stated “An increasing
number of studies have also implicated certain commonly occurring SNPs in MDR1 in
problems including altered drug levels and host susceptibility to diseases such as
Parkinson's disease, inflammatory bowel disease, refractory seizures, and CD4 cell
recovery during human immunodeficiency virus therapy” (Marzolini, Paus, Buclin, and
Kim 2004). Their work points an associating with both PD and IBD, but not directly with
CD. This is connected in our graph by the paper “MDR1 gene: susceptibility in Spanish
Crohn's disease and ulcerative colitis patients” [PMID16374256]. The authors concluded
that “considering our results and those from others, the MDR1 gene behaves as a
common risk factor for both CD and UC” (Urcelay et al. 2006)

4.5.4 Retrospective Study: PD and CD – Conclusions
After consideration, the results of our search with a maximum path length of two
(Figure E-1), cover all three expected high level concepts: Immunology, Cell Death, and
Genetics. The search results are again identical between the citational and non-citational
approaches, yielding the same P-R (Figure 87) and F1@K (Figure 88) curves.
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Figure 87. Precision – Recall Curve for Parkinson – Crohn Study

Figure 88. F1 @ K measure for Parkinson – Crohn Study
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However, the details of those connections were not able to explain those
associations and, as such, prompted several secondary searches to probe deeper. Of the
concepts that appeared within the subsequent searches a number only appeared due to the
use of citations.
With the Inflammation search (path length three) there were five separate
concepts that only appeared when using citations given our corpus. Comparing Figure
E-11 and Figure E-12, we find a difference for the concepts Interleukin-1 beta, TNF
gene, and Peroxisome Proliferator-Activated Receptors (PPAR). Interleukin-1 beta is
another cytokine, TNF gene is responsible for Tumor Necrosis Factor-alpha which we
discussed previously, and Peroxisome Proliferator-Activated Receptors are a group of
proteins that help regulate the expression of genes. Another cytokine, Interleukin-10, is
yet another example that appears when using citations (Figure E-15 and Figure E-16).
Lastly, the intermediate Apoptosis (Figure E-19) does not appear without citations.
With the Single Nucleotide Polymorphism the term P-Glycoprotein does not
appear without citations as well. This can be seen in the comparison of Figure E-24 and
Figure E-25. Although the ABCB1 gene was already present in the graph, the presence of
the corresponding P-Glycoprotein helps complete the overall semantic picture.

4.6 Summary
This chapter presented the results of five retrospective experiments performed to
determine the validity of a semantic-based LBD approach that makes use of bibliographic
citations. In two cases (e.g. the study of Somatomedin and Arginine and the study of
Testosterone and Sleep), strong relationships were found by examining predicates of path
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length two or less. In these situations we have shown that including citations does not
improve the results. However, in the other three studies the inclusion of citations
uncovered crucial or additional related concepts. In two of the three cases (Fish Oils and
Magnesium studies) a portion of the intermediates were only uncovered with the use of
citational information. In the last case, the Parkinson’s Disease – Crohn’s Disease study,
although all of the expected concepts appeared within the graph at a path length of two,
the supporting abstracts did not provide sufficient evidence to back the claim. This
prompted additional searches with a path length of three wherein multiple concepts
appeared due to using predicates included via citations. We conclude from these five
studies that the use of information from citationally related documents improves the
qualitative results as shown by F1 and Precision-Recall curves.
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Chapter 5
Summary

5.1 Foundation of Work
Cameron et al. (2015) devised a closed-discovery context-driven LBD approach
based upon the earlier graph-based semantic summarization methods. Their system
automatically generates one or more graphs representing the semantic associations
between two user-provided concepts. These graphs are then used to find semantically
related pathways from one concept to another. They performed multiple retrospective
studies, recovering many key intermediates while utilizing full-text.
In work later performed by Cameron as part of his dissertation, he attempted to
rediscover Swanson’s Raynaud Syndrome–Dietary Fish Oils hypothesis without the use
of full-text. Through a similar predicate analysis he noted that “these results collectively
suggest that titles and abstracts alone might NOT be sufficient” (Cameron et al. 2016).
The results of this study have shown that some intermediates can additionally be
uncovered by including cited documents when working with only titles and abstracts.

5.2 Summary of Results
We have performed five retrospective experiments performed to determine the
validity of a semantic-based LBD approach that makes use of bibliographic citations. In
two cases, such as the Somatomedin and Testosterone studies, strong relationships were
found by examining predicates constructing a path with length two or less. In these
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situations we have shown that including citations does not improve the results. However,
in the other three studies the inclusion of citations uncovered crucial or additional related
concepts.
The first study of these successfully reproduced Swanson’s original Fish Oils –
Raynaud Disease hypothesis without the use of full-text by modifying the approach by
Cameron et al. to incorporate bibliographically related documents. A detailed
examination shows that the intermediate Vascular Reactivity is not present in the core
references and only appears by using full-text or by including cited documents.
The Magnesium – Migraine Disorders discovery by Swanson was the second
study. For the eleven expected intermediate concepts, all of the seven that Cameron
found were found in our reduced corpus. For the other four concepts (Hypoxia, Stress,
Substance P, Spreading Depression) noticed by Swanson that Cameron did not find, we
were able to discover three - both Stress/Type A Personality and Hypoxia were found
within our original search, and Substance P was discovered via discovery browsing of
related concepts. Additionally, our results include a twelfth concept, Diabetes,
undiscovered by Swanson and Cameron, only included via cited documents.
The third study to yield strong results was a reproduction of Kostoff’s research on
the common factors of Parkinson’s disease and Crohn’s disease. Here, all three high
level concepts (Immunology, Cell Death, and Genetics), appeared in some fashion
without the use of cited documents, but the details of those connections were not able to
explain those associations. Thus, several secondary searches were used to probe deeper.
Of the concepts that appeared within the subsequent searches a number only appeared
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due to the use of citations. Between the three intermediate topics there were an additional
six separate concepts that only appeared when using citations given our corpus.
In conclusion, our findings conclude that the inclusion of citational relationships
can be used to improve the results of LBD research. Quantitative and qualitative
improvements are made by uncovering intermediates that would not be found otherwise.
This not only can improve the resulting Precision-Recall curves for the results, but can
provide additional meaning in cases where a supporting statement is too generic, such as
within our Parkinson’s disease – Crohn’s disease study.

5.3 Future Work
This research’s contribution is the illustration of the information contained within
citational references as it applies to LBD. While evidence suggests that it supports the
validity of this approach, this is also the biggest limitation of this work. This is relevant in
that although titles and abstracts for most documents tend to be easy to acquire due to
modern digitalization efforts, citational information from one document to others is not.
Further research leveraging these associations is possible, either in datasets where
citations are available, or in a more complex manner as greater amounts of this
information is recorded.
Also, due to the nature of our five retrospective studies and their focus on
bibliographic citations, each study was performed using a relatively small corpus. As
noted previously, this corpus was constructed from the references listed in each of the
original studies along with the papers that they themselves cited. As such, the entire
corpus contained only thousands of papers. Thus, despite the fact that concept IDF values
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were calculated using all of the MEDLINE papers, predicate graphs were constructed
only using the reduced corpus. An investigation should be made into the efficacy of using
bibliographic citations at full scale.
Additionally there are systemic limitations that should be addressed. First, and
foremost, is the reliance upon the generation of semantic predications from a NLP tool.
Both as noted in this paper and in the work by Cameron et al. (2016), several predicates
were found to be erroneous due to an incorrect concept. This is only one instance of the
potential difficulties. Further difficulties arrive when contracting semantic predications
are generated from text, either due to nuances in the way the text was composed, results
may be based upon apriori assumptions or situations, or changing/conflicting scientific
evidence.
In a similar fashion a more specific improvement can also be made regarding the
association of similar concepts. It was noticed several times during our exploratory
studies that there are separate concepts that are very similar (e.g. Magnesium, Magnesium
Deficiency, and Hypomagnesemia). When predicates are generated from documents
different concepts might be used, making it challenging to find a connecting path. For
example, perhaps there is a path connecting Magnesium Deficiency to Migraine
Disorders but this won’t be found for a search based on Magnesium. An expert user that
is well versed in the subject matter could be aware of such pitfalls and make searches
accordingly but an average user would miss out on potential connections. Modifications
could be made to treat concepts that are sufficiently similar but would need to do so
within a given context (referring back to section 2.5.2 in regards to LSA).
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Appendix A
Fish Oils – Raynaud Syndrome Study
Table A-1. Fish Oils – Raynaud Syndrome Core Corpus Medline IDs
53042

4002440

6229551

6340424

6775675

58309

4015748

6298902

6352267

6788326

277163

4082084

6301111

6365102

6812750

596950

6088955

6302714

6376801

6827988

2408588

6097237

6303363

6424425

6890719

2412054

6098049

6307322

6432198

7031981

2412071

6098051

6314583

6449756

7037038

2997286

6100033

6318123

6540787

7161779

3157318

6128596

6320840

6613908

7259326

3883365

6130329

6320945

6636033

7295999

3888229

6134122

6321621

6639916

7364865

3977414

6136879

6330926

6707529

7470209

3990714

6209510

6339921

6718836

14289442
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Figure A-1. Fish Oils – Raynaud Disease Search Parameters
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Figure A-2. Fish Oils – Raynaud Disease result 1 (with citations)

Figure A-3. Fish Oils – Raynaud Disease result 2 (with citations)
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Figure A-4. Fish Oils – Raynaud Disease result 3 (with citations)

Figure A-5. Fish Oils – Raynaud Disease result 4 (with citations)
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Figure A-6. Fish Oils – Raynaud Disease result 5 (with citations)

Figure A-7. Fish Oils – Raynaud Disease result 6 (with citations)
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Figure A-8. Fish Oils – Raynaud Disease result 7 (with citations)

Figure A-9. Fish Oils – Raynaud Disease result 8 (with citations)
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Figure A-10. Fish Oils – Raynaud
Disease result 9 (with citations)

Figure A-11. Fish Oils – Raynaud Disease
result 10 (with citations)
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Figure A-12. Fish Oils – Raynaud Disease result 11 (with citations)

Figure A-13. Fish Oils – Raynaud Disease result 12 (with citations)
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Figure A-14. Fish Oils – Raynaud Disease result 13 (with citations)

Figure A-15. Fish Oils – Raynaud Disease result 14 (with citations)
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Figure A-16. Fish Oils – Raynaud Disease result 15 (with citations)

Figure A-17. Fish Oils – Raynaud Disease result 16 (with citations)
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Figure A-18. Fish Oils – Raynaud Disease result 1 (no citations)

Figure A-19. Fish Oils – Raynaud Disease result 2 (no citations)
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Figure A-20. Fish Oils – Raynaud Disease result 3 (no citations)

Figure A-21. Fish Oils – Raynaud Disease result 4 (no citations)
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Figure A-22. Fish Oils – Raynaud Disease result 5 (no citations)

Figure A-23. Fish Oils – Raynaud Disease result 6 (no citations)
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Figure A-24. Fish Oils – Raynaud Disease result 7 (no citations)
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Figure A-25. Fish Oils – Raynaud Disease result 8 (no citations)
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Table A-2. Fish Oils – Raynaud Disease generated predicates
[PMID114606]
Abstract
“Both PGH2 and PGI2 could produce dose-dependent contraction or relaxation of
isolated arteries.”
[C0033567|Epoprostenol – CAUSES – C1140999|Contraction]
Abstract
“As PGI2 is the most potent cerebral vasodilator drug tested, it may be of clinical use
in the treatment of cerebral vasospasm.”
[C0033567|Epoprostenol – ISA – C0042402|Vasodilator Agents]
[C0033567|Epoprostenol – TREATS(SPEC) – C0265110|Cerebral Vasospasm]
[C0042402|Vasodilator Agents – TREATS – C0265110|Cerebral Vasospasm]
[PMID190267]
Abstract
“In contrast, when arachidonic acid is added directly to platelets, prior incubation with
dBcAMP or PGE1 does not inhibit production of the prostaglandins or their
metabolites.”
[C0002335|Alprostadil – NEG_INHIBITS – C0033554|Prostaglandins]
[C0003695|Arachidonic Acid – NEG_INHIBITS – C0033554|Prostaglandins]
Abstract
“Furthermore, dBcAMP and PGE1 both inhibit platelet aggregation induced by either
arachidonic acid or prostaglandin H2 without affecting the production of prostaglandin
metabolites from these compounds.”
[C0002335|Alprostadil – DISRUPTS – C0032176|Platelet aggregation]
[C0003695|Arachidonic Acid – AUGMENTS – C0032176|Platelet aggregation]
[C0072288|Prostaglandin H2 – AUGMENTS – C0032176|Platelet aggregation]
[PMID2408588]
Title
“Inhibition of platelet aggregation by a new stable prostacyclin introduced in therapy of
patients with progressive scleroderma.”
[C0033567|Epoprostenol – DISRUPTS – C0032176|Platelet aggregation]
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[PMID2412054]
Abstract
“The effects of serotonin and its pharmacological antagonists on the physical flow
properties of the blood have been studied far less than their effects on blood vessels,
although they may be equally important.”
[C0036751|Serotonin – AFFECTS – C0005847|Blood Vessels]
Abstract
“Indirect evidence suggests that in pathological circumstances serotonin may locally
increase whole blood viscosity, particularly at low shear rates, decrease red cell
deformability and increase the adhesiveness of white cells.”
[|C0036751|Serotonin – AUGMENTS – C0005848|Blood Viscosity]
Abstract
“Specific serotonergic-antagonists, administered either orally or intravenously,
normalize the increased whole blood viscosity and decreased blood filterability found
in essential hypertension, following myocardial infarction and in severe leg ischaemia”
[C0948013|Increased blood viscosity – COEXISTS_WITH – C0085580|Essential Hypertension]
Abstract
“8 Ketanserin given intravenously for seven days to patients with very severe leg
ischaemia, significantly improves whole blood viscosity, increases red cell transit time
and most dramatically decreases pore clogging.”
[C0022616|Ketanserin – AFFECTS – C0005848|Blood Viscosity]
[PMID364545]
Abstract
“The activity of prostacyclin (PGI2), PGE1 or PGD2 as inhibitors of platelet
aggregation in plasma from human, dog, rabbit, rat, sheep and horse was investigated.”
[C0002335|Alprostadil – DISRUPTS – C0032176|Platelet aggregation]
Abstract
“5 Theophylline or dipyridamole potentiated the inhibition of human platelet
aggregation by prostacyclin, PGE1 or PGD2.”
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[C0002335|Alprostadil – DISRUPTS – C0032176|Platelet aggregation]
[C0033567|Epoprostenol – DISRUPTS – C0032176|Platelet aggregation]
[PMID378308]
Abstract
“...due to the formation of platelet aggregates it is concluded that PGI2 is a most potent
anti-aggregatory prostaglandin…”
[C0033567|Epoprostenol – ISA – C0033554|Prostaglandins]
[PMID3883365]
Abstract
“As prostacyclin (PGI2) is of benefit in the treatment of RS in SS, we have measured
endogenous stable metabolites of PGI2 (PGI2m) in 42 patients with Raynaud’s
Phenomenon (RP) of varying aetiology (15 SS patients, 15 patients with Raynaud’s
Disease (RD) but no other symptoms, and 12 other RS patients with probable
connective tissue disorder).”
[C0033567|Epoprostenol – TREATS - |C0034734|Raynaud Disease]
[C0033567|Epoprostenol – TREATS(INFER) – C0034735|Raynaud Phenomenon]
[C0034734|Raynaud Disease – COEXISTS_WITH – C0036421|Systemic
Scleroderma]
[PMID3977414]
Abstract
“An improved thermographic response to cold stress testing after treatment of
Raynaud’s syndrome with PGE1 has also been shown for the first time.”
[C0002335|Alprostadil – TREATS – C0034734|Raynaud Disease]
[PMID531220]
Abstract – Taken from publisher’s site.
“In human platelet-rich plasma (PRP) eicosapentaenoic acid (EPA) inhibited platelet
aggregation induced by a stable analogue of PGH2 (U46619), arachidonic acid,
collagen or ADP.”
[C0000545|Eicosapentaenoic Acid – DISRUPTS – C0032176|Platelet aggregation]
[C0917834|U-44619 – ISA – C0072288|Prostaglandin H2]
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Abstract – Taken from publisher’s site.
“EPA incubated with PRP did not induce the generation of a thromboxane (TXA)-like
activity; indeed it prevented the formation of TXA2 induced by arachidonic acid or by
collagen.”
[C0000545|Eicosapentaenoic Acid – NEG_STIMULATES –
C0040061|Thromboxanes]
[C0003695|Arachidonic Acid – STIMULATES – C0040057|Thromboxane A2]
Abstract – Taken from publisher’s site.
“The anti-aggregatory activity of EPA was not influenced by inhibitors of cyclooxygenase and lipoxygenase.”
[C0000545|Eicosapentaenoic Acid – INHIBITS – C0023837|Lipoxygenase]
[C0000545|Eicosapentaenoic Acid – INHIBITS – C0033551|ProstaglandinEndoperoxide Synthase]
[PMID6303363]
Abstract
“Eicosapentaenoic acid (EPA), which is abundant in seafood, has been reported to be a
potent antagonist of platelet aggregation and also to reduce the incidence of
cardiovascular disorders.”
[C0000545|Eicosapentaenoic Acid – DISRUPTS – C0032176|Platelet aggregation]
Abstract
“We recently reported that EPA also reduces whole blood viscosity.”
[C0000545|Eicosapentaenoic Acid – DISRUPTS – C0005848|Blood Viscosity]
[PMID6314583]
Abstract
“EPA was not able to be converted to any prostaglandins (PGs) in murine and porcine
smooth muscle cells.”
[C0000545|Eicosapentaenoic Acid – CONVERTS_TO – C0033554|Prostaglandins]
Abstract
“In rat, EPA was not only being converted to no PGI3, but also being a blocker to PGI2
synthesis in vascular cells.”
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[C0000545|Eicosapentaenoic Acid – CONVERTS_TO|C0072294|prostaglandin I3]
[C0005773|Blood Cells – LOCATION_OF – C0033567|Epoprostenol]
[C0072294|prostaglandin I3 – ISA – C0033567|Epoprostenol]
Abstract
“Moreover, the rat EPA has much less activity in inhibiting thromboxane A2 (TXA2)
synthesis in platelets.”
[C0000545|Eicosapentaenoic Acid – INTERACTS_WITH – C0040057|Thromboxane A2]
Abstract
“On the contrary, in human EPA was not only easily converted to PGI3 in vascular
cells, but also blocking TXA2 synthesis in platelets.”
[C0000545|Eicosapentaenoic Acid – CONVERTS_TO – C0072294|prostaglandin I3]
[PMID6320945]
Title
“Beneficial effect of fish oil on blood viscosity in peripheral vascular disease.”
[C0016157|Fish Oils – AFFECTS – C0005848|Blood Viscosity]
[PMID6339921]
Title
“Controlled double-blind trial of nifedipine in the treatment of Raynaud’s
phenomenon”
[C0028066|Nifedipine – TREATS – C0034735|Raynaud Phenomenon]
Abstract – Taken from publisher’s site.
“The treatment of this condition is difficult.1 Nifedipine, a slow calcium-channel
antagonist, causes vascular smooth-muscle relaxation and relief of arterial vasospasm.”
[C0028066|Nifedipine – TREATS – C0085616|Vasospasm]
Abstract – Taken from publisher’s site.
“Nifedipine-induced vasodilation has been shown to result in a fall in peripheral
vascular resistance and an increase in peripheral blood flow.”
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[C0042401|Vasodilation – COEXISTS_WITH – C1258192|Total Peripheral
Resistance]
Abstract – Taken from publisher’s site.
“Nifedipine increases the skin blood flow by 50 to 150 per cent in normal persons and
has also been shown in vitro to inhibit norepinephrine-induced vasospasm of rabbit and
human peripheral arteries and veins.”
[C0028066|Nifedipine – AUGMENTS – C0232338|Blood flow]
Abstract – Taken from publisher’s site.
“The calcium-channel blockers nifedipine and verapamil have …”
[C0028066|Nifedipine – ISA – C0006684|Calcium Channel Blockers]
[PMID6365102]
Title
“Treatment of Raynaud’s phenomenon with ketanserin, a selective antagonist of the
serotonin2 (5-HT2) receptor.”
[C0022616|Ketanserin – TREATS – C0034735|Raynaud Phenomenon]
Abstract
“6 These findings lend support to the hypothesis that serotonin is an important element
in the pathogenesis of systemic sclerosis.”
[C0036751|Serotonin – CAUSES – C0036421|Systemic Scleroderma]
[PMID6432198]
Title
“Treatment of Raynaud’s phenomenon with ketanserin in patients with connective
tissue disorders.”
[C0022616|Ketanserin – TREATS - |C0034735|Raynaud Phenomenon]
Abstract
“The results of this study suggest that orally administered ketanserin may be an
effective and well tolerated treatment for Raynaud’s phenomenon associated with
connective tissue disorders, especially scleroderma.”
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[C0022616|Ketanserin – TREATS – C0034735|Raynaud Phenomenon]
[PMID6773615]
Abstract
“These results support our suggestion that a prostaglandin, in particular PGI2, is
required for hypercapnia to produce full cerebral vasodilatation.”
[C0033554|Prostaglandins – COEXISTS_WITH – C0033567|Epoprostenol]
[C0033567|Epoprostenol – ISA – C0033554|Prostaglandins]
[PMID6788326]
Title
“Effect of prostaglandins I2 and E1 on red cell deformability in patients with
Raynaud’s phenomenon and systemic sclerosis.”
[C0033567|Epoprostenol – TREATS(INFER) – C0034735|Raynaud Phenomenon]
[C0033567|Epoprostenol – TREATS(INFER) – C0036421|Systemic Scleroderma]
[PMID6812750]
Abstract
“This study suggests that ketanserin may be useful in the treatment of Raynaud’s
phenomenon”
[C0022616|Ketanserin – TREATS – C0034735|Raynaud Phenomenon]
[PMID6821892]
Abstract
“Formation of prostaglandins derived from eicosapentaenoic acid and interference of
eicosapentaenoic acid with formation and action of prostaglandins derived from
arachidonic acid were evident in vitro.”
[C0000545|Eicosapentaenoic Acid – CONVERTS_TO – C0033554|Prostaglandins]
[C0003695|Arachidonic Acid – CONVERTS_TO – C0033554|Prostaglandins]
[PMID7003784]
Abstract
“Prostaglandins E1 (PGE1) and I2 (prostacyclin, PGI2) are potent vasodilators and
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inhibitors of platelet aggregation which have been reported to be of value in the
treatment of peripheral ischemia.”
[C0002335|Alprostadil – DISRUPTS – C0032176|Platelet aggregation]
[C0033567|Epoprostenol – ISA – C0042402|Vasodilator Agents]
[PMID7025341]
Title
“Successful treatment of Raynaud’s Syndrome with prostacyclin.”
[C0033567|Epoprostenol – TREATS – C0034734|Raynaud Disease]
Abstract
“We evaluated the effect of prostacyclin (PGI2) a potent antiplatelet and vasodilator
agent in 5 female patients with Raynaud’s syndrome.”
[C0033567|Epoprostenol – TREATS(INFER) – C0034734|Raynaud Disease]
[C0042402|Vasodilator Agents – TREATS(INFER) – C0034734|Raynaud Disease]
[PMID7037038]
Title

“Treatment of Raynaud’s phenomenon by intravenous infusion of prostacyclin (PGI2)”

[C0033567|Epoprostenol – TREATS – C0034735|Raynaud Phenomenon]
[PMID7208950]
Abstract
“The effect of altering the abundance of precursors and inhibitors of prostaglandin
formation by dietary supplements of fish oil…”
[C0033554|Prostaglandins – INTERACTS_WITH – C0016157|Fish Oils]
[PMID7259326]
Abstract
“PGE1 may therefore be suitable treatment for Raynaud’s phenomenon and the
vascular insufficiency of systemic sclerosis and other connective tissue diseases.”
[C0002335|Alprostadil – TREATS – C0034735|Raynaud Phenomenon]
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[PMID7427564]
Abstract
“Prostaglandin E1, a vasodilator and potent inhibitor of platelet aggregation, was
administered to 26 patients with severe vasospastic disease of the hands.”
[C0002335|Alprostadil – DISRUPTS – C0032176|Platelet aggregation]
Abstract
“Intensity of digital vasospasm induced by cold water challenge was not objectively
affected by prostaglandin E1 despite an increased finger temperature after infusion.”
[C0002335|Alprostadil – AFFECTS – C0085616|Vasospasm]
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Table A-3. Precision and recall at each result using citations for Fish Oil study
Result

New Intermediate Terms

Relevancy (Topic)

Precision

Recall

d0

Epoprostenol
Alprostadil
Vasodilator Agents
Systemic Scleroderma

Platelet Aggregation
Platelet Aggregation
Vascular Reactivity
Not Relevant

0.667

0.667

d1

Prostaglandins

Platelet Aggregation

0.667

0.667

d2

Thromboxane A2

Platelet Aggregation

0.667

0.667

d3

Platelet Aggregation

Platelet Aggregation

0.667

0.667

d4

N/A

0.667

0.667

d5

Aspirin

0.667

0.667

d6

N/A

0.667

0.667

d7

Arachidonic Acid

0.5

0.667

d8

N/A

0.5

0.667

d9

Platelet Function

Platelet Aggregation

0.5

0.667

d10

Thromboxanes

Platelet Aggregation

0.5

0.667

d11

Myocardial Ischemia

Not Relevant

0.4

0.667

d12

Prostaglandin I3

Platelet Aggregation

0.4

0.667

d13

Drug Interactions

Not Relevant

0.333

0.667

d14

Blood Viscosity
Ketanserin

Blood Viscosity
Blood Viscosity

0.429

1.0

d15

Blood flow

Blood Viscosity

0.429

1.0

Platelet Aggregation

Not Relevant
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Table A-4. Precision and recall at each result not using citations for Fish Oil study
Result

New Intermediate Terms

Relevancy (Topic)

Precision

Recall

d0

Epoprostenol
Systemic Scleroderma

Platelet Aggregation
Not Relevant

0.5

0.333

d1

Thromboxane A2

Platelet Aggregation

0.5

0.333

d2

Prostaglandins

Platelet Aggregation

0.5

0.333

d3

Arachidonic Acid

Not Relevant

0.333

0.333

d4

Platelet Aggregation
Alprostadil

Platelet Aggregation
Platelet Aggregation

0.333

0.333

d5

N/A

0.333

0.333

d6

Prostaglandin I3

Platelet Aggregation

0.333

0.333

d7

Blood Viscosity
Blood flow

Blood Viscosity
Blood Viscosity

0.5

0.667
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Appendix B
Magnesium – Migraine Disorders Study
Table B-1. Magnesium – Migraine Disorders Core Corpus Medline IDs
90971

3523056

3897128

6116859

6784664

96740

3523058

3898850

6141289

6826350

108361

3524092

3908832

6146019

6836300

330466

3530775

3918779

6150068

6861894

414910

3530778

3946808

6163401

6869560

418838

3531248

3962783

6170210

6870999

630136

3536167

4016924

6172961

6878586

739264

3537077

4016926

6206779

6881926

750727

3582557

4016930

6230778

7085796

1110377

3585352

4016941

6275679

7120030

1262918

3607427

4016945

6296376

7181451

2408700

3616619

4016946

6316376

7334315

2425960

3705931

4019939

6339166

7348028

2433912

3713254

4021225

6375330

7400981

2435656

3715946

4167805

6392763

7402146

2864494

3724238

4323509

6438124

7443079

2867984

3733214

4725298

6464059

10303918

3022872

3758107

4842482

6481797

13295838

3107334

3758108

4978139

6503357

13597818

3160475

3763042

4990911

6525007

13645235

3300911

3771208

5514170

6609739

14212747

3308769

3797213

5573439

6620432

14338128

3458981

3801897

5703635

6643036

14399531

3513507

3827683

5763574

6680619

3514549

3827684

5956342

6689894

3515057

3880896

6115200

6708731

3521194

3881117

6116625

6751554
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Figure B-1. Magnesium – Migraine Disorders search parameters
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Figure B-2. Magnesium – Migraine Disorders result 1 (with citations)

Figure B-3. Magnesium – Migraine Disorders result 2 (with citations)
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Figure B-4. Magnesium – Migraine Disorders result 3 (with citations)

Figure B-5. Magnesium – Migraine Disorders result 4 (with citations)
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Figure B-6. Magnesium – Migraine Disorders result 5 (with citations)

Figure B-7. Magnesium – Migraine Disorders result 6 (with citations)
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Figure B-8. Magnesium – Migraine Disorders result 7 (with citations)

Figure B-9. Magnesium – Migraine Disorders result 8 (with citations)
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Figure B-10. Magnesium – Migraine Disorders result 9 (with citations)

Figure B-11. Magnesium – Migraine Disorders result 10 (with citations)
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Figure B-12. Magnesium – Migraine Disorders result 11 (with citations)

Figure B-13. Magnesium – Migraine Disorders result 12 (with citations)
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Figure B-14. Magnesium – Migraine Disorders result 13 (with citations)

Figure B-15. Magnesium – Migraine Disorders result 14 (with citations)
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Figure B-16. Magnesium – Migraine Disorders result 15 (with citations)

Figure B-17. Magnesium – Migraine Disorders result 16 (with citations)
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Figure B-18. Magnesium – Migraine Disorders result 17 (with citations)

Figure B-19. Magnesium – Migraine Disorders result 18 (with citations)
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Figure B-20. Magnesium – Migraine Disorders result 1 (no citations)

Figure B-21. Magnesium – Migraine Disorders result 2 (no citations)
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Figure B-22. Magnesium – Migraine Disorders result 3 (no citations)

Figure B-23. Magnesium – Migraine Disorders result 4 (no citations)

216

Figure B-24. Magnesium – Migraine Disorders result 5 (no citations)
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Figure B-25. Magnesium – Migraine Disorders result 6 (no citations)

Figure B-26. Magnesium – Migraine Disorders result 7 (no citations)
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Figure B-27. Magnesium – Migraine Disorders result 8 (no citations)

Figure B-28. Magnesium – Migraine Disorders result 9 (no citations)

219

Figure B-29. Magnesium – Migraine Disorders result 10 (no citations)

Figure B-30. Magnesium – Migraine Disorders result 11 (no citations)
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Figure B-31. Magnesium – Migraine Disorders result 12 (no citations)

Figure B-32. Magnesium – Migraine Disorders result 13 (no citations)
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Figure B-33. Magnesium – Migraine Disorders result 14 (no citations)
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Figure B-34. Magnesium – Migraine
Disorders result 15 (no citations)

Figure B-35. Magnesium – Migraine
Disorders result 16 (no citations)
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Table B-2. Magnesium – Migraine Disorders generated predicates
[PMID108361]
Title
“Cerebrospinal fluid concentrations of magnesium and inorganic phophate in epilepsy.”
[C0024467|Magnesium – ASSOCIATED_WITH – C0014544|Epilepsy]
[PMID1138583]
Title
“Increased platelet aggregation in early diabetus mellitus”
SemRep did not derive a predicate from this statement, but it is worth noting.
Abstract
“In view of the tendency toward vascular disease in diabetes mellitus, we studied
platelet aggregation in 15 normal, 7 prediabetic, 12 latent, and 20 frankly diabetic
subjects.”
[C0042373|Vascular Diseases – COEXISTS_WITH – C0011849|Diabetes Mellitus]
[C0042373|Vascular Diseases – COEXISTS_WITH – C0241863|Diabetic]
Abstract
“We conclude that platelet aggregation may be increased early in diabetes mellitus and
may be involved in the genesis of diabetic microangiopathy.”
[C0011849|Diabetes Mellitus – AFFECTS – C0025945|Microangiopathy, Diabetic]
[PMID1146499]
Title
“The significance of blood serotonin levels in migraine.”
[C1445983|Blood serotonin measurement – DIAGNOSES – C0149931|Migraine
Disorders]
Abstract
“If serotonin is effective in relieving migraine pain, this is probably due to extracellular
serotonin acting on the cardiovascular system.”
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[C0036751|Serotonin – ASSOCIATED_WITH – C0030193|Pain]
[C0036751|Serotonin – ASSOCIATED_WITH(SPEC) – C0149931|Migraine
Disorders]
[PMID1153064]
Abstract
“EEG changes suggest–according to the author–that migraine is a primary cerebral and
only secondarily a vascular disorder.”
[C0149931|Migraine Disorders – ISA – C0042373|Vascular Diseases]
[PMID1254466]
Title
“Serotonin (5HT) in migraine: levels in whole blood in and between attacks.”
[C0036751|Serotonin – ASSOCIATED_WITH – C0149931|Migraine Disorders]
[PMID1262918]
Title
“Cerebral arterial spasm. Part 4: in vitro effects of temperature, serotonin analogues,
large nonphysiological concentrations of serotonin, and extracellular calcium and
magnesium on serotonin-induced contractions of the canine basilar artery.”
[C0006675|Calcium – AFFECTS – C1140999|Contraction]
[C0024467|Magnesium – AFFECTS – C1140999|Contraction]
[C0036751|Serotonin – AFFECTS – C1140999|Contraction]
Abstract
“Extracellular magnesium, in contrast, was shown to inhibit serotonin-induced
contractions.”
[C0024467|Magnesium – DISRUPTS – C1140999|Contraction]
[PMID13214278]
Introductory Paragraph
“Among this group are headaches associated with hypertension, arteriosclerosis,
infection, brain tumor, hematoma, allergy, and cranial trauma.”
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[C0018681|Headache – ASSOCIATED_WITH – C0020538|Hypertensive disease]
[PMID14338128]
Title
“DISORDERS OF MAGNESIUM METABOLISM IN EPILEPSY.”
[C0024467|Magnesium – ASSOCIATED_WITH – C0014544|Epilepsy]
Introductory Paragraph
“The possibility that convulsions may occur in Mg deficiency led some investigators to
study the metabolism of this metal in the epilepsies, and a trend to low blood
concentrations was usually found.”
[C0009951|Convulsions – OCCURS_IN – C0024473|Magnesium Deficiency]
[PMID184066]
Abstract – Taken from publisher’s site.
“Since biochemical abnormalities reported herein were common to occlusive CVD and
migraine headache, it seems probable that they are due to ischemia associated with both
conditions and possibly related to the resultant disorder of cerebral energy
metabolism.”
[C0022116|Ischemia – CAUSES – C0149931|Migraine Disorders]
[PMID20784580]
Title
“The Pain Pathways in Migraine”
[C0030193|Pain – ASSOCIATED_WITH – C0149931|Migraine Disorders]
[PMID2424267]
Abstract
“The cardiovascular effects of different calcium channel blockers (CCB), exemplified
by nifedipine, verapamil and diltiazem, are not identical.”
[C0028066|Nifedipine – INTERACTS_WITH – C0006684|Calcium Channel Blockers]
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[C0042523|Verapamil – INTERACTS_WITH – C0006684|Calcium Channel Blockers]
[PMID2425960]
Abstract
“Three such drugs, nifedipine, verapamil, and diltiazem, are currently available in the
United States, although none are specifically approved for use in migraine.”
[C0028066|Nifedipine – TREATS – C0149931|Migraine Disorders]
[C0042523|Verapamil – TREATS – C0149931|Migraine Disorders]
Abstract
“Nifedipine and nimodipine also appear to be valuable for the treatment of cluster
headache.”
[C0028066|Nifedipine – TREATS – C0009088|Cluster Headache]
[C0028094|Nimodipine – TREATS – C0009088|Cluster Headache]
Abstract
“Two case reports describing favorable responses to flunarizine in childhood
hemiplegic migraine are the only available data concerning the utility of these drugs in
“complicated” migraine syndromes.”
[C0016295|Flunarizine – TREATS – C0270862|Hemiplegic migraine]
[PMID2433912]
Abstract
“Opiates and somatostatin inhibit the release of substance P from primary sensory
neurones and relieve both pain and autonomic symptoms of cluster headache attack.”
[C0037659|Somatostatin – TREATS – C0030193|Pain]
Abstract
“Plasma substance P-like immunoreactivity was decreased during spontaneous attack
of cluster headache and migraine and during histamine precipitated attack of cluster
headache. Taken together these data suggest that substance P and endogenous opioids
could be implicated in the pathophysiology of cluster headache and migraine.”
[PMID2452018]
Title
“Substance P in the human iris: possible involvement in echothiophate-induced miosis
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in cluster headache.”
[C0038585|Substance P – CAUSES – C0009088|Cluster Headache]
[PMID2981405]
Abstract – Taken from publisher’s site.
“Verapamil is a calcium-channel blocking agent that has been used extensively in the
treatment of coronary vasospasm and supraventricular arrhythmias.”
[C0042523|Verapamil – ISA – C0006684|Calcium Channel Blockers]
[PMID3458981]
Title
“Vasomotor effects of magnesium: a comparison with nifedipine and verapamil of in
vitro reactivity in feline cerebral and peripheral arteries.”
[C0024467|Magnesium – compared_with – C0028066|Nifedipine]
Abstract
“The order of potency for eliciting relaxation was: nifedipine greater than verapamil
greater than magnesium.”
[C0042523|Verapamil – compared_with – C0024467|Magnesium]
[PMID3521194]
Title
“Migraine treatment with calcium channel blockers.”
[C0006684|Calcium Channel Blockers – TREATS – C0149931|Migraine Disorders]
[PMID3585352]
Title
Laterality of pain in migraine distinguished by interictal rates of habituation of
electrodermal responses to visual and auditory stimuli.
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[C0030193|Pain – ASSOCIATED_WITH – C0149931|Migraine Disorders]
[PMID361756]
Abstract
Prostacyclin (PGI(2)) is an unstable prostaglandin which inhibits platelet aggregation
and serotonin release and causes vasodilation.
[C0033554|Prostaglandins – DISRUPTS – C0032176|Platelet aggregation]
[PMID3629724]
Abstract
“A stimulating effect of serotonin, guanine nucleotides and sodium fluoride is found as
well as a dependence of the catalytic activity of adenylate cyclase on magnesium and
manganese ions.”
[C0001492|Adenylate Cyclase – INTERACTS_WITH – C0024467|Magnesium]
[PMID372242]
Abstract
Endothelial cells synthesize prostacyclin (PGI(2)), an unstable prostaglandin that
inhibits platelet aggregation and serotonin release.
[C0033554|Prostaglandins – DISRUPTS – C0032176|Platelet aggregation]
[PMID379918]
Abstract
“However, in 1 X 10(-5)M concentrations PGI2 contracted the arterial muscle and did
not antagonize contractions induced by serotonin or PGF2 alpha.”
[C0012471|Dinoprost – CAUSES – C1140999|Contraction]
[C0036751|Serotonin – CAUSES – C1140999|Contraction]
[PMID386807]
Abstract – Taken from publisher’s site.
“Substantial species variability has been described for the effects of extracellular
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magnesium upon tension development, which arises out of striking calcium-magnesium
antagonism at an extracellular site in the rat and guinea pig.”
[C0024467|Magnesium – AFFECTS – C0233494|Tension]
[PMID3898850]
Abstract – Introductory paragraph obtained from publisher’s site and used.
“Prostacyclin is the most potent naturally occurring vasodilator and inhibitor of platelet
aggregation.”
[C0033567|Epoprostenol – DISRUPTS – C0032176|Platelet aggregation]
Abstract – Introductory paragraph obtained from publisher’s site and used.
“Magnesium is known to exert an inhibitory effect on coagulation and platelet function,
but, so far, little is known about its influence on prostacyclin metabolism. Therefore the
effect of magnesium sulfate on vascular prostacyclin synthesis and platelet prostacyclin
interaction was investigated.”
[C0024467|Magnesium – INTERACTS_WITH – C0033567|Epoprostenol]
[PMID390330]
Abstract
“Other direct studies, from our laboratory, indicate that [Mg2+]o regulates calcium
exchange and content of vascular smooth muscle.”
SemRep did not derive a predicate from this statement, but it is worth noting.
Abstract
“In summary, the concept to be presented suggests that a deficiency in dietary Mg2+ is
a key factor in the high incidence of mortality noted in SDIHD in nations of the
Western world.”
SemRep did not derive a predicate from this statement, but it is worth noting.
Abstract
”The hypomagnesemia produces progressive vasoconstriction, vasospasm and
ischemia, which, given time, will lead to SDIHD.”
[C0022116|Ischemia – CAUSES – C0151744|Myocardial Ischemia]
[C0085616|Vasospasm – CAUSES – C0151744|Myocardial Ischemia]
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[PMID4016946]
Title
“Relevance of prostaglandins in migraine.”
[C0033554|Prostaglandins – ASSOCIATED_WITH – C0149931|Migraine Disorders]
Abstract
“Prostaglandins (PG), particularly PGE, may be linked to the pathophysiology of
migraine in several important ways. PGE1 may “simulate” a migraine attack in healthy
volunteers. In animal experiments and in human infusions, PGEs cause vasodilation
and hyperalgesia, both typical reactions of inflammation.”
[C0033559|Prostaglandins E – ISA – C0033554|Prostaglandins]
Abstract
“The view that vascular headache is an “inflammatory reaction” allows the best
concept concerning the local role of PGs and the effectiveness of PG-inhibitors in the
treatment of migraine.
[C0033529|Prostaglandin Antagonists – TREATS – C0149931|Migraine Disorders]
[PMID4260015]
Title
“Magnesium metabolism from the viewpoint of cardioangiology. II. Findings in
magnesium metabolism in vascular diseases”
[C0024467|Magnesium – ASSOCIATED_WITH – C0042373|Vascular Diseases]
[PMID450213]
Abstract
“We performed in vitro experiments with a small volume chamber to determine the
inhibitory effect of nifedipine on serotonin-, phenylephrine-, and potassium-induced
contractions of canine basilar and femoral arteries.”
[C0028066|Nifedipine – INHIBITS – C0036751|Serotonin]
Abstract
“In contrast, nifedipine did not significantly inhibit the serotonin- and phenylephrine-
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induced contractions of the femoral artery but did inhibit potassium-induced
contractions of the femoral artery. Calcium-induced contractions of the basilar artery
were also inhibited by nifedipine.”
SemRep did not derive a predicate from this statement, but it is worth noting.
[PMID4760464]
Abstract – Taken from publisher’s site.
“Reserpine pretreatment did not alter the effect of magnesium on contractility to those
agents both in polarizing and calcium-free depolarizing solutions.”
[C0024467|Magnesium – NEG_AFFECTS – C1140999|Contraction]
Abstract – Taken from publisher’s site.
“However, such pretreatment modified the effect of magnesium on sensitivity of aortas
to acetylcholine and norepinephrine.”
[C0024467|Magnesium – INTERACTS_WITH – C0001041|Acetylcholine]
[C0024467|Magnesium – INTERACTS_WITH – C0028351|Norepinephrine]
Abstract – Taken from publisher’s site.
“These results suggest that magnesium and reserpine act to alter calcium binding, and
its availability to the contractile apparatus, by different mechanisms.”
[C0024467|Magnesium – AFFECTS – C1516144|Calcium Binding]
[PMID4814375]
Abstract
“Methylsergide reversibly blocked the artery’s response to serotonin and caused a
contraction of the basilar artery.”
[C0025842|Methysergide – AFFECTS – C0871261|response]
[C0036751|Serotonin – CAUSES – C1140999|Contraction]
[PMID4978139]
Introduction – Taken from paper itself.
“It is the purpose of this paper to examine the question of the relation of migraine and
epilepsy by an analysis of 1,800 cases of migraine seen at the Northcott Neurological
Centre since 1951 with particular reference to those cases in which migraine and
epilepsy were manifested in the same individual.”
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[C0014544|Epilepsy – COEXISTS_WITH – C0149931|Migraine Disorders]
[PMID527222]
Title
“Hypomagnesaemia in diabetes.”
[C0151723|Hypomagnesemia – COEXISTS_WITH – C0011847|Diabetes]
Abstract
“Although its significance is unclear, hypomagnesaemia could conceivably predispose
to ischaemic heart disease in diabetes.”
[C0151723|Hypomagnesemia – PREDISPOSES – C0151744|Myocardial Ischemia]
[PMID5297855]
Title
“Plasma serotonin in migraine and stress.”
[C0036751|Serotonin – ASSOCIATED_WITH – C0149931|Migraine Disorders]
Abstract – Taken from publisher’s site/paper
“Interest in the possible relationship of serotonin to the migraine syndrome had
quickened following Sicuteri’s preliminary trial of methysergide, a serotonin
“antagonist,” in the treatment of migraine.”
[C0025842|Methysergide – TREATS(SPEC) – C0149931|Migraine Disorders]
[C0036753|Serotonin Antagonists – TREATS – C0149931|Migraine Disorders]
Abstract – Taken from publisher’s site/paper
“Finally, total plasma serotonin was investigated after the intramuscular injection of
reserpine 2.5 mg, which has been reported to induce migraine headache in susceptible
patients.”
[C0036751|Serotonin – CAUSES – C0149931|Migraine Disorders]
Abstract – Taken from publisher’s site/paper
“The effect of injected serotonin on spontaneous and reserpine-induced headaches was
noted and correlated with serotonin levels.”
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[C0036751|Serotonin – ASSOCIATED_WITH – C0018681|Headache]
[PMID5483751]
Title
“Influence of magnesium and cysteine on vasopressin-induced contractions in various
canine blood vessels.”
[C0024467|Magnesium – AUGMENTS – C0005847|Blood Vessels]
[PMID5658323]
Title
“Plasma serotonin levels in migraine.”
[C0036751|Serotonin – ASSOCIATED_WITH – C0149931|Migraine Disorders]
[PMID5674982]
Title
“Magnesium-calcium antagonism in the contraction of arterioles”
[C0006684|Calcium Channel Blockers – TREATS – C1140999|Contraction]
Abstract – Taken from publisher’s site.
“Increasing the level of Mg in the blood inhibits the tone and contractility of the
resistance vessels in the muscle.”
SemRep did not derive a predicate from this statement, but it is worth noting.
[PMID5682248]
Abstract – Taken from publisher’s site
“Diabetes mellitus was the most common condition associated with hypomagnesemia.”
[C0151723|Hypomagnesemia – COEXISTS_WITH – C0011849|Diabetes Mellitus]
[PMID572225]
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Abstract
“FFA fell by a maximum of 65% or 0.44 meq/liter and Mg fell by a maximum of 0.31
meq/liter during the glucose-insulin infusions.”
[C0015688|Fatty Acids, Nonesterified – COEXISTS_WITH – C0021641|Insulin]
[C0024467|Magnesium – COEXISTS_WITH – C0021641|Insulin]
Abstract
“The sharp divergent changes in FFA and Mg after cessation of nicotinic acid infusion
support the prime role of FFA-effecting movements of Mg and the thesis that FFA bind
Mg.”
[C0015688|Fatty Acids, Nonesterified – INTERACTS_WITH –
C0024467|Magnesium]
[PMID5803690]
Introduction – Taken from paper itself.
“According to the classical theory the first (prodromal) phase in migraine is caused by
ischemia within the internal carotid system and the second phase (headache) by a
vasodilation, especially within the external carotid system.”
[C0022116|Ischemia – CAUSES – C0149931|Migraine Disorders]
[PMID597797]
Abstract
“These findings do not exclude the possibility of distension of the larger intracranial
arteries during migraine headache, but the angiographic evidence, however limited,
does not support this speculation.”
[C0012359|Pathological Dilatation – COEXISTS_WITH – C0149931|Migraine
Disorders]
[PMID6022537]
Title
“Serotonin, the carotid body, and cranial vessels in migraine.”
[C0036751|Serotonin – ASSOCIATED_WITH – C0149931|Migraine Disorders]
[PMID6116625]
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Abstract – Taken from article on www.researchgate.net
“Lowering (or removal) of magnesium ions enhances reactivity of a number of arterial,
arteriolar, and venous vessels to several neurohumoral agents (e.g., catecholamines,
angiotensin, acetylcholine, serotonin) and K+; relaxations induced by prostaglandins
and beta-adrenergic stimulation are often attenuated in the absence of magnesium
ions.”
[C0033554|Prostaglandins – STIMULATES – C0596876|Magnesium Ions]
[PMID6117893]
Abstract
“Prostacyclin is a potent vasodilator and the most potent inhibitor of platelet
aggregation so far described.”
[C0033567|Epoprostenol – DISRUPTS – C0032176|Platelet aggregation]
Abstract
“Additionally, since prostacyclin powerfully inhibits platelet aggregation and promotes
their disaggregation, this agent could have an important use in the therapy of conditions
in which increased platelet aggregation takes place and in which, perhaps, a
prostacyclin deficiency exists.”
[C0033567|Epoprostenol – DISRUPTS – C0032176|Platelet aggregation]
[C0033567|Epoprostenol – AUGMENTS – C0032176|Platelet aggregation]
[PMID6141690]
Title
“Magnesium requirement for somatostatin inhibition of insulin secretion.”
[C0024467|Magnesium – INHIBITS – C0037659|Somatostatin]
Abstract
“We observed that in the absence of magnesium, somatostatin concentrations of 0.5
and 2.0 ng/ml were without effect on first phase insulin secretion. However, these same
somatostatin levels produced 50% or more inhibition of insulin secretion in the
presence of magnesium at 0.3 or 0.6 mEq/l.”
[C0024467|Magnesium – DISRUPTS – C1256369|insulin secretion]
Abstract
“Therefore, magnesium ion is necessary for the full inhibitory effect of somatostatin to
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occur.”
[C0596876|Magnesium Ions – INHIBITS – C0037659|Somatostatin]
[PMID6149922]
Abstract
“A number of CHD and myocardial ischaemic syndromes such as unstable angina
pectoris, sudden death ischaemic heart disease, acute myocardial infarction and
ventricular arrhythmias have been associated with losses of myocardial magnesium and
potassium.”
[C0024467|Magnesium – ASSOCIATED_WITH – C0151744|Myocardial Ischemia]
Abstract
“Mg++ ions are essential for regulation of Na+ and K+ transport across cell
membranes, including those found in cardiac and vascular smooth muscle cells. Loss of
cellular Mg++ results in loss of critically important phosphagens: MgATP and creatine
phosphate. Thus, under conditions where cellular Mg++ is depleted (e.g. hypoxia,
ischaemia, anoxia), the Na+-K+ pump and phosphagen stores will be compromised,
leading to alterations in resting membrane potentials.”
N/A
Abstract
“Considerable evidence has accumulated to indicate that the extracellular concentration
of Mg++ is important in control of arterial tone and blood pressure via pressure via
regulation of vascular membrane Mg++-Ca++ exchange sites. A reduction in the
extracellular Mg++ concentration can produce hypertension, coronary vasospasm and
potentiation of vasoconstrictor agents by allowing excess entry of Ca++;
concomitantly, the potency of vasodilator agents is reduced.”
N/A
[PMID6171999]
Abstract
“Indirect evidence has abundantly been presented to support the view that substance P
(SP) is involved in the vasodilatation following activation of fine calibre pain fibres
(Lembeck & Holzer 1979).”
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[C0038585|Substance P – ASSOCIATED_WITH – C0595862|Vasodilation disorder]
Abstract
“We have also determined whether (D-Pro2, D-Phe7, D-Trp9)-SP specifically blocks
the vascular effects of SP.”
[C0038585|Substance P – AFFECTS – C0005847|Blood Vessels]
[PMID6184468]
Title
“The effects of substance P on histamine and 5-hydroxytryptamine release in the rat.”
[C0038585|Substance P – INTERACTS_WITH – C0019588|Histamine]
Abstract
“Substance P (SP) induces histamine release from isolated rat peritoneal mast cells at
concentrations of 0.1-10 muM.
[C0038585|Substance P – CAUSES – C0019595|Histamine Release]
Abstract
“Extracellular calcium (0.1-1 mM), magnesium (1-10 mM) and cobalt (0.01-0.1 mM)
all inhibit SP-induced histamine release when added before the peptide.”
[C0024467|Magnesium – DISRUPTS – C0019595|Histamine Release]
[PMID6193886]
Title
“Substance P and endogenous opioids: how and where they could play a role in cluster
headache.”
[C0038585|Substance P – AFFECTS – C0009088|Cluster Headache]
Abstract
“Substance P appears to be involved in the transmission of pain signals from the
periphery to the spinal cord and brain stem. Substance P containing neurons are
responsible for the neurogenic vasodilation identical to that obtained by substance P
release evoked by antidromic stimulation of these fibres.”
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N/A
[PMID6202853]
Abstract
“In NCB -20 cells, this voltage-sensitive 45Ca2+ uptake was inhibited selectively by
organic calcium antagonists such as nitrendipine, cinnarizine, verapamil, and diltiazem
(IC50 values = 6.4, 750, 1800, and 4500 nM, respectively).”
[C0008803|Cinnarizine – ISA – C0006684|Calcium Channel Blockers]
[C0012373|Diltiazem – ISA – C0006684|Calcium Channel Blockers]
[C0028127|Nitrendipine – ISA – C0006684|Calcium Channel Blockers]
[C0042523|Verapamil – ISA – C0006684|Calcium Channel Blockers]
[PMID6275679]
Title
“Serotonin and cyclic nucleotides in migraine.”
[C0036751|Serotonin – ASSOCIATED_WITH – C0149931|Migraine Disorders]
[PMID6279807]
Abstract
“The relation of circulating insulin and glucagon concentrations to effects of
magnesium deficiency was explored in experiment 3. The results of these experiments
suggest that magnesium deficiency alters PEPCK activity by affecting secretion of
pancreatic hormones.”
[C0021641|Insulin – AFFECTS – C0024473|Magnesium Deficiency]
[PMID6339937]
Title
“Nifedipine in the treatment of migraine in patients with Raynaud’s phenomenon.”
[C0028066|Nifedipine – TREATS – C0149931|Migraine Disorders]
[PMID6358126]

239

Abstract – Taken from publisher’s site.
“Since Wolff’s original proposal regarding the vascular etiology of cyclic head pain,
evidence has accumulated that the prodromes of migraine are due to cerebral
vasoconstriction and headaches of both cluster and migraine are due to painful
dilatation.”
[C0018681|Headache – CAUSES – C0149931|Migraine Disorders]
[C0149931|Migraine Disorders – ISA – C0018681|Headache]
[C1167661|Cerebral vasoconstriction – CAUSES – C0149931|Migraine Disorders]
Abstract – Taken from publisher’s site.
“Nifedipine and verapamil provided equivalent relief for cluster but produced more
side effects, and were less effective, than nimodipine in control of migraine.”
[C0028066|Nifedipine – TREATS – C0149931|Migraine Disorders]
[C0042523|Verapamil – TREATS – C0149931|Migraine Disorders]
Abstract – Taken from publisher’s site.
“Theories regarding their pathogenesis include cyclic release of vasoactive substances
from platelets and/or other sources (such as serotonin, catecholamines, histamine,
acetyl choline, prostaglandins, substance P, endogenous opiates). Drugs which modify
receptors (such as methysergide, alpha and beta blockers, antihistaminics,
anticholinergics, steroids and non-steriodal anti-inflammatory agents) have had some
therapeutic success in migraine but provide little benefit for cluster patients. Ca2+ entry
blockers (including nimodipine, nifedipine, verapamil) theoretically should diminish
cephalic vasoconstriction and –dilatation no matter what their cause.”
SemRep did not derive a predicate from this statement, but it is worth noting.
Abstract – Taken from publisher’s site.
“Within 10 days migraine prodromes became infrequent and after 2-4 weeks headache
frequency was significantly reduced for migraine and within 4-6 weeks for cluster.”
[C0149931|Migraine Disorders – ISA – C0018681|Headache]
[PMID6358127]
Abstract – Taken from publisher’s site.
“The calcium channel antagonists are a recently developed class of vasodilators that
prevent the influx of calcium into vascular smooth muscle. The unique pharmacologic
effects of these agents provide a theoretical basis for their use in the treatment of
migraine.”
[C0450442|Agent – TREATS – C0149931|Migraine Disorders]
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Abstract – Taken from publisher’s site.
“Clinically, two specific calcium antagonists (flunarizine, cinnarizine) and two nonspecific antagonists (cyproheptadine, amitriptyline) are effective in the treatment of
migraine.”
[C0006684|Calcium Channel Blockers – TREATS – C0149931|Migraine Disorders]
[PMID6375330]
Introductory Paragraph – Taken from article.
“In a sense, magnesium may be considered nature’s physiologic calcium blocker.”
[C0024467|Magnesium – INHIBITS – C0006675|Calcium]
[PMID6392763]
Title
“Reversible retinal vasospasm in magnesium-treated hypertension despite no
significant change in blood pressure.”
[C0085616|Vasospasm – COEXISTS_WITH – C0020538|Hypertensive disease]
[PMID6399344]
Abstract
“Experimental magnesium deficiency induces arterial damage, a loss of magnesium
and potassium and an increase in the calcium and sodium content of the cell.”
[C0024467|Magnesium – COEXISTS_WITH – C0006675|Calcium]
Abstract
“Magnesium and potassium depletion have also been reported in diabetes and the
vascular implications of this should be considered.”
[C0024467|Magnesium – ASSOCIATED_WITH – C0011847|Diabetes]
[PMID6407598]
Abstract
“The effect of magnesium on blood pressure may be direct or through influences on the
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internal balance of potassium, sodium, and calcium.”
[C0006675|Calcium – INTERACTS_WITH|C0024467|Magnesium|bacs,elii|bacs||
[PMID6503357]
Title
“Inhibition of calcium by magnesium in the contraction of rat aortic smooth muscle.”
[C0024467|Magnesium – ASSOCIATED_WITH – C1140999|Contraction]
[C0024467|Magnesium – INHIBITS – C0006675|Calcium]
[PMID6538269]
Abstract
“Cyproheptadine is equipotent (IC50 = 41 to 45 nM) in blocking contractions of canine
basilar artery segments induced by serotonin, norepinephrine, potassium, or calcium.”
[C0006675|Calcium – CAUSES – C1140999|Contraction]
[C0028351|Norepinephrine – CAUSES – C1140999|Contraction]
[C0036751|Serotonin – CAUSES – C1140999|Contraction]
Abstract
“Propranolol, at concentrations to 10 micromolar, had minimal effect on vessel
contractions.”
[C0033497|Propranolol – AFFECTS – C1140999|Contraction]
Abstract
“We conclude that the primary action of cyproheptadine in preventing induced
contractions of the canine basilar artery is antagonism of calcium channels.This action
is unique among drugs used for migraine prophylaxis and may have important
implications for the treatment of headache and other neurologic disorders.”
SemRep did not derive a predicate from this statement, but it is worth noting.
[PMID6539877]
Title
“Verapamil in prophylactic therapy of migraine.”
[C0042523|Verapamil – TREATS – C0149931|Migraine Disorders]
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Abstract
“Verapamil significantly reduced both headache frequency and duration with few side
effects.”
[C0042523|Verapamil – PREVENTS – C0018681|Headache]
[PMID65562]
Abstract
“No differences were found in plasma tryptophan, glucose, insulin, and free fatty acid
levels in the migraine/no-migraine categories.”
[C0017725|Glucose – ASSOCIATED_WITH – C0149931|Migraine Disorders]
[C0021641|Insulin – ASSOCIATED_WITH – C0149931|Migraine Disorders]
[PMID6680619]
Title
“Pharmacologic inhibition of cerebral vasospasm in ischemia, hallucinogen ingestion,
and hypomagnesemia: barbiturates, calcium antagonists, and magnesium.”
[C0006684|Calcium Channel Blockers – DISRUPTS – C0265110|Cerebral Vasospasm]
[C0024467|Magnesium – DISRUPTS – C0265110|Cerebral Vasospasm]
[C0265110|Cerebral Vasospasm – COEXISTS_WITH – C0022116|Ischemia]
[C0265110|Cerebral Vasospasm – COEXISTS_WITH – C0151723|Hypomagnesemia]
Abstract
“Experiments indicate that several different calcium antagonists have vasodilatory
properties which may be expressed selectively on different organ vascular beds.
Magnesium is a competitive calcium antagonist, and alterations in the extracellular
content of this ion have profound effects on cerebral vascular resistance.”
[C0006684|Calcium Channel Blockers – AFFECTS – C0042380|Vascular resistance]
[PMID6708731]
Abstract
“Flunarizine is a calcium entry blocking drug possessing antihypoxic activity in animal
models of cerebral and peripheral ischemia-anoxia and has clinical usefulness in
circulatory disorders of both central and peripheral origin.”
[C0016295|Flunarizine – ISA – C0006684|Calcium Channel Blockers]
Abstract
“This report compares the activity of flunarizine and verapamil, another calcium entry
blocking drug, on the central nervous system (CNS) and peripheral consequences of
cytotoxic hypoxia induced by high and low doses of KCN.”
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[C0042523|Verapamil – ISA – C0006684|Calcium Channel Blockers]
Abstract
“Since low doses of the cyanide ion render respiration quicker and deeper by an action
on chemoreceptive cells in peripheral arteries, the effect of verapamil against the
hypoxic effect of KCN is mediated by an action in the periphery.”
[C0042523|Verapamil – AFFECTS – C0242184|Hypoxia]
Abstract
“In summary, we have shown that the physiological consequences of cytotoxic hypoxia
can be affected by calcium entry blocking drugs having site-specific activities.”
[C0006684|Calcium Channel Blockers – AFFECTS – C0242184|Hypoxia]
[PMID6715160]
Title
“Relative potency and selectivity of calcium antagonists used in the treatment of
migraine.”
[C0006684|Calcium Channel Blockers – TREATS – C0149931|Migraine Disorders]
Abstract – Taken from publisher’s site.
“Calcium channel antagonists selectively block intracerebral vasoconstriction and
appear clinically effective in the treatment of migraine.”
[C0243076|antagonists – TREATS – C0149931|Migraine Disorders]
[PMID6802656]
Title
“Renal hypomagnesaemia in human diabetes mellitus: its relation to glucose
homeostasis.”
[C0151723|Hypomagnesemia – COEXISTS_WITH – C0011849|Diabetes Mellitus]
Abstract
“These data indicate that the net tubular reabsorption of magnesium is decreased in
diabetic patients in presence of hyperglycaemia, leading to hypermagnesiuria and
hypomagnesaemia.”
SemRep did not derive a predicate from this statement, but it is worth noting.
[PMID6830162]
Title
“Extracranial vascular changes and the source of pain in migraine headache.”
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[C0030193|Pain – ASSOCIATED_WITH – C0149931|Migraine Disorders]
[PMID6847018]
Title
“Calcium and magnesium nutrition in human hypertension.”
[C0006675|Calcium – ASSOCIATED_WITH – C0020538|Hypertensive disease]
Abstract
“Many studies suggest that reduced consumption of calcium or magnesium is
associated with an increased risk of developing hypertension and cardiovascular
disease.”
[C0024467|Magnesium – PREDISPOSES – C0020538|Hypertensive disease]
[C0006675|Calcium – PREDISPOSES – C0020538|Hypertensive disease]
[PMID6864566]
Abstract
“These results show that monoamines can modulate long-term changes in synaptic
function in the dentate gyrus, and suggest that 5-HT is more potent in this respect than
NA.”
[C0036751|Serotonin – compared_with – C0028351|Norepinephrine]
[C0036751|Serotonin – higher_than – C0028351|Norepinephrine]
[PMID6869560]
Abstract
“The vasodilator effect of Mg2+ on pial arterioles was enhanced in the presence of the
calcium antagonist verapamil (0.5 micrograms/ml), despite the fact that verapamil by
itself caused a 12-13% arteriolar dilation”.
[C0042523|Verapamil – CAUSES – C0012359|Pathological Dilatation]
[C0042523|Verapamil – ISA – C0006684|Calcium Channel Blockers]
[PMID6948814]
Abstract
“In isolated human pial arteries (diameter 0.4-0.5 mm), contractions were produced by
potassium, noradrenaline, serotonin, and prostaglandin F2 alpha.”
[C0028351|Norepinephrine – CAUSES – C1140999|Contraction]
[C0036751|Serotonin – CAUSES – C1140999|Contraction]
Abstract
“Both nifedipine and nimodipine effectively inhibited contraction elicited by
noradrenaline and serotonin in pial arteries.”
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[C0028066|Nifedipine – DISRUPTS – C1140999|Contraction]
[C0028094|Nimodipine – DISRUPTS – C1140999|Contraction]
[C0028351|Norepinephrine – AUGMENTS – C1140999|Contraction]
[C0036751|Serotonin – AUGMENTS – C1140999|Contraction]
Abstract
“Both nifedipine and nimodipine effectively inhibited contractions induced by calcium
in pial arteries pretreated in a calcium-free medium and depolarised by potassium.”
[C0006675|Calcium – CAUSES – C1140999|Contraction]
[C0028066|Nifedipine – DISRUPTS – C1140999|Contraction]
[PMID6992233]
Abstract
“Graft failure, as determined by reduction and ultimate cessation of renal blood flow
and urine production, can be abrogated in the short term by prostacyclin which is the
most potent inhibitor of platelet aggregation yet discovered.”
[C0033567|Epoprostenol – DISRUPTS – C0032176|Platelet aggregation]
[PMID7014260]
Abstract
“Further, authentic 6-keto-PGE1, like PGI2, escapes pulmonary degradation and is a
potent inhibitor of platelet aggregation.”
[C0033567|Epoprostenol – DISRUPTS – C0032176|Platelet aggregation]
[PMID7026501]
Title
“The effect of infused prostacyclin in migraine and cluster headache.”
[C0033567|Epoprostenol – AFFECTS – C0009088|Cluster Headache]
[C0033567|Epoprostenol – AFFECTS – C0149931|Migraine Disorders]
Abstract – Taken from publisher’s site.
Prostacyclin appears to be the most active of the vasodilating prostaglandins with
inflammatory and hyperalgesic properties.
[C0033567|Epoprostenol – ISA – C0033554|Prostaglandins]
Abstract – Taken from publisher’s site.
Its actions are very similar to those of prostaglandin E1, which has long been known to
cause “vascular-type” headaches.
[C0002335|Alprostadil – CAUSES – C0042376|Vascular Headaches]
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[PMID7048862]
Abstract
“Prostacyclin (PGI2), a strong vasodilator of cerebral vessels and potent inhibitor of
platelet aggregation, was infused intravenously into seven cats after induction of
prolonged vasospasm by hourly application of oxyhaemoglobin solution into the
subarachnoid space round the basilar artery.”
[C0033567|Epoprostenol – DISRUPTS – C0032176|Platelet aggregation]
[PMID7060640]
Abstract
“5-Hydroxytryptamine amplified the contractions evoked by threshold concentrations
of histamine, angiotensin II and prostaglandin F2 alpha; in all three cases, the
amplification was antagonized by comparable concentrations of ketanserin.”
[C0036751|Serotonin – AUGMENTS – C1140999|Contraction]
Abstract
“The inhibition by ketanserin of the amplifying effect of 5-hydroxytryptamine on
vascular responses may help explain the antihypertensive properties of the compound.”
[C0022616|Ketanserin – INHIBITS – C0036751|Serotonin]
[PMID7068108]
Abstract – taken from paper itself
“Hypomagnesemia has been reported to occur in diabetes mellitus in the course of
recovery from ketoacidoses, as well as during insulin maintenance therapy.”
[C0151723|Hypomagnesemia – COEXISTS_WITH – C0011849|Diabetes Mellitus]
[PMID7150872]
Title
“Withdrawal of magnesium enhances coronary arterial spasms produced by vasoactive
agents.”
[C0024467|Magnesium – AUGMENTS – C0010073|Coronary Artery Vasospasm]
Abstract
“The calcium channel blocking agent, verapamil (10(-6)M), inhibited completely
contractile responses to KCl; contractile responses elicited by angiotensin II and 5-HT
were attenuated by verapamil”
[C0036751|Serotonin – STIMULATES – C0042523|Verapamil]
[PMID7174304]
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Title
“Long-term study of propranolol in the treatment of migraine.”
[C0033497|Propranolol – TREATS – C0149931|Migraine Disorders]
[PMID7195070]
Abstract
“A specific calcium antagonist, verapamil, readily prevented (and reversed) PCPinduced vasospasm.”
[C0042523|Verapamil – ISA – C0006684|Calcium Channel Blockers]
[C0042523|Verapamil – PREVENTS – C0085616|Vasospasm]
[PMID7297597]
Abstract
“Previous studies on isolated blood vessels indicate that (1) withdrawal of magnesium
([Mg2+]0) induces calcium-dependent contractile responses, and (2) Mg2+]0 and
verapamil (VE) inhibit calcium influx across the cell membrane.”
[C0024467|Magnesium – STIMULATES – C0042523|Verapamil]
Abstract
“The present study, using isolated rat aortic strips and portal veins, was designed to
assess the interactions of [Mg2+]0 and VE on increases in active tension and
contractility induced by withdrawal of [Mg2+]0.[Mg2+]0 was found to: (1) enhance
VE-induced inhibition of portal vein amplitude, and (2) antagonize VE-induced
enhanced frequency of spontaneous phasic contractions in portal veins.”
[C0042523|Verapamil – AUGMENTS – C1140999|Contraction]
[C0042523|Verapamil – CAUSES – C1140999|Contraction]
Abstract
“Both [Mg2+]0 and VE could prevent and reverse the increases in active tension
developed in aortic smooth muscle upon removal of [Mg2+]0.[Mg2+]0 markedly
potentiated the inhibitory effect of verapamil on calcium-induced contractions of K+depolarized aorta but not in K+-depolarized portal vein.”
[C0042523|Verapamil – DISRUPTS – C1140999|Contraction]
[C0042523|Verapamil – TREATS – C0233494|Tension]
[PMID7305671]
Title
”Hypomagnesemia and vasoconstriction: possible relationship to etiology of sudden
death ischemic heart disease and hypertensive vascular diseases.”
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[C0085616|Vasospasm – CAUSES – C0020538|Hypertensive disease]
[C0085616|Vasospasm – CAUSES – C0151744|Myocardial Ischemia]
Abstract
”Hypomagnesemia and vasoconstriction: possible relationship to etiology of sudden
death ischemic heart disease and hypertensive vascular diseases.”
[C0085616|Vasospasm – CAUSES – C0020538|Hypertensive disease]
Abstract
“In-vitro experiments are presented which indicate that the concentration of
extracellular magnesium ions ([Mg2+]o) can exert profound influences on the
contractility and reactivity of arteries, arterioles and veins from a number of regional
vasculatures in several mammalian species, including man.”
SemRep did not derive a predicate from this statement, but it is worth noting.
Abstract
“Hypomagnesemia can potentiate the contractile activity of a variety of neurohumoral
substances and induce vasospasm. Hypermagnesemia can do the reverse, i.e., induce
hyporeactivity, relaxation and vasodilatation.”
SemRep did not derive a predicate from this statement, but it is worth noting.
Abstract
“Data are reviewed which suggest that certain vascular diseases (e.g., sudden-death
ischemic heart disease, hypertension, eclampsia, diabetes mellitus) are associated with
a Mg-deficiency.”
SemRep did not derive a predicate from this statement, but it is worth noting.
[PMID7310427]
Title
“Asymmetry of the aura and pain in migraine”
[C0030193|Pain – ASSOCIATED_WITH – C0149931|Migraine Disorders]
[PMID7437647]
Title
“Differential effects of the calcium antagonist, verapamil, on lumen sizes of terminal
arterioles and muscular venules in the rat mesenteric, pial and skeletal muscle
microvasculatures.”
[C0042523|Verapamil – INTERACTS_WITH – C0006684|Calcium Channel Blockers]
[C0042523|Verapamil – ISA – C0006684|Calcium Channel Blockers]
Abstract
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“Local application of verapamil (1 to 100 micrograms) to cremaster muscle arterioles
and venules of the rat induces dose-dependent vasodilatation and increased perfusion of
capillaries.”
[C0042523|Verapamil – CAUSES – C0042401|Vasodilation]
Abstract
“Although these direct in situ microvascular findings do indicate that verapamil can
induced dilatation of microscopic resistance and capacitance vessels in skeletal muscle,
our data do not support the concept that verapamil induces non-specific peripheral
vasodilatation.”
[C0042523|Verapamil – CAUSES – C1328540|Peripheral vasodilatation]
[PMID7443079]
Abstract – Taken from publisher’s site.
“Withdrawal of magnesium causes vasospasm while elevated magnesium produces
relaxation of tone in cerebral arteries.”
[C0024467|Magnesium – CAUSES – C0085616|Vasospasm]
[PMID773081]
Title
“Short-term clinical trial of phopranolol in racemic form (Inderal), D-propranolol and
placebo in migraine.”
[C0033497|Propranolol – TREATS – C0149931|Migraine Disorders]
Abstract
“The results indicate that beta-receptor blocking properties, but possibly also properties
other than the beta-blocking ones, may be of importance for the anti-migraine effect of
propranolol.”
SemRep did not derive a predicate from this statement, but it is worth noting.
[PMID89390]
Abstract
“The effectiveness of tolfenamic acid in acute migraine attacks accords with the
postulated role of prostaglandins in migraine.”
[C0033554|Prostaglandins – ASSOCIATED_WITH – C0149931|Migraine Disorders]
[PMID939020]
Abstract
“The aim of the studies was to develop a solution which, if infused into the coronary
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vessels just prior to the onset of ischemia, would rapidly induce arrest and would also
counteract several of the deleterious cellular changes known to occur during
myocardial ischemia.”
[C0022116|Ischemia – COEXISTS_WITH – C0151744|Myocardial Ischemia]
[PMID953864]
Abstract
“When taken in conjunction with other evidence these results suggest that the diuretics
exert their vascular effects by inhibiting prostaglandin synthesis whereas prolactin acts
by stimulating such synthesis.”
[C0033554|Prostaglandins – AFFECTS – C0005847|Blood Vessels]
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Table B-3. Precision and recall using citations for Magnesium study
Result

New Intermediate Terms

Relevancy (Topic)

Precision

Recall

d0

Epilepsy

Epilepsy

1.0

0.083

d1

Potassium
Verapamil
Dilitazam
Nifedipine
Calcium Channel Blockers
Serotonin

Calcium Channel Blockers
Calcium Channel Blockers
Calcium Channel Blockers
Calcium Channel Blockers
Calcium Channel Blockers
Serotonin

1.0

0.25

d2

Glucose
Insulin Secretion

Diabetes
Diabetes

1

0.333

d3

Pathological Dilatation

Vascular Mechanisms

1

0.417

d4

Insulin
Fatty Acids

Diabetes
Not Relevant

0.833

0.417

d5

Epoprostenol
Prostaglandins
Aspirin

Platelet Aggregation
Prostaglandins
Platelet Aggregation

0.875

0.583

d6

Sodium
Hypertensive Disease

Calcium Channel Blockers
Stress / Type A

0.889

0.667

d7

Pain
Somatostatin

Inflammation
Inflammation

0.9

0.75

d8

N/A

0.9

0.75

d9

Calcium

Calcium Channel Blockers

0.9

0.75

d10

Isoproterenol
Propranolol

Vascular Mechanisms
Vascular Mechanisms

0.9

0.75

d11

Norepinephrine
Clonidine

Serotonin
Vascular Mechanisms

0.9

0.75

d12

Homeostasis

Not Relevant

0.818

0.75

d13

N/A

0.818

0.75

d14

N/A

0.818

0.75

d15

Onset of illness

0.75

0.75

d16

N/A

0.75

0.75

d17

Myocardial Ischemia
Ischemia

0.769

0.833

Not Relevant

Hypoxia
Hypoxia
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Table B-4. Precision and recall not using citations for Magnesium study
Result

New Intermediate Terms

Relevancy (Topic)

Precision

Recall

d0

Excretory Function

Not Relevant

0.0

0.0

d1

Epilepsy

Epilepsy

0.5

0.083

d2

Potassium
Verapamil
Nifedipine
Calcium Channel Blockers

Calcium Channel Blockers
Calcium Channel Blockers
Calcium Channel Blockers
Calcium Channel Blockers

0.667

0.167

d3

Glucose
Insulin Secretion

Diabetes
Diabetes

0.75

0.25

d4

Serotonin
Pathological Dilatation

Serotonin
Vascular Mechanisms

0.833

0.417

d5

Insulin
Fatty Acids

Diabetes
Not Relevant

0.714

0.417

d6

Epoprostenol
Prostaglandins

Platelet Aggregation
Prostaglandins

0.778

0.583

d7

Hypertensive Disease

Stress / Type A

0.8

0.667

d8

Pain
Somatostatin

Inflammation
Inflammation

0.818

0.75

d9

N/A

0.818

0.75

d10

Dilitazam
Calcium

Calcium Channel Blockers
Calcium Channel Blockers

0.818

0.75

d11

ATP

Not Relevant

0.75

0.75

d12

N/A

0.75

0.75

d13

Falls

Not Relevant

0.692

0.75

d14

Vasospasm

Vascular Mechanisms

0.692

0.75

d15

Myocardial Ischemia
Ischemia

Hypoxia
Hypoxia

0.714

0.833
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Appendix C
Somatomedins – Arginine Study
Table C-1. Somatomedins – Arginine Core Corpus Medline IDs
412936

3075738

3690631

5459997

6754563

425782

3080468

3700933

5786514

6790230

430225

3080558

3731567

5841101

6846217

448444

3096900

3758932

5859253

6890417

492275

3099250

3782436

5877589

6989150

515169

3109352

3803997

5917038

6998997

606683

3127426

3833530

5929465

7007997

617386

3140744

3865530

5944094

7020137

632300

3259505

3884753

6176592

7038514

684614

3262126

3902942

6190641

7042736

686863

3288047

3918429

6202444

7045779

722344

3310600

3918442

6243390

7058674

744062

3315866

3923266

6262917

7079756

794768

3322823

4038409

6299718

7189195

839329

3380847

4056323

6324479

7193684

870020

3434631

4058978

6343062

7194884

893668

3499612

4158217

6363657

7194952

908965

3514981

4164428

6370513

7195462

939198

3525601

4205831

6373069

7197311

1110767

3533330

4430939

6414318

7197688

1120749

3546937

4538721

6416888

7198145

1254283

3558728

4550398

6427525

7198682

2536517

3558729

4568402

6428892

7213491

2648317

3569122

4624624

6540317

7264776

2840748

3652525

4631334

6583688

7327721

2897974

3653346

4696902

6609081

7350218

2899993

3654912

4919910

6639868

7391725

2938688

3665113

5059775

6681614

13429201

2959373

3668688

5165405

6684729

13491695

2972888

3683183

5347431

6749885

14328387
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Figure C-1. Somatomedins – Arginine search parameters
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Figure C-2. Somatomedins – Arginine result 1 (with citations)

Figure C-3. Somatomedins – Arginine result 2 (with citations)
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Figure C-4. Somatomedins – Arginine result 3 (with citations)

Figure C-5. Somatomedins – Arginine result 4 (with citations)
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Figure C-6. Somatomedins – Arginine result 5 (with citations)

Figure C-7. Somatomedins – Arginine result 6 (with citations)
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Figure C-8. Somatomedins – Arginine result 7 (with citations)

Figure C-9. Somatomedins – Arginine result 8 (with citations)
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Figure C-10. Somatomedins – Arginine result 9 (with citations)

Figure C-11. Somatomedins – Arginine result 10 (with citations)
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Figure C-12. Somatomedins – Arginine result 11 (with citations)

Figure C-13. Somatomedins – Arginine result 12 (with citations)
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Figure C-14. Somatomedins – Arginine result 13 (with citations)

Figure C-15. Somatomedins – Arginine result 14 (with citations)
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Figure C-16. Somatomedins – Arginine result 15 (with citations)

Figure C-17. Somatomedins – Arginine result 16 (with citations)
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Figure C-18. Somatomedins – Arginine result 1 (no citations)

Figure C-19. Somatomedins – Arginine result 2 (no citations)
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Figure C-20. Somatomedins – Arginine result 3 (no citations)

Figure C-21. Somatomedins – Arginine result 4 (no citations)
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Figure C-22. Somatomedins – Arginine result 5 (no citations)

Figure C-23. Somatomedins – Arginine result 6 (no citations)
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Figure C-24. Somatomedins – Arginine result 7 (no citations)

Figure C-25. Somatomedins – Arginine result 8 (no citations)
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Figure C-26. Somatomedins – Arginine result 9 (no citations)

Figure C-27. Somatomedins – Arginine result 10 (no citations)
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Figure C-28. Somatomedins – Arginine result 11 (no citations)

Figure C-29. Somatomedins – Arginine result 12 (no citations)
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Figure C-30. Somatomedins – Arginine result 13 (no citations)

Figure C-31. Somatomedins – Arginine result 14 (no citations)
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Figure C-32. Somatomedins – Arginine result 15 (no citations)

Figure C-33. Somatomedins – Arginine result 16 (no citations)
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Figure C-34. Somatomedins – Arginine result 17 (no citations)

Figure C-35. Somatomedins – Arginine result 18 (no citations)
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Table C-2. Somatomedins – Arginine generated predicates
[PMID105670]
Title
“Plasma somatomedin activity in protein calorie malnutrition.”
[C0037657|Somatomedins – ASSOCIATED_WITH – C0033677|Protein-Energy
Malnutrition]
[PMID107298]
Abstract – Taken from publisher’s site.
“These data suggest that dietary composition has a direct effect on plasma SM activity
and that the severe growth retardation associated with protein malnutrition may be
related to its additional effect on serum SM.”
[C0037657|Somatomedins – ASSOCIATED_WITH – C0022806|Kwashiorkor]
[PMID1128255]
Abstract – Taken from publisher’s site.
“Somatomedin (SM) is a growth hormone (GH)-dependent peptide, circulating in
normal serum, which directly causes skeletal growth.”
[C0037657|Somatomedins – AUGMENTS – C0018270|Growth]
Abstract – Taken from publisher’s site.
“It is hypothesized that GH produces skeletal growth indirectly by causing the
generation of a “sulfation factor,” now called “SM,” which acts directly to cause
proliferation of cartilage.”
[C0037663|Somatotropin – CAUSES – C0018270|Growth]
[PMID1128683]
Abstract – Taken from publisher’s site.
“In the whole animal a major function of GH is to stimulate the longitudinal growth of
the skeleton, and GH acts by controlling the production of a second series of hormones,
the somatomedins.”
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[C0037663|Somatotropin – AUGMENTS – C0018270|Growth]
[PMID1261514]
Abstract
“When compared with the results without hormone, the addition of 1000 muU/ml of
insulin per ml of medium during the 2nd to 6th period led to a significant increase in
perfusate somatomedin activity at all periods.”
[C0021641|Insulin – STIMULATES – C0037657|Somatomedins]
Abstract
“Differences in insulin concentration may explain some clinical situations in which
somatomedin concentrations cannot be correlated with GH levels.”
[C0021641|Insulin – COEXISTS_WITH – C0037657|Somatomedins]
[PMID132381]
Abstract
“Since diabetes mellitus is a condition in which poor growth occurs despite elevation of
plasma GH, we have attempted to determine if poor growth in diabetes, as in
malnutrition, could be associated with a decrease in somatomedin activity.”
[C0018270|Growth – ASSOCIATED_WITH – C0011847|Diabetes]
[C0018270|Growth – ASSOCIATED_WITH – C0162429|Malnutrition]
Abstract
“Administration of insulin to diabetic rats 48 hours after STZ led to significant
increases in SM and cartilage growth activity, and insulin therapy 24 hours after STZ
prevented the decreases in SM and cartilage growth activity which occurred without
insulin.”
[C0021641|Insulin – INHIBITS – C0037657|Somatomedins]
[PMID13251208]
Abstract – Taken from publisher’s site.
“In view of the notable influence of the growth hormone of the pituitary body on the
growth of cartilage knowledge of the effects of this principle on the metabolism of
cartilage becomes essential.”
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[C0037663|Somatotropin – AFFECTS – C0018270|Growth]
[PMID142677]
Abstract – Taken from publisher’s site.
“Observations of a growth hormone-resistant decrease in somatomedin activity
associated with conditions of insulinopenia suggest that somatomedin and growth
might be related to metabolic control in diabetes mellitus.”
[C0037657|Somatomedins – AFFECTS – C1513158|Metabolic Control]
[C0037657|Somatomedins – ASSOCIATED_WITH – C0011849|Diabetes Mellitus]
Abstract – Taken from publisher’s site.
“We examined this relationship by comparing measures of insulin effect with serum
somatomedin activity (porcine cartilage bioassay), cartilage growth activity (SO4
uptake in vitro), and change in body weight in streptozotocin-diabetic rats.”
[C0037657|Somatomedins – INTERACTS_WITH – C0021641|Insulin]
Abstract – Taken from publisher’s site.
“These studies demonstrate a close relationship between insulin efficacy, serum
somatomedin activity, cartilage growth activity, and weight gain and support the
hypothesis that through somatomedin, insulin may contribute to growth.”
[C0021641|Insulin – AFFECTS – C0018270|Growth]
[PMID20276173]
Title
“The rôle of arginine in growth with some observations on the effects of argininic
acid.”
[C0003765|Arginine – AFFECTS – C0018270|Growth]
[PMID2408950]
Abstract
“Islet cell IGF was identified as predominantly IGF-I or a closely related species and
not IGF-II”
[C0021665|Insulin-Like Growth Factor I – ISA – C0037657|Somatomedins]
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Abstract
“Growth hormone did not consistently increase IGF-I synthesis, suggesting that the
previously described effects of growth hormone on islet cell replication do not result
from stimulation of IGF-I synthesis by islet cells.”
[C0037663|Somatotropin – AFFECTS – C0007590|Cell division]
[C0037663|Somatotropin – STIMULATES – C0021665|Insulin-Like Growth Factor I]
Abstract
“Thus, although the IGF-I synthesized by islet cells may be a physiologically relevant
growth factor for these cells, the mitogenic effects of growth hormone in islet cells
appear to be independent and not mediated by IGF-I.”
[C0018284|Growth Factor – INTERACTS_WITH – C0037663|Somatotropin]
[C0021665|Insulin-Like Growth Factor I – INTERACTS_WITH –
C0037663|Somatotropin]
[C0021665|Insulin-Like Growth Factor I – ISA – C0018284|Growth Factor]
[PMID2413420]
Abstract
“Insulin promotes the growth of these cells by binding, with low affinity, to the type I
insulin-like growth factor (IGF) receptor, not through the high affinity insulin
receptor.”
[C0021641|Insulin – AUGMENTS – C0018270|Growth]
Abstract
“In other cell types, such as hepatocytes, embryonal carcinoma cells, or mammary
tumor cells, the type I IGF receptor is virtually absent, and insulin stimulates the
growth of these cells at physiological concentrations by binding to the high affinity
insulin receptor.”
[C0021641|Insulin – AUGMENTS – C0018270|Growth]
[C0140079|Insulin-Like Growth Factor Receptor – AUGMENTS – C0018270|Growth]
Abstract
“Poor growth follows impaired insulin secretion in diabetes mellitus.”
[C0018270|Growth – ASSOCIATED_WITH – C0011849|Diabetes Mellitus]
Abstract
“This is associated with reduced circulating levels of IGF’s which may be partly
responsible for the growth failure.”
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[C0037657|Somatomedins – CAUSES – C0878787|Growth failure]
Abstract
“Diabetic children, treated conventionally, have normal circulating IGF levels, but both
growth rate and serum IGF concentration may increase dramatically when diabetic
control is optimized”
[C0037657|Somatomedins – AFFECTS – C0241863|Diabetic]
[PMID2899993]
Abstract
“Growth hormone stimulates protein synthesis during hypocaloric parenteral nutrition.”
[C0037663|Somatotropin – AUGMENTS – C0597295|Protein Biosynthesis]
Abstract
“The influence of growth hormone (GH) on protein metabolism and fuel utilization was
investigated in eight paired studies of normal volunteers.”
[C0037663|Somatotropin – AFFECTS – C0597299|Protein Metabolism]
Abstract
“GH was associated with an increase in insulin and insulin-like growth factor-I
concentrations (IGF-I, 9.1 +/- 0.6 IU/ml vs. 3.3 +/- 0.5, p less than 0.001).”
[C0037663|Somatotropin – STIMULATES – C0021641|Insulin]
[C0037663|Somatotropin – STIMULATES – C0021665|Insulin-Like Growth Factor I]
[PMID3099250]
Title
“Serum insulin-like growth factors I and II concentrations and growth hormone and
insulin responses to arginine infusion in children with protein-energy malnutrition
before and after nutritional rehabilitation.”
[C0003765|Arginine – TREATS(INFER) – C0033677|Protein-Energy Malnutrition]
Abstract
“GH responses to arginine were depressed in the three malnourished groups and
improved significantly in marasmic-kwashiorkor and marasmic children after
nutritional rehabilitation.”
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[C0003765|Arginine – TREATS – C0342914|Marasmic kwashiorkor]
Abstract
“Insulin responses to arginine were impaired in kwashiorkor, and marasmickwashiorkor children and improved significantly after refeeding.”
[C0003765|Arginine – DISRUPTS – C0022806|Kwashiorkor]
[C0003765|Arginine – DISRUPTS – C0342914|Marasmic kwashiorkor]
[PMID3259505]
Abstract
“It was found that GH does not show any effect on the recovery of SRBC receptor, but
it may act through the increase of SM level.”
[C0037663|Somatotropin – STIMULATES – C0037657|Somatomedins]
[PMID3322823]
Abstract
“Levels of circulating IGF I and IGF II are affected by growth hormone, but the former
peptide is the more sensitive to growth hormone.”
[C0037663|Somatotropin – INTERACTS_WITH – C0021665|Insulin-Like Growth
Factor I]
Abstract
“There is good evidence that the reduction in levels of circulating IGF I is related to
decreased secretion of growth hormone that accompanies aging.”
[C0021665|Insulin-Like Growth Factor - INHIBITS- C0037663|Somatotropin]
[PMID3380847]
Title
“Somatomedins: do they play a pivotal role in wound healing?”
[C0037657|Somatomedins – AFFECTS – C0043240|Wound Healing]
Abstract
“An understanding of the role of somatomedins in normal wound healing might be able
to help us understand abnormalities of the repair process such as keloid formation.”
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[C0037657|Somatomedins – AFFECTS – C0043240|Wound Healing]
[PMID3690631]
Abstract
“It is concluded that IGF-I is likely to be involved in the repair of the intima in injured
arteries.”
[C0021665|Insulin-Like Growth Factor I – AFFECTS – C0043240|Wound Healing]
[PMID3803997]
Abstract
“These results show that old rats respond to GH in a mechanism involving
somatomedin and that significant increases in somatic growth can be obtained, even at
advanced age.”
[C0037663|Somatotropin – INTERACTS_WITH – C0037657|Somatomedins]
[PMID3898005]
Abstract
“Recent reports indicate that children with normal growth hormone responses who
have very low integrated concentration of growth hormone may have the potential to
improve their growth with growth hormone therapy.”
[C0037663|Somatotropin – AFFECTS – C0018270|Growth]
[PMID3923266]
Abstract
“The experiments indicate that high arginine levels in IVH solutions improve wound
healing and thymic immune function following injury.”
[C0003765|Arginine – AFFECTS – C0043240|Wound Healing]
[PMID412936]
Abstract
“This study was undertaken to define the interrelationships of somatomedin, growth

279

hormone, and an inhibitor of SM in protein-calorie malnutrition.”
[C0037657|Somatomedins – ASSOCIATED_WITH – C0033677|Protein-Energy
Malnutrition]
[C0037663|Somatotropin – ASSOCIATED_WITH – C0033677|Protein-Energy
Malnutrition]
[PMID4201417]
Abstract – Taken from publisher’s site.
“Arginine infusion elicited an associated release in PRL and GH with a dissociated
time course of approximately 15 min earlier for PRL than for GH.”
[C0003765|Arginine – COEXISTS_WITH – C0037663|Somatotropin]
[PMID430225]
Abstract – Taken from publisher’s site.
“The diet supplemented with arginine and glycine improved growth before and after
trauma, and nitrogen retention after trauma.”
[C0003765|Arginine – AFFECTS – C0018270|Growth]
[PMID430251]
Title
“Inhibitory effect of dietary arginine on growth of Ehrlich ascites tumor cells in mice.”
[C0003765|Arginine – DISRUPTS – C0018270|Growth]
Abstract
“The effect of dietary L-arginine on the growth and development of transplantable
Ehrlich Ascites tumor cells was examined.”
[C0003765|Arginine – AFFECTS – C0018270|Growth]
Abstract
“Supplemental dietary arginine at 3 or 5% did not significantly affect the growth of
non-tumor bearing mice.”
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[C0003765|Arginine – AFFECTS – C0018270|Growth]
Abstract
“Dietary arginine may play a critical role in growth of normal as well as neoplastic
tissue.”
[C0003765|Arginine – AFFECTS – C0018270|Growth]
[PMID4430939]
Title
“Effect of arginine deficiency on growth and intermediary metabolism in rats.”
[C0003765|Arginine – AFFECTS – C0018270|Growth]
[PMID4506104]
Abstract
“The action of growth hormone on skeletal tissue is mediated through somatomedin, a
low molecular weight peptide found in serum.”
[C0037663|Somatotropin – INTERACTS_WITH – C0037657|Somatomedins]
Abstract
“Since at least some of the metabolic effects of insulin on target cells are initiated by a
highly specific interaction with receptors on cell membranes, this study was undertaken
to determine whether somatomedin might interact with the same binding sites.”
[C0037657|Somatomedins – INTERACTS_WITH – C0021641|Insulin]
[PMID4538721]
Abstract – Taken from publisher’s site.
“The significance of pituitary growth hormone (GH) for the regulation of skeletal
growth is uniformly recognized.”
[C0037663|Somatotropin – AFFECTS – C0018270|Growth]
[PMID4903729]
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Abstract – Taken from publisher’s site.
“All individuals responded to arginine infusion with an increase in the IRI
concentrations.”
[C0003765|Arginine – STIMULATES – C0021641|Insulin]
Abstract – Taken from publisher’s site.
“Four of the five females and two of the five males responded to the initial infusion of
arginine with a significant increase in plasma GH concentration.”
[C0003765|Arginine – STIMULATES – C0037663|Somatotropin]
Abstract – Taken from publisher’s site.
“It is concluded (1) that saline is not a stimulus to GH release, (2) that arginine
consistently increases IRI concentration, (3) that plasma glucose levels usually, but not
invariably, increase with arginine infusion and (4) that some males have a variable GH
response to arginine, which is independent of estrogen replacement.”
[C0003765|Arginine – STIMULATES – C0021641|Insulin]
[PMID521015]
Title
“Prolactin nonresponsiveness to arginine in diabetes mellitus.”
[C0003765|Arginine – ASSOCIATED_WITH – C0011849|Diabetes Mellitus]
[PMID5361695]
Abstract – Taken from publisher’s site.
“The apparently normal production of growth hormone and the impaired insulin, which
was persistently demonstrated by these infants, along with the poor growth in cell mass
of those under 11 months of age, suggest that gains in cell mass in the younger infant
may be primarily dependent on insulin and not on growth hormone.”
[C0018270|Growth – PRODUCES – C0021641|Insulin]
[C0018270|Growth – PRODUCES – C0037663|Somatotropin]
[PMID5917038]
Abstract – Taken from publisher’s site.
“During the course of experience with subjects who were given infusions of arginine,
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we observed that female subjects showed a greater rise in serum insulin and in serum
HGH than did males of a comparable age.”
[C0003765|Arginine – COEXISTS_WITH – C0021641|Insulin]
[C0003765|Arginine – COEXISTS_WITH – C0169964|Somatropin]
[PMID6027286]
Title
“Effect of arginine on serum levels of insulin and growth hormone in obese subjects.”
[C0037663|Somatotropin – INTERACTS_WITH – C0003765|Arginine]
[C0021641|Insulin – INTERACTS_WITH – C0003765|Arginine]
[PMID6153391]
Abstract
“This peptide has been classified as a somatomedin on the basis of its biological actions
and growth hormone dependence.”
[C0037657|Somatomedins – INTERACTS_WITH – C0037663|Somatotropin]
[C0037663|Somatotropin – INTERACTS_WITH – C0037657|Somatomedins]
Abstract
“We have generated an antibody to the synthetic 12 amino acid C-peptide region of
insulin-like growth factor-I and used it to compare three somatomedin preparations to
insulin-like growth factor-I.”
[C0037657|Somatomedins – compared_with – C0021665|Insulin-Like Growth Factor
I]
Abstract
“We also compared these somatomedin preparations to insulin-like growth factor-I
using the standard SM-C RIA.”
[C0037657|Somatomedins – compared_with – C0021665|Insulin-Like Growth Factor
I]
[PMID6181237]
Abstract
“The possible mechanism(s) by which arginine can modify mammary growth are
discussed.”
[C0003765|Arginine – AFFECTS – C0018270|Growth]
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[PMID6243390]
Abstract – Taken from publisher’s site.
“It is now over 20 years since Salmon and Daughaday hypothesized that stimulation of
growth by growth hormone (somatotropin) was mediated by a circulating ‘sulfation
factor’.”
[C0037663|Somatotropin – AUGMENTS – C0018270|Growth]
[PMID6338399]
Abstract – Taken from publisher’s site.
“Plasma IGF-I levels reflect circulating concentrations of pituitary growth hormone
(GH), and exogenous IGF-I substitutes for GH in inducing somatic and skeletal growth
in GH-deficient rats2.”
[C0021665|Insulin-Like Growth Factor I – COEXISTS_WITH –
C0037663|Somatotropin]
Abstract – Taken from publisher’s site.
“By contrast, both GH and PL stimulate IGF-I synthesis in fibroblasts from older rats
with no effect on IGF-II synthesis.”
[C0037663|Somatotropin – STIMULATES – C0021665|Insulin-Like Growth Factor I]
[PMID6368579]
Abstract
“During simultaneous incubation with PDGF and SM-C-deficient PPP, however,
hydrocortisone, T4, EGF, and insulin produced concentration-dependent increases in
IR-SM production.”
[C0021641|Insulin – STIMULATES – C0037657|Somatomedins]
[PMID6385593]
Abstract
“There was also a significantly enhanced increase of SM-C/IGF I in the presence of
GH during culture in comparison to the controls.”
[C0037663|Somatotropin – STIMULATES – C0021665|Insulin-Like Growth Factor I]
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Abstract
“Evidently IGF I is produced locally in bone and mediates the effect of GH on bone
formation.”
[C0021665|Insulin-Like Growth Factor I – INTERACTS_WITH –
C0037663|Somatotropin]
[PMID6639868]
Abstract
“The acceleration resulting from growth hormone and thyroxine administration may be
due to an increased production of somatomedins locally or systemically or by direct
action on connective tissue.”
[C0037663|Somatotropin – PRODUCES – C0037657|Somatomedins]
[PMID6751804]
Abstract
“The addition of human growth hormone (25 micrograms/ml) and/or insulin (1 mU/ml)
to the perfusates caused a significant increase in somatomedin after 120 minutes of
recirculation.”
[C0021641|Insulin – COEXISTS_WITH – C0037657|Somatomedins]
Abstract
“The effect of insulin on the release of somatomedin was greater in hypox rats than that
observed in normal rats.”
[C0037657|Somatomedins – INTERACTS_WITH- C0021641|Insulin]
[PMID6754563]
Abstract
“These data suggest that glucose intolerance during arginine deficiency is related to
decreased insulin release immediately following glucose administration and possibly a
mild insulin resistance.”
[C0003765|Arginine – COEXISTS_WITH – C0021641|Insulin]
[PMID6986740]
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Abstract – Taken from publisher’s site.
“The addition of GH (1 mU/ml) or insulin (0.25-1 mU/ml) to the culture dishes
significantly increased the SM activity of the medium and a dose-dependent effect was
observed with insulin.”
[C0021641|Insulin – STIMULATES – C0037657|Somatomedins]
“These findings suggest that: 1) SM is synthesized by rat liver in organ culture; 2)
insulin plays an important role in SM generation, as it itself is capable of both
stimulating the release of SM and amplifying the stimulatory effect of GH.”
[C0021641|Insulin – INTERACTS_WITH – C0037657|Somatomedins]
[PMID702022]
Title
“Production of somatomedin activity in vitro in the presence of growth hormone and
cycloheximide.”
[C0037663|Somatotropin – PRODUCES – C0037657|Somatomedins]
[PMID7424474]
Abstract
“The effect of growth hormone on somatomedin generation was abolished in
hypophysectomized rats fed with low-protein diet.”
[C0037663|Somatotropin – INTERACTS_WITH – C0037657|Somatomedins]
[PMID807324]
Title
“Inhibitory effect of L-arginine on growth of rat mammary tumors induced by 7,12dimethylbenz(a)anthracene.”
[C0003765|Arginine – DISRUPTS – C0018270|Growth]
[PMID862560]
Abstract
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“The roles of growth hormone and somatomedin in stimulating muscle cell
proliferation were investigated in a series of experiments on myoblast growth in
culture.”
[C0037657|Somatomedins – AUGMENTS – C0018270|Growth]
[C0037663|Somatotropin – AUGMENTS – C0018270|Growth]
[PMID895522]
Abstract – Taken from publisher’s site.
“Although pituitary hormones, particularly growth hormone (GH), are known to
influence skeletal growth, there is no evidence for a direct effect of GH or GHdependent factors (somatomedins) on bone as opposed to cartilage.”
[C0037663|Somatotropin – AFFECTS – C0018270|Growth]
[PMID96201]
Title
“Sulphation factor (somatomedin activity) in experimental protein malnutrition in the
rat.”
[C0037657|Somatomedins – ASSOCIATED_WITH – C0022806|Kwashiorkor]
Abstract
“In a rat model of protein malnutrition in which the failure of growth is a major feature,
a low level of bioassayable sulphation factor activity was present in the serum,
associated with normal levels of growth hormone and low insulin in the plasma.”
[C0021641|Insulin – ASSOCIATED_WITH – C0022806|Kwashiorkor]
[C0037663|Somatotropin – ASSOCIATED_WITH – C0022806|Kwashiorkor]
Abstract
“The administration of pharmacological doses of human or bovine growth hormone did
not increase the amount of sulphation factor activity in the serum or the width of the
tibial epiphyses in the protein-malnourished animals.”
[C0520986|growth hormone, bovine – NEG_STIMULATES – C0037657|Somatomedins]
[PMID967246]
Abstract – Taken from publisher’s site.
“SOMATOMEDINS are growth hormone-dependent polypeptides that have been
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proposed as the mediators of the peripheral actions of growth hormone on skeletal
tissue.”
[C0037657|Somatomedins – STIMULATES – C0037663|Somatotropin]
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Table C-3. Precision and recall using citations for Somatomedins study
Result

New Intermediate Terms

Relevancy (Topic)

Precision

Recall

d0

Growth

Body Weight

1.0

0.2

d1

Somatotropin

Growth Hormone

1.0

0.4

d2

Insulin

Diabetes

1.0

0.6

d3

Glucose

Diabetes

1.0

0.6

d4

Wound Healing

Wound Healing

1.0

0.8

d5

Ornithine

Not Relevant

0.8

0.8

d6

Testosterone

Not Relevant

0.667

0.8

d7

Protein Biosynthesis

Growth Hormone

0.667

0.8

d8

Diabetes Mellitus

Diabetes

0.667

0.8

d9

Somatropin

Growth Hormone

0.667

0.8

d10

Somatostatin

Growth Hormone

0.667

0.8

d11

Exocytosis

Not Relevant

0.571

0.8

d12

Leucine

Not Relevant

0.5

0.8

d13

Androgens

Not Relevant

0.444

0.8

d14

Kwashiorkor

Malnutrition

0.5

1.0

d15

Protein-Energy
Malnutrition

Malnutrition

0.5

1.0
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Table C-4. Precision and recall not using citations for Somatomedins study
Result

New Intermediate Terms

Relevancy (Topic)

Precision

Recall

d0

Growth

Body Weight

1.0

0.2

d1

Somatotropin

Growth Hormone

1.0

0.4

d2

Insulin

Diabetes

1.0

0.6

d3

Glucose

Diabetes

1.0

0.6

d4

Wound Healing

Wound Healing

1.0

0.8

d5

Infant

Not Relevant

0.8

0.8

d6

Ornithine

Not Relevant

0.667

0.8

d7

Testosterone

Not Relevant

0.571

0.8

d8

Protein Biosynthesis

Growth Hormone

0.571

0.8

d9

Diabetes Mellitus

Diabetes

0.571

0.8

d10

Somatropin

Growth Hormone

0.571

0.8

d11

Somatostatin

Growth Hormone

0.571

0.8

d12

Exocytosis

Not Relevant

0.5

0.8

d13

Leucine

Not Relevant

0.444

0.8

d14

Glycine

Not Relevant

0.4

0.8

d15

Androgens

Not Relevant

0.364

0.8

d16

Kwashiorkor

Malnutrition

0.417

1.0

d17

Protein-Energy
Malnutrition

Malnutrition

0.417

1.0
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Appendix D
Testosterone – Sleep Study
Table D-1. Testosterone – Sleep Core Corpus Medline IDs
1740593

10484567

14687700

17201728

19647784

4321505

10566905

15714228

17253619

19684340

4326799

10628505

15724043

17520786

19738366

6348068

10774867

15728214

18035227

19769952

6405703

10785345

15743338

18248637

20026350

6781027

10938176

15841103

18413429

20171018

6822642

11238497

15914523

18519168

20497841

7089154

11297573

16453977

18710368

20675620

7440701

12055986

16453985

19075717

9329339

12843160

16890403

19212126

10344587

12915643

17032928

19602101

Figure D-1. Testosterone – Sleep search parameters
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Figure D-2. Testosterone – Sleep result 1

Figure D-3. Testosterone – Sleep result 2
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Figure D-4. Testosterone – Sleep result 3

Figure D-5. Testosterone – Sleep result 4
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Figure D-6. Testosterone – Sleep result 5

Figure D-7. Testosterone – Sleep result 6
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Figure D-8. Testosterone – Sleep result 7

Figure D-9. Testosterone – Sleep result 8
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Figure D-10. Testosterone – Sleep result 9

Figure D-11. Testosterone – Sleep result 10

Figure D-12. Testosterone – Sleep result 11
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Figure D-13. Testosterone – Sleep result 12

Figure D-14. Testosterone – Sleep result 13
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Table D-2. Testosterone – Sleep generated predicates
[PMID10841212]
Abstract
“The study compared sleep, cortisol, and sleep-cortisol correlations under baseline and
“stress” conditions in men and women.”
[C0020268|Hydrocortisone – AFFECTS – C0037313|Sleep]
[PMID10956236]
Title
“IL-1 is a mediator of increases in slow-wave sleep induced by CRH receptor
blockade.”
[C0021753|Interleukin-1 beta – AUGMENTS – C0234451|Sleep, Slow-Wave]
Abstract
“IL-1 promotes sleep, and glucocorticoids inhibit IL-1 synthesis.”
[C0017710|Glucocorticoids – AUGMENTS – C0037313|Sleep]
[C0021753|Interleukin-1 beta – AUGMENTS – C0037313|Sleep]
[PMID12000022]
Title
“The role of cytokines in physiological sleep regulation.”
[C0079189|cytokine – AFFECTS – C0037313|Sleep]
Abstract
“Several growth factors (GFs) are implicated in sleep regulation.”
[C0018284|Growth Factor – AFFECTS – C0037313|Sleep]
Abstract
“Among these substances, the most extensively studied for their role in sleep regulation
are interleukin-1beta (IL-1) and tumor necrosis factor alpha (TNF).”
[C0021753|Interleukin-1 beta – AFFECTS – C0037313|Sleep]
[C1456820|Tumor Necrosis Factor-alpha – AFFECTS – C0037313|Sleep]
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Abstract
“Inhibition of either IL-1 or TNF inhibits spontaneous sleep and the sleep rebound that
occurs after sleep deprivation.”
[C0021753|Interleukin-1 beta – DISRUPTS – C0037313|Sleep]
[C1456820|Tumor Necrosis Factor-alpha – DISRUPTS – C0037313|Sleep]
Abstract
“IL-1 and TNF are part of a complex biochemical cascade regulating sleep.”
[C0021753|Interleukin-1 beta – AFFECTS – C0037313|Sleep]
[C1456820|Tumor Necrosis Factor-alpha – AFFECTS – C0037313|Sleep]
[PMID12531038]
Title
“Treatment of sleep disturbance in Alzheimer’s disease”
[C0037317|Sleep disturbances – COEXISTS_WITH – C0002395|Alzheimer’s Disease]
Abstract
“Nevertheless, the study of sleep in AD is relatively new.”
[C0037313|Sleep – ASSOCIATED_WITH – C0002395|Alzheimer’s Disease]
[PMID15240608]
Abstract
“Testosterone has immune-modulating properties, and current in vitro evidence
suggests that testosterone may suppress the expression of the proinflammatory
cytokines TNFalpha, IL-1beta, and IL-6 and potentiate the expression of the
antiinflammatory cytokine IL-10.”
[C0039601|Testosterone – INHIBITS – C0021753|Interleukin-1 beta]
[C0039601|Testosterone – INHIBITS – C0021760|Interleukin-6]
[C0039601|Testosterone – STIMULATES – C0085295|Interleukin-10]
[PMID15724043]
Abstract
“Unlike the norm in the adult, where testosterone production is often inhibited by
cortisol, in the fetus there is a positive link between the two.”
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[C0020268|Hydrocortisone – INHIBITS – C0039601|Testosterone]
[PMID15841103]
Title
“Testosterone suppression of CRH-stimulated cortisol in men.”
[C0039601|Testosterone – INHIBITS – C0020268|Hydrocortisone]
Abstract
“These data demonstrate that testosterone regulates CRH-stimulated HPA axis activity
in men, with the divergent effects on ACTH and cortisol suggesting a peripheral
(adrenal) locus for the suppressive effects on cortisol.”
[C0039601|Testosterone – STIMULATES – C0001655|Corticotropin]
[C0039601|Testosterone – STIMULATES – C0020268|Hydrocortisone]
[PMID15886244]
Abstract
“Despite the absence of sex differences in estradiol or testosterone at the time of
testing, men showed increased stimulated ACTH (repeated-measures ANOVA for
CRH, P &lt; 0.005) and cortisol (repeated-measures ANOVA for exercise, P &lt; 0.05)
compared with women.”
[C0014912|Estradiol – STIMULATES – C0010132|Corticotropin-Releasing Hormone]
[C0014912|Estradiol - STIMULATES – C0020268|Hydrocortisone]
[C0039601|Testosterone – STIMULATES – C0010132|Corticotropin-Releasing
Hormone]
[C0039601|Testosterone – STIMULATES – C0020268|Hydrocortisone]
[PMID15914523]
Abstract
“In conclusion, testosterone increased during sleep and fell during waking, whereas
circadian effects seemed marginal.”
[C0039601|Testosterone – AUGMENTS – C0037313|Sleep]
[PMID16344336]
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Title
“Effects of testosterone on cognition and mood in male patients with mild Alzheimer
disease and healthy elderly men.”
[C0039601|Testosterone – TREATS(INFER) – C0002395|Alzheimer’s Disease]
[PMID18519168]
Title
“The effects of testosterone on sleep and sleep-disordered breathing in men: its
bidirectional interaction with erectile function”
[C0039601|Testosterone – AFFECTS – C0035203|Respiration]
[C0039601|Testosterone – AFFECTS – C0037313|Sleep]
[PMID2541159]
Title
“Influences of corticotropin-releasing hormone, adrenocorticotropin, and cortisol on
sleep in normal man.”
[C0001655|Corticotropin – AFFECTS – C0037313|Sleep]
[C0010132|Corticotropin-Releasing Hormone – AFFECTS – C0037313|Sleep]
[C0020268|Hydrocortisone – AFFECTS – C0037313|Sleep]
[PMID3661052]
Title
“Differential effects of hydrocortisone, fluocortolone, and aldosterone on nocturnal
sleep in humans.”
[C0020268|Hydrocortisone – AFFECTS – C0037313|Sleep]
Abstract
“The results demonstrate differential effects of synthetic glucocorticoid, cortisol, and
aldosterone on sleep in humans, which may be attributed to the heterogeneity of
corticosteroid receptors in the brain.”
[C0020268|Hydrocortisone – AFFECTS – C0037313|Sleep]
[PMID3790626]
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Abstract
“The pattern of nocturnal cortisol secretion appeared to be synchronized with the
periodicity of sleep: rapid eye movement (REM) sleep was found to be primarily
present when cortisol concentrations were decreasing, indicating a diminished or absent
secretory activity of the adrenals at that time; wakefulness and Stage 1 sleep, by
contrast, were associated with increasing plasma cortisol concentrations.”
[C0020268|Hydrocortisone – AFFECTS – C0037313|Sleep]
[PMID6822642]
Title
“Cortisol secretion is inhibited during sleep in normal man.”
[C0020268|Hydrocortisone – DISRUPTS – C0037313|Sleep]
Abstract
“In order to test the hypothesis that cortisol secretion is inhibited during sleep, six
healthy young men (ages 18-24) were studied in a 4-day protocol.”
[C0020268|Hydrocortisone – DISRUPTS – C0037313|Sleep]
[PMID8077308]
Title
“Corticotropin-releasing hormone-induced adrenocorticotropin and cortisol secretion
depends on sleep and wakefulness.”
[C0001655|Corticotropin – AUGMENTS – C0037313|Sleep]
[C0001655|Corticotropin – AUGMENTS – C0043012|Wakefulness]
[C0020268|Hydrocortisone - AUGMENTS – C0037313|Sleep]
[C0020268|Hydrocortisone – AUGMENTS – C0043012|Wakefulness]
[PMID8548511]
Abstract
“Cortisol secretion is also related to sleep processes with the 24 hr nadir occurring, like
the sleep dependent GH secretory surge, during the first half of nocturnal sleep.”
[C0020268|Hydrocortisone – AUGMENTS – C0037313|Sleep]

302

Abstract
“Age-related changes in sleep-dependent secretion of GH and cortisol correlated
significantly (r = .47, r = -.55, respectively; p &lt; .05) with an age-dependent decrease
in slow wave sleep.”
[C0020268|Hydrocortisone – AUGMENTS – C0234451|Sleep, Slow-Wave]
[C0037663|Somatotropin – AUGMENTS – C0234451|Sleep, Slow-Wave]
Abstract
“Both changes in GH and cortisol secretion may act together to reduce anabolic
functions of sleep in the aged.”
[C0020268|Hydrocortisone – DISRUPTS – C0037313|Sleep]
[C0037663|Somatotropin – DISRUPTS – C0037313|Sleep]
[PMID9329339]
Abstract
“The possible role of gonadal steroids in regulating sleep and circadian rhythms in
humans has received relatively little attention despite the importance of the topic to
several clinical syndromes.”
[C0036884|Gonadal Steroid Hormones – AFFECTS – C0037313|Sleep]
Abstract
“These results indicate that testosterone has relatively specific and discrete effects on
sleep and hormonal rhythms in men.”
[C0039601|Testosterone – AFFECTS – C0037313|Sleep]
[PMID9530230]
Abstract
“IL-1 beta dose dependently increased non-rapid eye movement sleep (NREMS) and
suppressed rapid eye movement sleep (REMS) in the controls.”
[C0021753|Interleukin-1 beta – AUGMENTS – C0037322|Sleep, REM]
[C0021753|Interleukin-1 beta – AUGMENTS – C0234451|Sleep, Slow-Wave]
Abstract
“These results 1) provide further evidence that IL-1 beta is involved in sleep regulation,
2) indicate that the effects of IL-1 beta on sleep are mediated by the type I receptor, and
3) suggest that TNF-alpha is capable of inducing sleep without the involvement of IL1”
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[C0021753|Interleukin-1 beta – AFFECTS – C0037313|Sleep|orgf|orgf||
[C0597357|receptor – INTERACTS_WITH – C0021753|Interleukin-1 beta]
[PMID956348]
Abstract
“It was concluded that administration of cortisol leading to plasma levels as seen under
treatment with ACTH suppresses testosterone by abolishing or flattening the nocturnal
rise.”
[C0020268|Hydrocortisone – INHIBITS – C0039601|Testosterone]
[PMID9781819]
Abstract
“Much evidence implicates interleukin-1beta (IL-1beta) in sleep regulation.”
[C0021753|Interleukin-1 beta – AFFECTS – C0037313|Sleep]
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Table D-3. Precision and recall using citations for Testosterone study
Result

New Intermediate Terms

d0

N/A – Direct Connection

d1

Gonadal Steroid Hormones

d2

Obesity

d3

Hormones

d4

Parkinson Disease

d5

Aging

Relevancy (Topic)

Precision

Recall

1.0

0.333

0.5

0.333

0.5

0.333

0.333

0.333

Hormones

0.333

0.333

d6

Growth Hormone Secretion Hormones

0.333

0.333

d7

Circadian Rhythms

Hormones

0.333

0.333

d8

Interleukin-1 beta

IL-1 Beta

0.5

0.667

d9

Hydrocortisone

Hydrocortisone

0.6

1

Hormones

Hormones

Table D-4. Precision and recall not using citations for Testosterone study
Result

New Intermediate Terms

d0

N/A – Direct Connection

d1

Gonadal Steroid Hormones

d2

Obesity

d3

Hormones

d4

Parkinson Disease

d5

Aging

Relevancy (Topic)

Precision

Recall

1.0

0.333

0.5

0.333

0.5

0.333

0.333

0.333

Hormones

0.333

0.333

d6

Growth Hormone Secretion Hormones

0.333

0.333

d7

Circadian Rhythms

Hormones

0.333

0.333

d8

Interleukin-1 beta

IL-1 Beta

0.5

0.667

d9

Hydrocortisone

Hydrocortisone

0.6

1

Hormones

Hormones
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Appendix E
Parkinson’s Disease – Crohn’s Disease Study
Table E-1. PD – CD Core Corpus Medline IDs
1374941

16773678

18430617

19093628

19416630

7834804

17062028

18456695

19120480

19470958

8739179

17268543

18489401

19221313

19481107

12105943

18034589

18535002

19221317

19524782

15342082

18242711

18586394

19265190

19568370

15370396

18274903

18628756

19289138

19723294

15784530

18308354

Figure E-1. PD – CD, PL2(path length two) search parameters
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Figure E-2. PD – CD, PL2 result 1

Figure E-3. PD – CD, PL2 result 2
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Figure E-4. PD – CD, PL2 result 3

Figure E-5. PD – CD, PL2 result 4
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Figure E-6. PD – CD, PL2 result 5

Figure E-7. PD – CD, PL2 result 6

Figure E-8. PD – CD, PL2 result 7
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Figure E-9. PD – CD, PL2 result 8
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Figure E-10. PD – CD, PL3 Inflammation search parameters
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Figure E-11. PD – CD, PL3 Inflammation result 1 (with citations)

Figure E-12. PD – CD, PL3 Inflammation result 1 (without citations)
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Figure E-13. PD – CD, PL3 Inflammation result 2 (with citations)

Figure E-14. PD – CD, PL3 Inflammation result 2 (without citations)
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Figure E-15. PD – CD, PL3 Inflammation result 3 (with citations)

<Not Present>
Figure E-16. PD – CD, PL3 Inflammation result 3 (without citations)
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Figure E-17. PD – CD, PL3 Inflammation result 4 (without citations)

Figure E-18. PD – CD, PL3 Inflammation result 4 (without citations)
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Figure E-19. PD – CD, PL3 Inflammation result 5 (with citations)

<Not Present>
Figure E-20. PD – CD, PL3 Inflammation result 5 (without citations)
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Figure E-21. PD – CD, PL3 Inflammation result 6 (with citations)

Figure E-22. PD – CD, PL3 Inflammation result 6 (without citations)

317

Figure E-23. PD – CD, PL3 SNP search parameters
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Figure E-24. PD – CD, PL3 SNP result 1 (with citations)
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Figure E-25. PD – CD, PL3 SNP result 1 (without citations)

320

Table E-2. PD – CD generated predicates
[PMID10400088]
Title
“Increase in level of tumor necrosis factor (TNF)-alpha in 6-hydroxydopaminelesioned striatum in rats without influence of systemic L-DOPA on the TNF-alpha
induction.”
[C0023570|Levodopa – STIMULATES – C1448177|TNF protein, human]
Abstract
“We previously reported that the levels of proinflammatory cytokines such as tumor
necrosis factor (TNF)-alpha are increased in the striatum and cerebrospinal fluid from
patients with Parkinson’s disease (PD) and in the striatum from 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP)-treated mice, a murine model of PD.”
[C1456820|Tumor Necrosis Factor-alpha – ISA – C0079189|cytokine]
Abstract
“Presently we examined the changes in cytokine levels in the nigrostriatal
dopaminergic regions in rats treated with an intrastriatal injection of 6hydroxydopamine (6-OHDA) as a model of slowly progressive neurodegeneration
similar to that seen in PD.”
[C0079189|cytokine – ASSOCIATED_WITH – C0030567|Parkinson Disease]
[PMID11052175]
Title
“Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel
disease: biological and clinical significance.”
[C0023810|Lipopolysaccharides – ASSOCIATED_WITH – C0021390|Inflammatory
Bowel Diseases]
[C0079189|cytokine – ASSOCIATED_WITH – C0021390|Inflammatory Bowel
Diseases]
Abstract
“Ulcerative colitis (UC) and Crohn’s disease (CD) [inflammatory bowel disease (IBD)]
are both characterized by an exaggerated immune response at the gut associated
lymphoreticular tissue level.”
[C0301872|Immune response – ASSOCIATED_WITH – C0009324|Ulcerative Colitis]
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[C0301872|Immune response – ASSOCIATED_WITH – C0010346|Crohn’s disease]
Abstract
“Such an abnormal and dysregulated immune response may be directed against luminal
and/or enteric bacterial antigens, as also supported by murine models of inflammatory
bowel disease (IBD) caused by organisms such as Citrobacter rodentium and
Helicobacter hepaticus.”
[C0029235|Organism – CAUSES – C0021390|Inflammatory Bowel Diseases]
[C0887836|Citrobacter rodentium – CAUSES(SPEC) – C0021390|Inflammatory
Bowel Diseases]
[C0887836|Citrobacter rodentium – ISA – C0029235|Organism]
[C1003868|Helicobacter hepaticus – CAUSES(SPEC) – C0021390|Inflammatory
Bowel Diseases]
[C1003868|Helicobacter hepaticus – ISA – C0029235|Organism]
Abstract
“On these grounds, in experimental models and in human IBD, anti-cytokine
monoclonal antibodies and interleukin receptor antagonists are under investigation for
their capacity to neutralize the noxious effects of immune mediators.”
[C0206553|Interleukin Receptor – DISRUPTS – C0021390|Inflammatory Bowel
Diseases]
[PMID11743591]
Title
“Infliximab for the treatment of Crohn’s disease: efficacy, safety and
pharmacoeconomics.”
00000000.tx.1|relation|C0666743|infliximab|aapp,gngm,imft,phsu|aapp|||TREATS|C00
10346|Crohn’s disease|dsyn|dsyn||
Abstract
“Conventional medical treatment of Crohn’s disease includes the use of nonspecific
anti-inflammatory drugs, immunosuppressives and antibiotics.”
00000000.tx.4|relation|C0003209|Anti-Inflammatory
Agents|phsu|phsu|||TREATS|C0010346|Crohn’s disease|dsyn|dsyn||
00000000.tx.4|relation|C0003232|Antibiotics|antb|antb|||TREATS|C0010346|Crohn’s
disease|dsyn|dsyn||
Abstract
“Infliximab, a chimeric monoclonal antibody directed toward tumour necrosis factor
alpha, is highly effective for the treatment of active Crohn’s disease.”
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00000000.tx.7|relation|C1456820|Tumor Necrosis Factoralpha|aapp,gngm,imft|aapp|||TREATS|C0010346|Crohn’s disease|dsyn|dsyn||
Abstract
“Moreover, infliximab is the only medical therapy that has been shown to be effective
for the treatment of fistulizing Crohn’s disease.”
[C0666743|infliximab|aapp,gngm,imft,phsu|aapp|||TREATS(SPEC)|C0010346|Crohn’s
disease|dsyn|dsyn||
Abstract
“Infliximab is recommended for the treatment of active Crohn’s disease refractory to
conventional drugs, and is the treatment of choice for fistulizing Crohn’s disease.”
00000000.tx.14|relation|C0087111|Therapeutic
procedure|topp|topp|||TREATS|C0010346|Crohn’s disease|dsyn|dsyn||
[PMID11922776]
Abstract
“Injection with rolipram, an inhibitor of TNF-alpha expression, or use of IL-6 knockout
mice was ineffective at impairing thymic apoptosis induction by the toxin cotreatment,
suggesting that these cytokines did not mediate LPS potentiation.”
[C0079189|cytokine – CAUSES – C0162638|Apoptosis]
[PMID12205053]
Title
“Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity:
implications for Parkinson’s disease.”
[C0077503|Tumor Necrosis Factor Receptor – AFFECTS – C0030567|Parkinson
Disease]
Abstract
“Recent findings suggest that inflammatory processes are associated with several
neurodegenerative disorders, including PD.”
[C0524851|Neurodegenerative Disorders – AFFECTS – C1512753|Inflammation
Process]
Abstract
“Enhanced expression of the proinflammatory cytokine, tumor necrosis factor (TNF)alpha, has been found in association with glial cells in the substantia nigra of patients
with PD.”
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[C1448177|TNF protein, human – ISA – C0079189|cytokine]
Abstract
“To determine the potential role for TNF-alpha in PD, we examined the effects of the
1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP), a dopaminergic neurotoxin that
mimics some of the key features associated with PD, using transgenic mice lacking
TNF receptors.”
[C1448177|TNF protein, human – ASSOCIATED_WITH – C0030567|Parkinson
Disease]
Abstract
“The data indicate that the proinflammatory cytokine TNF-alpha is an obligatory
component of dopaminergic neurodegeneration.”
[C1456820|Tumor Necrosis Factor-alpha – ISA – C0079189|cytokine]
[PMID12474223]
Title
“Chemokine expression in IBD.”
[C0282554|chemokine – ASSOCIATED_WITH – C0021390|Inflammatory Bowel
Diseases]
Abstract
“Mucosal chemokine expression is unselectively increased in both ulcerative colitis and
Crohn’s disease.”
[C0282554|chemokine – AUGMENTS – C0009324|Ulcerative Colitis]
[C0282554|chemokine – AUGMENTS – C0010346|Crohn’s disease]
Abstract
“Individual chemokine expression was found to be significantly up-regulated in IBD
when patients were compared with the non-diseased group in all areas of the mucosal
sections.”
[C0282554|chemokine – AUGMENTS – C0021390|Inflammatory Bowel Diseases]
Abstract
“It is concluded that human colonic chemokine expression is non-selectively upregulated in IBD.”
[C0282554|chemokine – AUGMENTS – C0021390|Inflammatory Bowel Diseases]
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Abstract
“The results supported the hypothesis that the degree of local inflammation and tissue
damage in UC and CD is dependent on local expression of specific chemokines within
IBD tissues.”
[C0010957|Tissue damage – COEXISTS_WITH – C0009324|Ulcerative Colitis]
[C0010957|Tissue damage – COEXISTS_WITH – C0010346|Crohn’s disease]
[C0021368|Inflammation – COEXISTS_WITH – C0009324|Ulcerative Colitis]
[C0021368|Inflammation – COEXISTS_WITH – C0010346|Crohn’s disease]
[PMID12724617]
Title
“Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link
between environmental and genetic factors in Parkinson’s disease.”
[C0376622|ABCB1 gene - ASSOCIATED_WITH – C0030567|Parkinson Disease]
Abstract
“Thus, it appears that mutation of the MDR1 gene predisposes to damaging effects of
pesticides, and possibly other toxic xenobiotics transported by P-glycoprotein, leading
to Parkinson’s disease.”
[C0242643|P-Glycoprotein – CAUSES – C0030567|Parkinson Disease]
[PMID14724828]
Title
“A murine model of chronic inflammation-induced intestinal fibrosis down-regulated
by antisense NF-kappa B.”
[C0079904|NF-kappa B – DISRUPTS – C0016059|Fibrosis]
Abstract
“To elucidate extracellular matrix (ECM) changes underlying intestinal fibrosis, a
frequent complication of inflammatory bowel disease, we developed a murine model of
chronic colitis associated with intestinal fibrosis.”
[C0016059|Fibrosis – COEXISTS_WITH – C0267375|Chronic colitis]
Abstract
“Colonic expression of collagens (Col1a2, Col3a2), ECM remodeling genes (matrix
metalloproteinase [MMP]-1, -3, and tissue inhibitor of matrix metalloproteinase
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[TIMP]-1), and inflammation-modulating cytokines (tumor necrosis factor alpha [TNFalpha], interferon gamma [IFN-gamma], transforming growth factor beta 1 [TGF-beta
1], and insulin-like growth factor 1 [IGF-1]) were assessed by semiquantitative reversetranscription polymerase chain reaction.”
[C1448177|TNF protein, human – ISA – C0079189|cytokine]
[PMID14749689]
Abstract
“P-glycoprotein, the encoded product of the human MDR1 (ABCB1) gene, is of
particular clinical relevance in that this transporter has broad substrate specificity,
including a variety of structurally divergent drugs in clinical use today.”
[C0376622|ABCB1 gene – PRODUCES - C0242643|P-Glycoprotein]
Abstract
“Recently, a number of single-nucleotide polymorphisms (SNPs) in MDR1 have been
identified.”
[C0752046|Single Nucleotide Polymorphism - COEXISTS_WITH C0376622|ABCB1 gene]
Abstract
“An increasing number of studies have also implicated certain commonly occurring
SNPs in MDR1 in problems including altered drug levels and host susceptibility to
diseases such as Parkinson's disease, inflammatory bowel disease, refractory seizures,
and CD4 cell recovery during human immunodeficiency virus therapy.”
[C0376622|ABCB1 gene – TREATS - C0001175|Acquired Immunodeficiency
Syndrome]
[C0752046|Single Nucleotide Polymorphism - COEXISTS_WITH –
C0376622|ABCB1 gene]
[PMID15058528]
Abstract
“Intestinal fibrostenosis is a frequent and debilitating complication of Crohn’s disease
(CD), not only resulting in small bowel obstruction, but eventually in repeated bowel
resection and short bowel syndrome.”
[C0010346|Crohn’s disease – CAUSES – C0036992|Short Bowel Syndrome]
[C0010346|Crohn’s disease – CAUSES – C0235329|Small bowel obstruction NOS]
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Abstract
“Intestinal fibrosis is a consequence of chronic transmural inflammation in CD.”
[C0021376|Chronic inflammation – COEXISTS_WITH – C0010346|Crohn’s disease]
Abstract
“Tumor necrosis factor, on the other hand, has antifibrotic bioactivity and
pharmacologic inhibition of this cytokine carries a theoretical risk of enhanced stricture
formation.”
[C1456820|Tumor Necrosis Factor-alpha – INHIBITS – C0079189|cytokine]
[PMID15109580]
Title
“Inflammation and neurodegeneration in Parkinson’s disease.”
[C0021368|Inflammation – COEXISTS_WITH – C0030567|Parkinson Disease]
[C0027746|Nerve Degeneration – COEXISTS_WITH – C0030567|Parkinson Disease]
Abstract
“Reports in the literature indicate that antiinflammatory agents inhibit dopaminergic
cell death in animal models of PD, and there is one epidemiological report that their use
significantly diminishes the risk of PD in humans.”
[C0003209|Anti-Inflammatory Agents – DISRUPTS – C0007587|Cell Death]

Abstract
“These data support the hypothesis that chronic inflammation may play an important
role, if secondary, in the pathogenesis of PD.”
[C0021376|Chronic inflammation – CAUSES – C0030567|Parkinson Disease]
[PMID15256718]
Abstract
“In particular, genetic variations of the human ABCB1 (P-glycoprotein/MDR1) gene
have been most extensively studied. Hitherto more than fifty single nucleotide
polymorphisms (SNPs) and insertion/deletion polymorphisms in the ABCB1 gene have
been reported.”
[C0752046|Single Nucleotide Polymorphism – COEXISTS_WITH –
C0376622|ABCB1]
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[PMID15503194]
Abstract
“Accumulating evidence has suggested that inflammation in the brain participates in
the pathogenesis of Parkinson’s disease (PD).”
[C0021368|Inflammation – CAUSES – C0030567|Parkinson Disease]
[PMID15580149]
Title
“Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: overview
of randomized clinical studies.”
[C0243076|antagonists – TREATS – C0010346|Crohn’s disease]
Abstract
“The past decade has brought forth a series of novel biologic agents targeting tumor
necrosis factor (TNF) for the treatment of Crohn’s disease.”
[C1456820|Tumor Necrosis Factor-alpha – TREATS – C0010346|Crohn’s disease]
Abstract
“However, the anti-TNF strategies might not have identical efficacy and safety profiles
and might differ in dosing compared with therapy for rheumatoid arthritis.”
[C1456820|Tumor Necrosis Factor-alpha – TREATS – C0003873|Rheumatoid
Arthritis]
Abstract
“Most recently, adalimumab has been approved by the US Food and Drug
Administration for the treatment of rheumatoid arthritis and is undergoing evaluation in
Crohn’s disease, with promising initial results.”
[C1122087|adalimumab – ASSOCIATED_WITH – C0010346|Crohn’s disease]
Abstract
“This review discusses the results of controlled clinical trials of anti-TNF agents for
Crohn’s disease.”
[C0040616|Anti-Anxiety Agents – TREATS – C0010346|Crohn’s disease]
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[PMID15685540]
Abstract
“The G2677T SNP was not associated with UC or CD.”
[C0752046|Single Nucleotide Polymorphism – NEG_ASSOCIATED_WITH –
C0009324|Ulcerative Colitis]
[C0752046|Single Nucleotide Polymorphism – NEG_ASSOCIATED_WITH –
C0010346|Crohn’s disease]
[PMID15778431]
Abstract
“Crohn’s disease (CD) is a chronic, relapsing inflammatory bowel disease,
characterized by transmural inflammation.”
[C0010346|Crohn’s disease – ISA – C0021390|Inflammatory Bowel Diseases]
[C0021368|Inflammation – COEXISTS_WITH – C0021390|Inflammatory Bowel
Diseases]
[C0021368|Inflammation – COEXISTS_WITH(SPEC) – C0010346|Crohn’s disease]
Abstract
“Because transforming growth factor (TGF)-beta1 can mediate both fibrosis and
mesenchymal cell proliferation; we studied the effects of delivering adenoviral vectors
encoding spontaneously active TGF-beta1 into the colons of mice.”
[C0080222|TGFB1 – ASSOCIATED_WITH – C0016059|Fibrosis]
[PMID15869932]
Title
“Oxidative stress and inflammation in Parkinson’s disease: is there a causal link?”
[C0021368|Inflammation – COEXISTS_WITH – C0030567|Parkinson Disease]
[C0242606|Oxidative Stress – COEXISTS_WITH – C0030567|Parkinson Disease]
Abstract
“Parkinson’s disease (PD) is a neurodegenerative disorder characterized by a dramatic
loss of dopaminergic neurons in the substantia nigra (SN).”
[C0030567|Parkinson Disease – ISA – C0524851|Neurodegenerative Disorders]
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Abstract
“Perhaps not surprisingly, non-steroidal anti-inflammatory drugs (NSAIDs) have been
shown to reduce the risk of developing PD.”
[C0003211|Anti-Inflammatory Agents, Non-Steroidal – PREVENTS –
C0030567|Parkinson Disease]
[PMID15879017]
Abstract
“The extract was then tested for its ability to alter in vitro production of TH1 cytokines
(interleukin-2 [IL-2] and gamma interferon) and TH2 cytokines (IL-4 and IL-10) by
murine splenocytes.”
[C0021740|Recombinant Interferon-gamma – ISA|C0079189|cytokine]
[C0021756|Interleukin-2 – ISA – C0079189|cytokine]
[C0021758|Interleukin-4 – ISA – C0079189|cytokine]
[C0085295|Interleukin-10 – ISA – C0079189|cytokine]
[PMID16252231]
Abstract
“We identified 11 SNPs that were associated with PD (P&lt;.01) in both tier 1 and tier
2 samples and had the same direction of effect.”
[C0752046|Single Nucleotide Polymorphism – ASSOCIATED_WITHC0030567|Parkinson Disease]
Abstract
“The protein encoded by this gene plays an important role in neurogenesis and in
neuronal apoptosis, which is consistent with existing hypotheses regarding PD
pathogenesis.”
[C0030567|Parkinson Disease – AFFECTS – C0162638|Apoptosis]
[C0030567|Parkinson Disease – AFFECTS – C0814002|Neural Development]
[PMID16374256]
Abstract
“The multidrug resistance MDR1 gene codes for a membrane transporter associated
with inflammatory bowel disease.”
[C0376622|ABCB1 gene – ISA – C0376623|Multidrug Resistance Gene]
[C0596902|Membrane Transport Proteins – ASSOCIATED_WITH –
C0021390|Inflammatory Bowel Diseases]
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Abstract
“We studied the association of both polymorphisms in an independent population to
reveal the impact of the MDR1 gene on predisposition to inflammatory bowel disease.”
[C0376622|ABCB1 gene – PREDISPOSES – C0021390|Inflammatory Bowel
Diseases]
Abstract
“Therefore, considering our results and those from others, the MDR1 gene behaves as a
common risk factor for both CD and UC.”
[C0376622|ABCB1 gene – PREDISPOSES – C0009324|Ulcerative Colitis]
[C0376622|ABCB1 gene – PREDISPOSES – C0010346|Crohn’s disease]
Abstract
“We discovered that the C3435 allele conferring susceptibility to CD is different from
the described 3435T UC risk allele.”
[C0010346|Crohn’s disease – PREDISPOSES – C0009324|Ulcerative Colitis]
[PMID16461743]
Abstract
“These data indicate that the NOD2fs mutation results in a loss-of-function phenotype
in human myeloid DC and imply decreased immune regulation by IL-10 as a possible
mechanism for this mutation in CD.”
[C0085295|Interleukin-10 – ASSOCIATED_WITH – C0010346|Crohn’s disease]
[PMID16493072]
Abstract
“We found that AKBA potentiated the apoptosis induced by TNF and
chemotherapeutic agents, suppressed TNF-induced invasion, and inhibited receptor
activator of NF-kappaB ligand-induced osteoclastogenesis, all of which are known to
require NF-kappaB activation.”
[C0003392|Antineoplastic Agents – CAUSES – C0162638|Apoptosis]
[C0812246|TNF gene – CAUSES – C0162638|Apoptosis]
Abstract
“Overall, our results indicated that AKBA enhances apoptosis induced by cytokines
and chemotherapeutic agents, inhibits invasion, and suppresses osteoclastogenesis
through inhibition of NF-kappaB-regulated gene expression.”
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[C0003392|Antineoplastic Agents – CAUSES – C0162638|Apoptosis]
[C0079189|cytokine – CAUSES – C0162638|Apoptosis]
[PMID16717254]
Abstract
“This raises the possibility that anti-apoptotic agents might be neuroprotective in PD.”
[C0040616|Anti-Anxiety Agents – TREATS – C0030567|Parkinson Disease]
Abstract
“Propargylamines have been demonstrated to be potent anti-apoptotic agents in both in
vitro and in vivo studies, presumably by maintaining glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) as a dimer and thereby preventing its nuclear translocation
where it blocks upregulation of anti-apoptotic proteins.”
[C0040616|Anti-Anxiety Agents – STIMULATES – C1565114|Apoptosis Inhibiting
Proteins]
[PMID17052658]
Title
“Lack of replication of thirteen single-nucleotide polymorphisms implicated in
Parkinson’s disease: a large-scale international study.”
[C0752046|Single Nucleotide Polymorphism – ASSOCIATED_WITH –
C0030567|Parkinson Disease]
Abstract
“A genome-wide association study identified 13 single-nucleotide polymorphisms
(SNPs) significantly associated with Parkinson’s disease.”
[C0752046|Single Nucleotide Polymorphism – ASSOCIATED_WITH –
C0030567|Parkinson Disease]
[PMID17156147]
Title
“Fibrogenesis in Crohn’s disease.”
[C0596570|fibrogenesis – ASSOCIATED_WITH – C0010346|Crohn’s disease]
Abstract
“While the pathogenesis of inflammation in CD has been extensively investigated,

332

knowledge of stricture pathogenesis remains limited.”
[C0021368|Inflammation – COEXISTS_WITH – C0010346|Crohn’s disease]
[PMID17185560]
Abstract
“We report that a synonymous SNP in the Multidrug Resistance 1 (MDR1) gene, part
of a haplotype previously linked to altered function of the MDR1 gene product Pglycoprotein (P-gp), nonetheless results in P-gp with altered drug and inhibitor
interactions.”
[C0752046|Single Nucleotide Polymorphism - COEXISTS_WITH C0376622|ABCB1 gene]
[PMID17339843]
Title
“Inflammation as a causative factor in the aetiology of Parkinson’s disease.”
[C0021368|Inflammation – CAUSES – C0030567|Parkinson Disease]
Abstract
“Parkinson’s disease (PD) is a progressive neurodegenerative disorder affecting mainly
the elderly, although a small proportion of PD patients develop the illness at a much
younger age.”
[C0030567|Parkinson Disease – ISA – C0524851|Neurodegenerative Disorders]
Abstract
“These factors are examined in this review along with a consideration of the possible
use of anti-inflammatory drugs in PD.”
[C0003209|Anti-Inflammatory Agents – TREATS – C0030567|Parkinson Disease]
[PMID17470824]
Abstract
“Adalimumab, a fully human tumor necrosis factor (TNF) antagonist, is an effective
treatment for patients with Crohn disease who are naïve to the chimeric TNF
antagonist, infliximab.”
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[C0666743|infliximab – TREATS(INFER) – C0010346|Crohn’s disease]
[C1122087|adalimumab - INHIBITS – C1448177|TNF protein, human]
Abstract
“No anti-TNF agent has been evaluated prospectively in patients with Crohn disease
who had responded to another anti-TNF agent and then lost that response or were
intolerant of the agent.”
[C0040616|Anti-Anxiety Agents – TREATS(INFER) – C0010346|Crohn’s disease]
Abstract
“To determine whether adalimumab induces remissions more frequently than placebo
in adult patients with Crohn disease who have symptoms despite infliximab therapy or
who cannot take infliximab because of adverse events.”
[C1122087|adalimumab – TREATS(INFER) – C0010346|Crohn’s disease]
Abstract
“Adalimumab induces remissions more frequently than placebo in adult patients with
Crohn disease who cannot tolerate infliximab or have symptoms despite receiving
infliximab therapy.”
[C1122087|adalimumab – TREATS(INFER) – C0010346|Crohn’s disease]
[PMID17908040]
Abstract
“TNF-alpha is secreted by the brain resident marcophage (the microglial cell) in
response to various stimuli. It has been demonstrated to play a major role in central
nervous system (CNS) neuroinflammation-mediated cell death in AD, PD and
amyotrophic lateral sclerosis (ALS) as well as several other CNS complications.”
[C0002395|Alzheimer's Disease – AFFECTS - C0007587|Cell Death]
[C0002736|Amyotrophic Lateral Sclerosis – AFFECTS - C0007587|Cell Death]
[C0030567|Parkinson Disease - AFFECTS - C0007587|Cell Death]
[PMID17984451]
Title
“Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease.”
[C0003211|Anti-Inflammatory Agents, Non-Steroidal – PREVENTS –
C0030567|Parkinson Disease]

334

Abstract
“Markers of neuroinflammation, including activated microglia and increased levels of
circulating proinflammatory cytokines, have been observed in the brains and CSF of
patients with Parkinson disease (PD).”
[C0079189|cytokine – ASSOCIATED_WITH(INFER) – C0030567|Parkinson Disease]
Abstract
“Our study contributes to the growing body of literature suggesting a protective role for
nonsteroidal anti-inflammatory drugs (NSAIDs) in Parkinson disease (PD).”
[C0003211|Anti-Inflammatory Agents, Non-Steroidal – TREATS –
C0030567|Parkinson Disease]
Abstract
“Yet the link between anti-inflammatory agents and PD in humans remains uncertain,
despite indications that neuroinflammation may contribute to cell death in the PD brain
and experimental evidence of anti-inflammatory agents such as nonsteroidal antiinflammatory drugs (NSAIDs) exerting neuroprotective effects in animal models.”
[C0003209|Anti-Inflammatory Agents – AFFECTS – C0007587|Cell Death]
[PMID19221310]
Abstract
“Imaging of nondopaminergic targets such as inflammation or alpha-synuclein
deposition may provide further insight into the etiology of PD.”
[C0021368|Inflammation – CAUSES – C0030567|Parkinson Disease]
[PMID8015728]
Abstract
“Since TNF-alpha is an important signal transducer of the immune system with
cytotoxic and stimulator properties, these results suggest that an immune response may
occur in the nigrostriatal dopaminergic regions in Parkinson’s disease and that TNFalpha may be related, at least in part, to the neuronal degeneration.”
[C0301872|Immune response – ASSOCIATED_WITH – C0030567|Parkinson
Disease]
[C1456820|Tumor Necrosis Factor-alpha – DISRUPTS – C0027746|Nerve
Degeneration]
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[PMID8196673]
Abstract
“An understanding of the molecular basis of the complex I defect in PD and its
relationship to other biochemical changes will provide important insight into the
potential chain of events that lead to dopaminergic cell death in PD.”
[C0030567|Parkinson Disease – AFFECTS - C0007587|Cell Death]
[PMID9422513]
Abstract
“Various molecules such as cytokines and anticancer drugs, as well as factor
deprivation, rapidly induce apoptosis (programmed cell death), which is
morphologically characterized by cell shrinkage and the blebbing of plasma
membranes and by nuclear condensation.”
[C0079189|cytokine – CAUSES - C0162638|Apoptosis]
[PMID9550432]
Title
“A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's
disease.”
[C0079189|cytokine – CAUSES - C0010346|Crohn's disease]
[C1456820|Tumor Necrosis Factor-alpha – CAUSES - C0010346|Crohn's disease]
Abstract
“To assess the role of TNF-alpha in mucosal cytokine regulation, the effects of TNFalpha on lamina propria mononuclear cell (LPMC) Th1 production were determined.”
[C1456820|Tumor Necrosis Factor-alpha - INTERACTS_WITH - C0079189|cytokine]
[PMID9820396]
Abstract
“This study aimed to shed more light on the interrelation between DHEAS and cortisol
(and humoral markers of inflammation) in chronic inflammatory bowel disease.”
[C0020268|Hydrocortisone - ASSOCIATED_WITH - C0021390|Inflammatory Bowel
Diseases]
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[C0057277|Dehydroepiandrosterone Sulfate - ASSOCIATED_WITH C0021390|Inflammatory Bowel Diseases]
Abstract
“DHEAS was lower in patients with CD (p &lt; 0.005) and UC (p &lt; 0.005) than in
controls, which was, in part, dependent on previous corticosteroid treatment (p &lt;
0.01).”
[C0057277|Dehydroepiandrosterone Sulfate - TREATS(INFER) C0009324|Ulcerative Colitis]
[C0057277|Dehydroepiandrosterone Sulfate - TREATS(INFER) - C0010346|Crohn's
disease]
Abstract
“DHEAS as a marker of inflammation was low in CD and UC.”
[C0009324|Ulcerative Colitis – ISA - C0021368|Inflammation]
[C0010346|Crohn's disease – ISA - C0021368|Inflammation]
[C0057277|Dehydroepiandrosterone Sulfate – PREDISPOSES C0021368|Inflammation]
[C0057277|Dehydroepiandrosterone Sulfate - PREDISPOSES(SPEC) C0009324|Ulcerative Colitis]
[C0057277|Dehydroepiandrosterone Sulfate - PREDISPOSES(SPEC) C0010346|Crohn's disease]
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Table E-3. Precision and recall using citations for Parkinson – Crohn study
Result

New Intermediate Terms

Relevancy (Topic)

Precision

Recall

d0

Inflammation

Neuroimmunology

1

0.333

d1

Anti-Apoptotic Agents

Cell Death

1

0.667

d2

Single Nucleotide
Polymorphism

Genetics

1

1

d3

Chronic Inflammation

Neuroimmunology

1

1

d4

Immune Response

Neuroimmunology

1

1

d5

Cytokine

Neuroimmunology

1

1

d6

Anti-Inflammatory Agents

Neuroimmunology

1

1

d7

ABCB1 Gene

Genetics

1

1

Table E-4. Precision and recall not using citations for Parkinson – Crohn study
Result

New Intermediate Terms

Relevancy (Topic)

Precision

Recall

d0

Inflammation

Neuroimmunology

1

0.333

d1

Anti-Apoptotic Agents

Cell Death

1

0.667

d2

Single Nucleotide
Polymorphism

Genetics

1

1

d3

Chronic Inflammation

Neuroimmunology

1

1

d4

Immune Response

Neuroimmunology

1

1

d5

Cytokine

Neuroimmunology

1

1

d6

Anti-Inflammatory Agents

Neuroimmunology

1

1

d7

ABCB1 Gene

Genetics

1

1
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Appendix F
MeSH Details
Table F-1. MeSH Categories

A – Anatomy
B – Organisms
C – Diseases
D – Chemicals and Drugs
E – Analytical, Diagnostic and Therapeutic Techniques, and Equipment
F – Psychiatry and Psychology
G – Phenomena and Processes
H – Disciplines and Occupations
I – Anthropology, Education, Sociology, and Social Phenomena
J – Technology, Industry, and Agriculture
K – Humanities
L – Information Science
M – Named Groupos
N – Health Care
V – Publication Characteristics
Z – Geographicals

339

References
Aamodt, A. H., Stovner, L. J., Midthjell, K., Hagen, K., & Zwart, J. A. (2007). Headache
prevalence related to diabetes mellitus. The Head‐HUNT study. European Journal of
Neurology, 14(7), 738-744.
Abu-Jbara, A., & Radev, D. (2011, June). Coherent citation-based summarization of
scientific papers. In Proceedings of the 49th Annual Meeting of the Association for
Computational Linguistics: Human Language Technologies-Volume 1 (pp. 500-509).
Association for Computational Linguistics.
Adams, S. O., Nissley, S. P., Handwerger, S., & Rechler, M. M. (1983). Developmental
patterns of insulin-like growth factor-I and-II synthesis and regulation in rat fibroblasts.
Nature, 302(5904), 150.
Ahlers, C. B., Hristovski, D., Kilicoglu, H., & Rindflesch, T. C. (2007). Using the
literature-based discovery paradigm to investigate drug mechanisms. In Proceedings of
the American Medical Informatics Association Annual Symposium (Vol. 2007, p. 6).
American Medical Informatics Association.
Allahyari, M., Pouriyeh, S., Assefi, M., Safaei, S., Trippe, E. D., Gutierrez, J. B., &
Kochut, K. (2017). Text summarization techniques: a brief survey. arXiv preprint
arXiv:1707.02268.
Allen, G. S., Gross, C. J., Henderson, L. M., & Chou, S. N. (1976). Cerebral arterial
spasm: Part 4: In vitro effects of temperature, serotonin analogues, large
nonphysiological concentrations of serotonin, and extracellular calcium and magnesium
on serotonin-induced contractions of the canine basilar artery. Journal of Neurosurgery,
44(5), 585-593.
Altura, B. M. (1970). Influence of magnesium and cysteine on vasopressin-induced
contractions in various canine blood vessels. Experientia, 26(10), 1089-1090.
Altura, B. M. (1981). Magnesium ions and contraction of vascular smooth muscles:
relationship to some vascular diseases. In Federation Proceedings (Vol. 40, pp. 26722679).
Altura, B. M., & Turlapaty, P. D. (1982). Withdrawal of magnesium enhances coronary
arterial spasms produced by vasoactive agents. British Journal of Pharmacology, 77(4),
649-659.

340

Altura, B. M., & Altura, B. T. (1983). Pharmacologic inhibition of cerebral vasospasm in
ischemia, hallucinogen ingestion, and hypomagnesemia: barbiturates, calcium
antagonists, and magnesium. The American Journal of Emergency Medicine, 1(2), 180190.
Altura, B. M., & Altura, B. T. (1984). Magnesium, electrolyte transport and coronary
vascular tone. Drugs, 28(1), 120-142.
Andersen, M. L., & Tufik, S. (2008). The effects of testosterone on sleep and sleepdisordered breathing in men: its bidirectional interaction with erectile function. Sleep
Medicine Reviews, 12(5), 365-379.
Anderson, W. W., Lewis, D. V., Swartzwelder, H. S., & Wilson, W. A. (1986).
Magnesium-free medium activates seizure-like events in the rat hippocampal slice. Brain
Research, 398(1), 215-219.
Andersson, K. E. (1986). Pharmacodynamic profiles of different calcium channel
blockers. Basic & Clinical Pharmacology & Toxicology, 58(S2), 31-42.
Anthony, M. (1982). Serotonin and cyclic nucleotides in migraine. Advances in
neurology, 33, 45.
Athenikos, S. J., & Han, H. (2010). Biomedical question answering: A survey. Computer
Methods and Programs in Biomedicine, 99(1), 1-24.
Axelsson, J., Ingre, M., Åkerstedt, T., & Holmbäck, U. (2005). Effects of acutely
displaced sleep on testosterone. The Journal of Clinical Endocrinology &
Metabolism, 90(8), 4530-4535.
Baeza-Yates, R., & Ribeiro-Neto, B. (1999). Modern Information Retrieval (Vol. 463).
New York: ACM press.
Bakal, G., Talari, P., Kakani, E. V., & Kavuluru, R. (2018). Exploiting semantic patterns
over biomedical knowledge graphs for predicting treatment and causative relations.
Journal of Biomedical Informatics, 82, 189-199.
Barbul, A., Fishel, R. S., Shimazu, S., Wasserkrug, H. L., Yoshimura, N. N., Tao, R. C.,
& Efron, G. (1985). Intravenous hyperalimentation with high arginine levels improves
wound healing and immune function. Journal of Surgical Research, 38(4), 328-334.
Basser, L. S. (1969). The relation of migraine and epilepsy. Brain, 92(2), 285-300.
Belch, J. J. F., Newman, P., Drury, J. K., Capell, H., Leiberman, P., James, W. B.,
Forbes, C. D., & Prentice, C. R. M. (1981). Successful treatment of Raynaud's syndrome
with prostacyclin. Thrombosis and Haemostasis, 46(03), 255-256.

341

Berge, L. I., Riise, T., Fasmer, O. B., Hundal, Ø., Oedegaard, K. J., Midthjell, K., &
Lund, A. (2013). Does diabetes have a protective effect on migraine?. Epidemiology,
129-134.
Binoux, M., Hossenlopp, P., Lassarre, C., & Seurin, D. (1980). Somatomedin production
by rat liver in organ culture. I. Validity of the technique. Influence of the released
material on cartilage sulphation. Effects of growth hormone and insulin. Acta
Endocrinologica, 93(1), 73.
Borman, A., Wood, T. R., Black, H. C., Anderson, E. G., Oestekling, M., Womack, M.,
& Rose, W. C. (1946). The role of arginine in growth, with some observations on the
effects of argininic acid. Journal of Biological Chemistry, 166, 585-594.
Brandt, L., Andersson, K. E., Edvinsson, L., & Ljunggren, B. (1981). Effects of
extracellular calcium and of calcium antagonists on the contractile responses of isolated
human pial and mesenteric arteries. Journal of Cerebral Blood Flow & Metabolism, 1(3),
339-347.
Briel, R. C., Lippert, T. H., & Zahradnik, H. P. (1985). Action of magnesium sulfate on
platelet prostacyclin interaction and prostacyclin of blood vessels. American Journal of
Obstetrics & Gynecology, 153(2), 232.
Briel, R. C., Lippert, T. H., & Zahradnik, H. P. (1987). Changes in blood coagulation,
thrombocyte function and vascular prostacyclin synthesis caused by magnesium sulfate.
Geburtshilfe und Frauenheilkunde, 47(5), 332-336.
Bücking, H., & Baumgartner, G. (1974). Clinical and pathophysiological considerations
on initial neurological symptoms of focal migraine (author's transl). Archiv fur
Psychiatrie und Nervenkrankheiten, 219(1), 37.
Burke, J. P., Mulsow, J. J., O'keane, C., Docherty, N. G., Watson, R. W. G., & O'connell,
P. R. (2007). Fibrogenesis in Crohn's disease. The American Journal of
Gastroenterology, 102(2), 439.
Cameron, D., Bodenreider, O., Yalamanchili, H., Danh, T., Vallabhaneni, S.,
Thirunarayan, K., Sheth, A. P., & Rindflesch, T. C. (2013). A graph-based recovery and
decomposition of Swanson’s hypothesis using semantic predications. Journal of
Biomedical Informatics, 46(2), 238-251.
Cameron, D. H. (2014). A Context-driven Subgraph Model for Literature-based
Discovery (Doctoral dissertation, Wright State University).
Cameron, D., Kavuluru, R., Rindflesch, T. C., Sheth, A. P., Thirunarayan, K., &
Bodenreider, O. (2015). Context-driven automatic subgraph creation for literature-based
discovery. Journal of Biomedical Informatics, 54, 141-157.

342

Canelas, H. M., De Assis, L. M., & De Jorge, F. B. (1965). Disorders of magnesium
metabolism in epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry, 28(4), 378.
Carlson, L. A., Ekelund, L. G., & Orö, L. (1968). Clinical and metabolic effects of
different doses of prostaglandin E1 in man. Journal of Internal Medicine, 183(1‐6), 423 430.
Chang, F. C., & Opp, M. R. (2000). IL-1 is a mediator of increases in slow-wave sleep
induced by CRH receptor blockade. American Journal of Physiology-Regulatory,
Integrative and Comparative Physiology, 279(3), R793-R802.
Chen, C., Chen, Y., Horowitz, M., Hou, H., Liu, Z., & Pellegrino, D. (2009). Towards an
explanatory and computational theory of scientific discovery. Journal of Informetrics,
3(3), 191-209.
Chevrier, M. R., Ryan, A. E., Lee, D. Y. W., Zhongze, M., Wu-Yan, Z., & Via, C. S.
(2005). Boswellia carterii extract inhibits TH1 cytokines and promotes TH2 cytokines in
vitro. Clinical and diagnostic laboratory immunology, 12(5), 575-580.
Daughaday, W. H., Phillips, L. S., & Herington, A. C. (1975). [6] Measurement of
somatomedin by cartilage in Vitro. In Methods in Enzymology (Vol. 37, pp. 93-109).
Academic Press.
DiGiacomo, R. A., Kremer, J. M., & Shah, D. M. (1989). Fish-oil dietary
supplementation in patients with Raynaud's phenomenon: a double-blind, controlled,
prospective study. The American Journal of Medicine, 86(2), 158-164.
Divoli, A., Nakov, P., & Hearst, M. A. (2012). Do peers see more in a paper than its
authors? Advances in Bioinformatics, 2012.
Doerr, P., & Pirke, K. M. (1976). Cortisol-induced suppression of plasma testosterone in
normal adult males. The Journal of Clinical Endocrinology & Metabolism, 43(3), 622629.
Domzal, T. (1975). Electroencephalographic studies in migraine. Neurologia I
Neurochirurgia Polska, 9(3), 337-341.
Edmundson, H. P. (1969). New methods in automatic extracting. Journal of the ACM
(JACM), 16(2), 264-285.

343

Elbaz, A., Nelson, L. M., Payami, H., Ioannidis, J. P., Fiske, B. K., Annesi, G., Carmine
Belin, A., Factor, S.A., Ferrarese, C., Hadjigeorgiou, G.M., Higgins, D.S., Kawakami,
H., Krüger, R., Marder, K.S., Mayeux, R.P., Mellick, G.D., Nutt, J.G., Ritz, B., Samii,
A., Tanner, C.M., Van Broeckhoven, C., Van Den Eeden, S.K., Wirdefeldt, K., Zabetian,
C.P., Dehem, M., Montimurro, J.S., Southwick, A., Myers, R.M., & Trikalinos, T.A.
(2006). Lack of replication of thirteen single-nucleotide polymorphisms implicated in
Parkinson's disease: a large-scale international study. The Lancet Neurology, 5(11), 917923.
Elkiss, A., Shen, S., Fader, A., Erkan, G., States, D., & Radev, D. (2008). Blind men and
elephants: What do citation summaries tell us about a research article? Journal of the
Association for Information Science and Technology, 59(1), 51-62.
Espiritu, J. R. D. (2008). Aging-related sleep changes. Clinics in Geriatric
Medicine, 24(1), 1-14.
Fagherazzi, G., El Fatouhi, D., Fournier, A., Gusto, G., Mancini, F., Balkau, B., BoutronRuault, M., Kurth, T., & Bonnet, F. (2019). Associations Between Migraine and Type 2
Diabetes in Women. Jama Neurology.
Fanciullacci, M., Pietrini, U., Geppetti, P., Nicolodi, M., Curradi, C., & Sicuteri, F.
(1988). Substance P in the human iris: possible involvement in echothiophate-induced
miosis in cluster headache. Cephalalgia, 8(1), 49-53.
Fang, J., Wang, Y., & Krueger, J. M. (1998). Effects of interleukin-1β on sleep are
mediated by the type I receptor. American Journal of Physiology-Regulatory, Integrative
and Comparative Physiology, 274(3), R655-R660.
Feldman, R., & Sanger, J. (2007). The Text Mining Handbook: Advanced Approaches in
Analyzing Unstructured Data. Cambridge University Press.
Feller, I. & Stern, P. C. (2007). A Strategy for Assessing Science: Behavioral and Social
Research on Aging. National Academies Press.
Fewtrell, C. M. S., Foreman, J. C., Jordan, C. C., Oehme, P., Renner, H., & Stewart, J. M.
(1982). The effects of substance P on histamine and 5-hydroxytryptamine release in the
rat. The Journal of Physiology, 330(1), 393-411.
Firth, J. R. (1957). A synopsis of linguistic theory, 1930-1955. Studies in linguistic
analysis.
Fiszman, M., Rindflesch, T. C., & Kilicoglu, H. (2004, May). Abstraction summarization
for Managing the Biomedical Research Literature. In Proceedings of the HLT-NAACL
Workshop on Computational Lexical Semantics (pp. 76-83). Association for
Computational Linguistics.

344

Flink, E. B., Shane, S. R., Scobbo, R. R., Blehschmidt, N. G., & McDowell, P. (1979).
Relationship of free fatty acids and magnesium in ethanol withdrawal in dogs.
Metabolism-Clinical and Experimental, 28(8), 858-865.
Francis, M. J. O., & Hill, D. J. (1975). Prolactin-stimulated production of somatomedin
by rat liver. Nature, 255(5504), 167.
Friedman, A. P., Von Storch, T. J., & Merritt, H. H. (1954). Migraine and tension
headaches: clinical study of two thousand cases. Neurology.
Frijters, R., Van Vugt, M., Smeets, R., Van Schaik, R., De Vlieg, J., & Alkema, W.
(2010). Literature mining for the discovery of hidden connections between drugs, genes
and diseases. PLoS Comput Biol, 6(9), e1000943.
Fujii, S., Takemura, T., Wada, M., Akai, T., & Okuda, K. (1982). Magnesium levels in
plasma, erythrocyte and urine in patients with diabetes mellitus. Hormone and Metabolic
Research, 14(03), 161-162.
Ganiz, M. C., Pottenger, W. M., & Janneck, C. D. (2005). Recent advances in literature
based discovery. Journal of the American Society for Information Science and
Technology, JASIST (Submitted).
Gitau, R., Adams, D., Fisk, N. M., & Glover, V. (2005). Fetal plasma testosterone
correlates positively with cortisol. Archives of Disease in Childhood-Fetal and Neonatal
Edition, 90(2), F166-F169.
Gong, Y., & Liu, X. (2001, September). Generic text summarization using relevance
measure and latent semantic analysis. In Proceedings of the 24th Annual International
ACM SIGIR Conference on Research and Development in Information Retrieval (pp. 1925).
Gordon, M. D., & Lindsay, R. K. (1996). Toward discovery support systems: A
replication, re‐examination, and extension of Swanson's work on literature‐ base d
discovery of a connection between Raynaud's and fish oil. Journal of the American
Society for Information Science, 47(2), 116-128.
Gordon, M. D., & Dumais, S. (1998). Using latent semantic indexing for literature based
discovery. Journal of the American Society for Information Science, 49(8), 674-685.
Gordon, M., Lindsay, R. K., & Fan, W. (2002). Literature-based discovery on the World
Wide Web. ACM Transactions on Internet Technology (TOIT), 2(4), 261-275.
Hachinski, V. C., Olesen, J., Norris, J. A., Larsen, B., Enevoldsen, E., & Lassen, N. A.
(1977). Cerebral hemodynamics in migraine. Canadian Journal of Neurological
Sciences, 4(4), 245-249.

345

Haghighi, F. S., Rahmanian, M., Namiranian, N., Arzaghi, S. M., Dehghan, F.,
Chavoshzade, F., & Sepehri, F. (2015). Migraine and type 2 diabetes; is there any
association?. Journal of Diabetes & Metabolic Disorders, 15(1), 37.
Hall K 1972 Human somatomedin: determination, occurrence, biological activity and
purification. Acta Endocrinol [Suppl] (Copenh) 163:1-52
Hammerman, M. R. (1987). Insulin-like growth factors and aging. Endocrinology and
Metabolism Clinics of North America, 16(4), 995-1011.
Hanauer, S. B. (2004). Efficacy and safety of tumor necrosis factor antagonists in Crohn's
disease: overview of randomized clinical studies. Reviews in Gastroenterological
Disorders, 4, S18-24.
Hanington, E., Jones, R. J., Amess, J. A. L., & Wachowicz, B. (1981). Migraine: a
platelet disorder. The Lancet, 318(8249), 720-723.
Hanington, E. (1986). The platelet and migraine. Headache: The Journal of Head and
Face Pain, 26(8), 411-415.
Hansen, A. J., & Zeuthen, T. (1981). Extracellular ion concentrations during spreading
depression and ischemia in the rat brain cortex. Acta Physiologica, 113(4), 437-445.
Hansson, H. A., Jennische, E., & Skottner, A. (1987). Regenerating endothelial cells
express insulin-like growth factor-I immunoreactivity after arterial injury. Cell and
Tissue Research, 250(3), 499-505.
Healy, M. D., Ward, J. A., & Wang, P. I. W. G. (1984). Inhibition of calcium by
magnesium in the contraction of rat aortic smooth muscle. I. Mathematical model of
calcium and magnesium binding. Magnesium, 3(2), 63-72.
Hearst, M. A. (1999, June). Untangling text data mining. In Proceedings of the 37th
Annual Meeting of the Association for Computational Linguistics on Computational
Linguistics (pp. 3-10). Association for Computational Linguistics.
Hill, D. J., & Milner, R. D. G. (1985). Insulin as a growth factor. Pediatric Research,
19(9), 879.
Hintz, R. L., Suskind, R., Amatayakul, K., Thanangkul, O., & Olson, R. (1978). Plasma
somatomedin and growth hormone values in children with protein-calorie malnutrition.
The Journal of Pediatrics, 92(1), 153-156.
Hintz, R. L., Liu, F., Marshall, L. B., & Chang, D. (1980). Interaction of somatomedin-C
with an antibody directed against the synthetic C-peptide region of insulin-like growth
factor-I. The Journal of Clinical Endocrinology & Metabolism, 50(2), 405-407.

346

Ho, G. T., Nimmo, E. R., Tenesa, A., Fennell, J., Drummond, H., Mowat, C., Arnott,
I.D., & Satsangi, J. (2005). Allelic variations of the multidrug resistance gene determine
susceptibility and disease behavior in ulcerative colitis. Gastroenterology, 128(2), 288296.
Horrobin, D. F. (1977). Prostaglandins and migraine. Headache: The Journal of Head
and Face Pain, 17(3), 113-117.
Hristovski, D., Friedman, C., Rindflesch, T. C., & Peterlin, B. (2006). Exploiting
semantic relations for literature-based discovery. In Proceedings of American Medical
Medical Association Annual Symposium (Vol. 2006, p. 349). American Medical
Informatics Association.
Hsu, L. K. G., Kalucy, R. S., Crisp, A. H., Koval, J., Chen, C. N., Carruthers, M., &
Zilkha, K. J. (1977). Early morning migraine: nocturnal plasma levels of catecholamines,
tryptophan, glucose, and free fatty acids and sleep encephalographs. The Lancet,
309(8009), 447-451.
Hu, X., Li, G., Yoo, I., Zhang, X., & Xu, X. (2005, July). A semantic-based approach for
mining undiscovered public knowledge from biomedical literature. In Proceedings of
IEEE International Conference on Granular Computing, 2005 IEEE International
Conference on (Vol. 1, pp. 22-27).
Hu, X., Yoo, I., Song, M., Zhang, Y., & Song, I. Y. (2005, October). Mining
undiscovered public knowledge from complementary and non-interactive biomedical
literature through semantic pruning. In Proceedings of the 14th ACM International
Conference on Information and Knowledge Management (pp. 249-250). ACM.
Ishikawa, T., Onishi, Y., Hirano, H., Oosumi, K., Nagakura, M., & Tarui, S. (2004).
Pharmacogenomics of drug transporters: a new approach to functional analysis of the
genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1). Biological and
Pharmaceutical Bulletin, 27(7), 939-948.
Jackson, C. E., & Meier, D. W. (1968). Routine serum magnesium analysis: correlation
with clinical state in 5,100 patients. Annals of Internal Medicine, 69(4), 743-748.
Jiang, J. J., & Conrath, D. W. (1997). Semantic similarity based on corpus statistics and
lexical taxonomy. arXiv preprint cmp-lg/9709008.
Jinha, A. E. (2010). Article 50 million: an estimate of the number of scholarly articles in
existence. Learned Publishing, 23(3), 258-263.
Joon Ho Lee, Myoung Ho Kim, and Yoon Joon Lee. (1993) Information retrieval based
on conceptual distance in IS-A hierarchies. Journal of Documentation, 49(2), 188-207.
Joseph, R., & Welch, K. M. A. (1987). The platelet and migraine: a nonspecific
association. Headache: The Journal of Head and Face Pain, 27(7), 375-380.

347

Kan, M. Y., McKeown, K. R., & Klavans, J. L. (2001). Domain-specific informative and
indicative summarization for information retrieval. In Proc. of the Document
Understanding Conference (DUC) (pp. 19-26).
Keller, J., Kaltenecker, A., Schricker, K. T., Neidhardt, B., & Hornstein, O. P. (1985).
Inhibition of platelet aggregation by a new stable prostacyclin introduced in therapy of
patients with progressive scleroderma. Archives of Dermatological Research, 277(4),
323-325.
Kern, W., Dodt, C., Born, J., & Fehm, H. L. (1996). Changes in cortisol and growth
hormone secretion during nocturnal sleep in the course of aging. The Journals of
Gerontology Series A: Biological Sciences and Medical Sciences, 51(1), M3-M9.
Kilicoglu, H., Fiszman, M., Rodriguez, A., Shin, D., Ripple, A., & Rindflesch, T. C.
(2008, September). Semantic MEDLINE: a web application for managing the results of
PubMed Searches. In Proceedings of the Third International Symposium for Semantic
Mining in Biomedicine (Vol. 2008, pp. 69-76).
Kilicoglu, H., Rosemblat, G., & Rindflesch, T. C. (2017). Assigning factuality values to
semantic relations extracted from biomedical research literature. PloS one, 12(7),
e0179926.
Kogawa, M., TAKANO, K., HIZUKA, N., ASAKAWA, K., & SHIZUME, K. (1982).
Effect of GH and insulin on the generation of somatomedin by perfused rat liver.
Endocrinologia Japonica, 29(2), 141-147.
Kostoff, R. N. (2008). Literature-related discovery (LRD): Potential treatments for
cataracts. Technological Forecasting and Social Change, 75(2), 215-225.
Kostoff, R. N., Block, J. A., Solka, J. L., Briggs, M. B., Rushenberg, R. L., Stump, J. A.,
Johnson, D., Lyons, T. J., & Wyatt, J. R. (2009). Literature‐related discovery. Annual
Review of Information Science and Technology, 43(1), 1-71.
Kostoff, R. N. (2014). Literature-related discovery: common factors for Parkinson’s
Disease and Crohn’s Disease. Scientometrics, 100(3), 623-657.
Krallinger, M., Rabal, O., Lourenço, A., Oyarzabal, J., & Valencia, A. (2017).
Information Retrieval and Text Mining Technologies for Chemistry. Chemical Reviews.
Kramer, M., Netea, M. G., De Jong, D. J., Kullberg, B. J., & Adema, G. J. (2006).
Impaired dendritic cell function in Crohn’s disease patients with NOD2 3020insC
mutation. Journal of Leukocyte Biology, 79(4), 860-866.

348

Krueger, J. M., Obál, F., Fang, J., Kubota, T., & Taishi, P. (2001). The role of cytokines
in physiological sleep regulation. Annals of the New York Academy of Sciences, 933(1),
211-221.
Landauer, T. K., Foltz, P. W., & Laham, D. (1998). An introduction to latent semantic
analysis. Discourse Processes, 25(2-3), 259-284.
Le Roith, D., Shapiro, M., Jabotinsky, K., & Spitz, I. M. (1979). Prolactin
nonresponsiveness to arginine in diabetes mellitus. Hormone and Metabolic Research,
11(10), 583-584.
Leibenluft, E., Schmidt, P. J., Turner, E. H., Danaceau, M. A., Ashman, S. B., Wehr, T.
A., & Rubinow, D. R. (1997). Effects of leuprolide-induced hypogonadism and
testosterone replacement on sleep, melatonin, and prolactin secretion in men. The Journal
of Clinical Endocrinology & Metabolism, 82(10), 3203-3207.
Li, F. Q., Wang, T., Pei, Z., Liu, B., & Hong, J. S. (2005). Inhibition of microglial
activation by the herbal flavonoid baicalein attenuates inflammation-mediated
degeneration of dopaminergic neurons. Journal of Neural Transmission, 112(3), 331-347.
Li, J., Zhu, X., & Chen, J. Y. (2010). Discovering breast cancer drug candidates from
biomedical literature. International Journal of Data Mining and Bioinformatics, 4(3),
241-255.
Liddy, E. D. (2001). Natural language processing. Encyclopedia of Library and
Information Science. Marcel Decker.
Lin, D. (1998, July). An information-theoretic definition of similarity. In Proceedings of
the 15th International Conference on Machine Learning, (Vol. 98, No. 1998, pp. 296304).
Lindsay, R. K., & Gordon, M. D. (1999). Literature-based discovery by lexical statistics.
Journal of the Association for Information Science and Technology, 50(7), 574.
Liu, Y., McInnes, B. T., Pedersen, T., Melton-Meaux, G., & Pakhomov, S. (2012,
January). Semantic relatedness study using second order co-occurrence vectors computed
from biomedical corpora, UMLS and WordNet. In Proceedings of the 2nd ACM SIGHIT
International Health Informatics Symposium (pp. 363-372).
Lu, P. H., Masterman, D. A., Mulnard, R., Cotman, C., Miller, B., Yaffe, K., Reback, E.,
Porter, V., Swerdloff, R., & Cummings, J. L. (2006). Effects of testosterone on cognition
and mood in male patients with mild Alzheimer disease and healthy elderly
men. Archives of Neurology, 63(2), 177-185.

349

López-de-Andrés, A., del Barrio, J. L., Hernández-Barrera, V., de Miguel-Díez, J.,
Jimenez-Trujillo, I., Martinez-Huedo, M. A., & Jimenez-García, R. (2018). Migraine in
adults with diabetes; is there an association? Results of a population-based study.
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 11, 367.
Lussier, Y., Borlawsky, T., Rappaport, D., Liu, Y., & Friedman, C. (2006). PhenoGO:
assigning phenotypic context to gene ontology annotations with natural language
processing. In Proceedings of Pacific Symposium on Biocomputing. Pacific Symposium
on Biocomputing (p. 64). NIH Public Access.
Malkin, C. J., Pugh, P. J., Jones, R. D., Kapoor, D., Channer, K. S., & Jones, T. H.
(2004). The effect of testosterone replacement on endogenous inflammatory cytokines
and lipid profiles in hypogonadal men. The Journal of Clinical Endocrinology &
Metabolism, 89(7), 3313-3318.
Mani, I. (1999). Advances in Automatic Text Summarization. MIT press.
Manning, C. D., Raghavan, P., & Schütze, H. (2008). Introduction to information
retrieval (Vol. 39). Cambridge University Press.
Manson, J. M., Smith, R. J., & Wilmore, D. W. (1988). Growth hormone stimulates
protein synthesis during hypocaloric parenteral nutrition. Role of hormonal-substrate
environment. Annals of Surgery, 208(2), 136.
Maraganore, D. M., De Andrade, M., Lesnick, T. G., Strain, K. J., Farrer, M. J., Rocca,
W. A., Pant, P.V., Frazer, K.A., Cox, D.R., & Ballinger, D. G. (2005). High-resolution
whole-genome association study of Parkinson disease. The American Journal of Human
Genetics, 77(5), 685-693.
Markley, H. G., Cheronis, J. C., & Piepho, R. W. (1984). Verapamil in prophylactic
therapy of migraine. Neurology, 34(7), 973-973.
Martin, M. F., Dowd, P. M., Ring, E. F., Cooke, E. D., Dieppe, P. A., & Kirby, J. D.
(1981). Prostaglandin E1 infusions for vascular insufficiency in progressive systemic
sclerosis. Annals of the Rheumatic Diseases, 40(4), 350.
Marzolini, C., Paus, E., Buclin, T., & Kim, R. B. (2004). Polymorphisms in human
MDR1 (P‐glycoprotein): recent advances and clinical relevance. Clinical Pharmacology
& Therapeutics, 75(1), 13-33.
McCarron, D. A. (1983). Calcium and magnesium nutrition in human hypertension.
Annals of Internal Medicine, 98(5_Part_2), 800-805.
McCurry, S. M., Reynolds III, C. F., Ancoli-Israel, S., Teri, L., & Vitiello, M. V. (2000).
Treatment of sleep disturbance in Alzheimer's disease. Sleep Medicine Reviews, 4(6),
603-628.

350

McGeer, P. L., & McGeer, E. G. (2004). Inflammation and neurodegeneration in
Parkinson's disease. Parkinsonism & Related Disorders, 10, S3-S7.
McNair, P., Christensen, M. S., Christiansen, C., Madsbad, S., & Transbøl, I. B. (1982).
Renal hypomagnesaemia in human diabetes mellitus: its relation to glucose homeostasis.
European Journal of Clinical Investigation, 12(1), 81-85.
Merimee, T. J., Burgess, J. A., & Rabinowitz, D. (1966). Sex-determined variation in
serum insulin and growth hormone response to amino acid stimulation. The Journal of
Clinical Endocrinology & Metabolism, 26(7), 791-793.
Meyer, J. S., & Hardenberg, J. (1983). Clinical effectiveness of calcium entry blockers in
prophylactic treatment of migraine and cluster headaches. Headache: The Journal of
Head and Face Pain, 23(6), 266-277.
Miller, C. M., Rindflesch, T. C., Fiszman, M., Hristovski, D., Shin, D., Rosemblat, G,
Zhang, H., & Strohl, K. P. (2012). A closed literature-based discovery technique finds a
mechanistic link between hypogonadism and diminished sleep quality in aging
men. Sleep, 35(2), 279-285.
Milner, J. A., Wakeling, A. E., & Visek, W. J. (1974). Effect of arginine deficiency on
growth and intermediary metabolism in rats. The Journal of Nutrition, 104(12), 16811689.
Milner, J. A., & Stepanovich, L. V. (1979). Inhibitory effect of dietary arginine on
growth of Ehrlich ascites tumor cells in mice. The Journal of Nutrition, 109(3), 489-494.
Milojević, S. (2012). How are academic age, productivity and collaboration related to
citing behavior of researchers?. PloS one, 7(11), e49176.
Mishra, R., Bian, J., Fiszman, M., Weir, C. R., Jonnalagadda, S., Mostafa, J., & Del Fiol,
G. (2014). Text summarization in the biomedical domain: a systematic review of recent
research. Journal of Biomedical Informatics, 52, 457-467.
Mogi, M., Togari, A., Tanaka, K. I., Ogawa, N., Ichinose, H., & Nagatsu, T. (1999).
Increase in level of tumor necrosis factor (TNF)-α in 6-hydroxydopamine-lesioned
striatum in rats without influence of systemic L-DOPA on the TNF-α
induction. Neuroscience Letters, 268(2), 101-104.
Moses, A. C., NISSLEY, S. P., Cohen, K. L., & RECHLER, M. M. (1976). Specific
binding of a somatomedin-like polypeptide in rat serum depends on growth hormone.
Nature, 263(5573), 137.
Moskowitz, M., Romero, J., Reinhard JR, J., Melamed, E., & Pettibone, D. (1979).
Neurotransmitters and the fifth cranial nerve: is there a relation to the headache phase of
migraine?. The Lancet, 314(8148), 883-885.

351

Mtabaji, J. P., Manku, M. S., & Horrobin, D. F. (1976). Vascular actions of furosemide
and bumetanide on the rat superior mesenteric vascular bed: interactions with prolactin
and prostaglandins. Canadian Journal of Physiology and Pharmacology, 54(3), 357-366.
Nakov, P. I., Schwartz, A. S., & Hearst, M. (2004). Citances: Citation sentences for
semantic analysis of bioscience text. In Proceedings of the Special Interest Group on
Information Retrieval (Vol. 4, pp. 81-88).
Nicolaisen, J. (2007). Citation analysis. Annual Review of Information Science and
Technology, 41(1), 609-641.
Okun, M. S., Fernandez, H. H., Rodriguez, R. L., Romrell, J., Suelter, M., Munson, S.,
Louid E.D., Mulligan T., Foster P.S., Shenel B.V., Armaghani, S. J., Jacobson C., Wu S.,
& Crucian G. (2006). Testosterone therapy in men with Parkinson disease: results of the
TEST-PD Study. Archives of Neurology, 63(5), 729-735.
Olanow, C. W. (2006). Rationale for considering that propargylamines might be
neuroprotective in Parkinson’s disease. Neurology, 66(10 suppl 4), S69-S79.
Parantainen, J., Vapaatalo, H., & Hokkanen, E. (1985). Relevance of prostaglandins in
migraine. Cephalalgia, 5(2_suppl), 93-97.
Peatfield, R. C., Gawel, M. J., & Rose, F. C. (1981). The effect of infused prostacyclin in
migraine and cluster headache. Headache: The Journal of Head and Face Pain, 21(5),
190-195.
Peroutka, S. J. (1983). The Pharmacology of Calcium Channel Antagonists: a Novel
Class of Anti‐migraine Agents?. Headache: The Journal of Head and Face Pain, 23(6),
278-283.
Pertseva, M. N., & Soltitskaia, L. P. (1987). Properties of the adenylate cyclase system in
the muscle tissue of the mollusk Anodonta cygnea. Ukrainskii biokhimicheskii zhurnal
(1978), 59(4), 14-20.
Peters, J. A. (1959). Classic Papers in Genetics. Prentice Hall.
Phillips, L. S., & Orawski, A. T. (1977). Nutrition and Somatomedin: III. Diabetic
Control, Somatomedin, and Growth in Rats. Diabetes, 26(9), 864-869.
Phillips, L. S., Vassilopoulou-Sellin, R., & Reichard, L. A. (1979). Nutrition and
Somatomedin. VIM. The “Somatomedin Inhibitor” in Diabetic Rat Serum is a General
Inhibitor of Growing Cartilage. Diabetes, 28(10), 919-924.
Plaza, L., Díaz, A., & Gervás, P. (2011). A semantic graph-based approach to biomedical
summarisation. Artificial Intelligence in Medicine, 53(1), 1-14.

352

Pratt, W., & Yetisgen-Yildiz, M. (2003, October). LitLinker: capturing connections
across the biomedical literature. In Proceedings of the 2nd International Conference on
Knowledge Capture (pp. 105-112). ACM.
Prinz, P. N., Bailey, S. L., & Woods, D. L. (2000). Sleep impairments in healthy seniors:
roles of stress, cortisol, and interleukin-1 beta. Chronobiology international, 17(3), 391404.
Pui, Y. M. L., & Fisher, H. (1979). Factorial supplementation with arginine and glycine
on nitrogen retention and body weight gain in the traumatized rat. The Journal of
Nutrition, 109(2), 240-246.
Quintana, L., Konda, R., Ishibashi, Y., Yoshimoto, T., & Suzuki, J. (1982). The effect of
prostacyclin on cerebral vasospasm an experimental study. Acta Neurochirurgica, 62(34), 187-193.
Rada, R., Mili, H., Bicknell, E., & Blettner, M. (1989). Development and application of a
metric on semantic nets. IEEE Transactions on Systems, Man, and Cybernetics, 19(1),
17-30.
Rayssiguier, Y. (1984). Role of magnesium and potassium in the pathogenesis of
arteriosclerosis. Magnesium, 3(4-6), 226-238.
Reeves, R. D., Dickinson, L., Lee, J., Kilgore, B., Branham, B., & Elders, M. J. (1979).
Effects of dietary composition on somatomedin activity in growing rats. The Journal of
Nutrition, 109(4), 613-620.
Resnik, P. (1995). Using information content to evaluate semantic similarity in a
taxonomy. In Proceedings of the 14th International Joint Conference on Artificial
Intelligence. Vol. 1, 448-453.
Rindflesch, T. C., & Fiszman, M. (2003). The interaction of domain knowledge and
linguistic structure in natural language processing: interpreting hypernymic propositions
in biomedical text. Journal of Biomedical Informatics, 36(6), 462-477.
Rosell, S., Olgart, L., Gazelius, B., Panopoulos, P., Folkers, K., & Hörig, J. (1981).
Inhibition of antidromic and substance P‐induced vasodilatation by a substance P
antagonist. Acta Physiologica, 111(3), 381-382.
Ross, S. (2014). A First Course in Probability. Pearson.
Sagel, J., Colwell, J. A., Crook, L., & Laimins, M. (1975). Increased platelet aggregation
in early diabetus mellitus. Annals of Internal Medicine, 82(6), 733-738.
Salmon, W. D., & Daughaday, W. H. (1957). A hormonally controlled serum factor
which stimulates sulfate incorporation by cartilage in vitro. The Journal of Laboratory
and Clinical Medicine, 49(6), 825-836.

353

Sandborn, W. J., Rutgeerts, P., Enns, R., Hanauer, S. B., Colombel, J. F., Panaccione, R.,
D’Haens, G., Li, J., Rosenfeld, M.R., & Pollack, P. F. (2007). Adalimumab induction
therapy for Crohn disease previously treated with infliximab: a randomized trial. Annals
of Internal Medicine, 146(12), 829-838.
Shi, B., & Weninger, T. (2016). Discriminative predicate path mining for fact checking in
knowledge graphs. Knowledge-Based Systems, 104, 123-133.
Shine, K. I. (1979). Myocardial effects of magnesium. American Journal of PhysiologyHeart and Circulatory Physiology, 237(4), H413-H423.
Sicuteri, F., Rainò, L., & Geppetti, P. (1983). Substance P and endogenous opioids: how
and where they could play a role in cluster headache. Cephalalgia, 3(1_suppl), 143-145.
Sicuteri, F., Renzi, D., & Geppetti, P. (1986). Substance P and enkephalins: a creditable
tandem in the pathophysiology of cluster headache and migraine. Advances in
experimental Medicine and Biology, 198, 145-152.
Sjögren, A., & Edvinsson, L. (1986). Vasomotor effects of magnesium: a comparison
with nifedipine and verapamil of in vitro reactivity in feline cerebral and peripheral
arteries. Magnesium, 5(2), 66-75.
Skinhoj, E., & Paulson, O. B. (1969). Regional blood flow in internal carotid distribution
during migraine attack. British Medical Journal, 3(5670), 569.
Smalheiser, N. R., & Swanson, D. R. (1996). Linking estrogen to Alzheimer's disease: an
informatics approach. Neurology, 47(3), 809-810.
Smalheiser, N. R., & Torvik, V. I. (2008). The place of literature-based discovery in
contemporary scientific practice. Literature-Based Discovery, 13-22.
Smalheiser, N. R., Torvik, V. I., & Zhou, W. (2009). Arrowsmith two-node search
interface: a tutorial on finding meaningful links between two disparate sets of articles in
MEDLINE. Computer Methods and Programs in Biomedicine, 94(2), 190-197.
Smalheiser, N. R. (2012). Literature-based discovery: Beyond the ABCs. Journal of the
Association for Information Science and Technology, 63(2), 218-224.
Soliman, A. T., Abd El Hadi, I. H., Aref, M. K., Hintz, R. L., Rosenfeld, R. G., & Rogol,
A. D. (1986). Serum insulin-like growth factors I and II concentrations and growth
hormone and insulin responses to arginine infusion in children with protein-energy
malnutrition before and after nutritional rehabilitation. Pediatric Research, 20(11), 1122.
Soma, M., Cunnane, S. C., Horrobin, D. F., Manku, M. S., Honda, M., & Hatano, M.
(1988). Effects of low magnesium diet on the vascular prostaglandin and fatty acid
metabolism in rats. Prostaglandins, 36(4), 431-441.

354

Song, M., Heo, G. E., & Ding, Y. (2015). SemPathFinder: Semantic path analysis for
discovering publicly unknown knowledge. Journal of Informetrics, 9(4), 686-703.
Sparck Jones, K. (1972). A statistical interpretation of term specificity and its application
in retrieval. Journal of Documentation, 28(1), 11-21.
Spencer, E. M., Skover, G., & Hunt, T. K. (1988). Somatomedins: do they play a pivotal
role in wound healing?. Progress in Clinical and Biological Research, 266, 103-116.
Srinivasan, P. (2004). Text mining: generating hypotheses from MEDLINE. Journal of
the American Society for Information Science and Technology, 55(5), 396-413.
Sriram, K., Matheson, J. M., Benkovic, S. A., Miller, D. B., Luster, M. I., &
O’Callaghan, J. P. (2002). Mice deficient in TNF receptors are protected against
dopaminergic neurotoxicity: implications for Parkinson’s disease. The Federation of
American Societies for Experimental Biology Journal, 16(11), 1474-1476.
Steiner, T. J., Joseph, R., & Rose, F. C. (1985). Migraine is not a platelet disorder.
Headache: The Journal of Head and Face Pain, 25(8), 434-440.
Stracke, H., Schulz, A., Moeller, D., Rossol, S., & Schatz, H. (1984). Effect of growth
hormone on osteoblasts and demonstration of somatomedin-C/IGF I in bone organ
culture. Acta Endocrinologica, 107(1), 16-24.
Sutton, W. S. 1902. On the morphology of the chromosome group in Brachystola magna.
Biological Bulletin, 4:24-39.
Swanson DR. Fish oil, Raynaud’s syndrome, and undiscovered public knowledge.
Perspectives in Biology and Medicine 1986;30(1):7–18.
Swanson, D. R. (1988). Migraine and magnesium: eleven neglected connections.
Perspectives in Biology and Medicine, 31(4), 526-557.
Swanson, D. R. (1989). Online search for logically-related noninteractive medical
literatures: a systematic trial-and-error strategy. Journal of the American Society for
Information Science (1986-1998), 40(5), 356.
Swanson, D. R. (1990). Somatomedin C and arginine: implicit connections between
mutually isolated literatures. Perspectives in Biology and Medicine, 33(2), 157-186.
Swanson, D. R., Smalheiser, N. R., & Torvik, V. I. (2006). Ranking indirect connections
in literature‐based discovery: T he role of medical subject headings. Journal of the
American Society for Information Science and Technology, 57(11), 1427-1439.
Swanson, D. R. (2008). Literature-based discovery? The very idea. Literature-Based
Discovery, 3-11.

355

Taishi, P., Chen, Z., OBÁL JR, F. E. R. E. N. C., Hansen, M. K., Zhang, J., Fang, J., &
Krueger, J. M. (1998). Sleep-associated changes in interleukin-1β mRNA in the
brain. Journal of Interferon & Cytokine Research, 18(9), 793-798.
Terano, T., Hirai, A., Hamazaki, T., Kobayashi, S., Fujita, T., Tamura, Y., & Kumagai,
A. (1983). Effect of oral administration of highly purified eicosapentaenoic acid on
platelet function, blood viscosity and red cell deformability in healthy human subjects.
Atherosclerosis, 46(3), 321-331.
Trenell, M. I., Marshall, N. S., & Rogers, N. L. (2007). Sleep and metabolic control:
waking to a problem? Clinical and Experimental Pharmacology and Physiology, 34(1-2),
1-9.
Turlapaty, P. D., Weiner, R., & Altura, B. M. (1981). Interactions of magnesium and
verapamil on tone and contractility of vascular smooth muscle. European Journal of
Pharmacology, 74(4), 263-272.
Tweedie, D., Sambamurti, K., & Greig, N. H. (2007). TNF-α inhibition as a treatment
strategy for neurodegenerative disorders: new drug candidates and targets. Current
Alzheimer Research, 4(4), 378-385.
Urcelay, E., Mendoza, J. L., Martín, C. M., Mas, A., Martínez, A., Taxonera, C.,
Fernandez-Arquero, M., Diaz-Rubio, M., & de la Concha, E. G. (2006). MDR1 gene:
susceptibility in Spanish Crohn's disease and ulcerative colitis patients. Inflammatory
Bowel Diseases, 12(1), 33-37.
Vallance, B. A., Gunawan, M. I., Hewlett, B., Bercik, P., Van Kampen, C., Galeazzi, F.,
Sime, P.J., Gauldie, J., & Collins, S. M. (2005). TGF-β1 gene transfer to the mouse colon
leads to intestinal fibrosis. American Journal of Physiology-Gastrointestinal and Liver
Physiology, 289(1), G116-G128.
Van Harreveld, A. (1978). Two mechanisms for spreading depression in the chicken
retina. Developmental Neurobiology, 9(6), 419-431.
Van Harreveld, A. (1984). The nature of the chick's magnesium‐sensitive retinal
spreading depression. Developmental Neurobiology, 15(5), 333-343.
Wahner, A. D., Bronstein, J. M., Bordelon, Y. M., & Ritz, B. (2007). Nonsteroidal antiinflammatory drugs may protect against Parkinson disease. Neurology, 69(19), 18361842.
Walther, H., Lambert, J. D. C., Jones, R. S. G., Heinemann, U., & Hamon, B. (1986).
Epileptiform activity in combined slices of the hippocampus, subiculum and entorhinal
cortex during perfusion with low magnesium medium. Neuroscience Letters, 69(2), 156161.

356

Weeber, M., Klein, H., de Jong‐van den Berg, L., & Vos, R. (2001). Using concepts in
literature‐based discovery: Simulating Swanson's Raynaud –fish oil and migraine–
magnesium discoveries. Journal of the Association for Information Science and
Technology, 52(7), 548-557.
Weeber, M., Vos, R., Klein, H., Aronson, A. R., & Molema, G. (2003). Generating
hypotheses by discovering implicit associations in the literature: a case report of a search
for new potential therapeutic uses for thalidomide. Journal of the American Medical
Informatics Association, 10(3), 252-259.
Weeber, M., Kors, J. A., & Mons, B. (2005). Online tools to support literature-based
discovery in the life sciences. Briefings in Bioinformatics, 6(3), 277-286.
Welch, K. M. A., Chabi, E., Nell, J. H., Bartosh, K., Chee, A. N. C., Mathew, N. T., &
Achar, V. S. (1976). Biochemical comparison of migraine and stroke. Headache: The
Journal of Head and Face Pain, 16(4), 160-167.
Wilkowski, B., Fiszman, M., Miller, C. M., Hristovski, D., Arabandi, S., Rosemblat, G.,
& Rindflesch, T. C. (2011). Graph-based methods for discovery browsing with semantic
predications. In Proceedings of the American Medical Informatics Association Annual
Symposium (Vol. 2011, p. 1514). American Medical Informatics Association.
Wren, J. D. (2004). Extending the mutual information measure to rank inferred literature
relationships. BMC Bioinformatics, 5(1), 145.
Wren, J. D., Bekeredjian, R., Stewart, J. A., Shohet, R. V., & Garner, H. R. (2004).
Knowledge discovery by automated identification and ranking of implicit relationships.
Bioinformatics, 20(3), 389-398.
Wren, J. D. (2008). The ‘open discovery’ challenge. Literature-Based Discovery, 39-55.
Xun, G., Jha, K., Gopalakrishnan, V., Li, Y., & Zhang, A. (2017, November). Generating
Medical Hypotheses Based on Evolutionary Medical Concepts. In Data Mining (ICDM),
2017 IEEE International Conference on Data Mining (pp. 535-544). IEEE.
Yetisgen-Yildiz, M., & Pratt, W. (2006). Using statistical and knowledge-based
approaches for literature-based discovery. Journal of Biomedical Informatics, 39(6), 600611.
Yetisgen-Yildiz, M., & Pratt, W. (2008). Evaluation of literature-based discovery
systems. In Literature-Based Discovery (pp. 101-113). Springer, Berlin, Heidelberg.
Yogan, J. K., Goh, O. S., Halizah, B., Ngo, H. C., & Puspalata, C. (2016). A review on
automatic text summarization approaches. Journal of Computer Science, 12(4), 178-190.

357

Youn, H., Strumsky, D., Bettencourt, L. M., & Lobo, J. (2015). Invention as a
combinatorial process: evidence from US patents. Journal of The Royal Society Interface,
12(106), 20150272.
Zhang, G., Ding, Y., & Milojević, S. (2013). Citation content analysis (cca): A
framework for syntactic and semantic analysis of citation content. Journal of the
Association for Information Science and Technology, 64(7), 1490-1503.
Zhang, H., Fiszman, M., Shin, D., Miller, C. M., Rosemblat, G., & Rindflesch, T. C.
(2011). Degree centrality for semantic abstraction summarization of therapeutic studies.
Journal of Biomedical Informatics, 44(5), 830-838.
Zhang, H., Fiszman, M., Shin, D., Wilkowski, B., & Rindflesch, T. C. (2013). Clustering
cliques for graph-based summarization of the biomedical research literature. BMC
Bioinformatics, 14(1), 182.
Zipf, G. K. (1949). Human Behaviour and the Principle of Least-Effort.

